Document:

EXHIBIT
10.2

 

CONFIDENTIAL
TREATMENT

 

EPIX Medical, Inc. has
requested that the marked portions of this document be accorded confidential
treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.

 

 

Final Version

 

COLLABORATIVE RESEARCH AGREEMENT

 

between

 

EPIX

 

and

 

SCHERING

 

 

TABLE OF CONTENTS

 

	
  1.

  	
  DEFINITIONS

  
	
   

  	
   

  	
   

  	
   

  
	
  2.

  	
  RESEARCH PROGRAM

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  2.1

  	
  Objectives
  of the Research Program; Term; Exclusivity

  
	
   

  	
  2.2

  	
  Obligations of the Parties

  
	
   

  	
   

  	
  2.2.1

  	
  Research Plan(s)

  
	
   

  	
   

  	
  2.2.2

  	
  Due Diligence;
  Commitment of FTE’s

  
	
   

  	
   

  	
  2.2.3

  	
  Information Exchange;
  Reports

  
	
   

  	
   

  	
  2.2.4

  	
  Supply of Proprietary
  Materials

  
	
   

  	
  2.3

  	
  Contract Services and Goods

  
	
   

  	
  2.4

  	
  Discovery of Lead Compounds

  
	
   

  	
   

  	
   

  	
   

  
	
  3.

  	
  RESEARCH FUNDING

  
	
   

  	
   

  
	
   

  	
  3.1

  	
  Payments
  by SCHERING

  
	
   

  	
  3.2

  	
  Loan
  by SCHERING to EPIX

  
	
   

  	
   

  	
   

  	
   

  
	
  4.

  	
  OPTION
  RIGHTS FOR DEVELOPMENT CANDIDATES AND JOINT TECHNOLOGY

  
	
   

  	
   

  
	
   

  	
  4.1

  	
  SCHERING
  License Option

  
	
   

  	
   

  	
  4.1.1

  	
  Option Grant

  
	
   

  	
   

  	
  4.1.2

  	
  Exercise of SCHERING Option

  
	
   

  	
  4.2

  	
  Failure to
  Exercise; EPIX License Option

  
	
   

  	
  4.3

  	
  Failure to
  Exercise the Option by both Parties

  
	
   

  	
  4.4

  	
  Joint
  Technology Option

  
	
   

  	
   

  	
   

  	
   

  
	
  5.

  	
  ADMINISTRATION OF
  THE COLLABORATION

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  5.1

  	
  Establishment and
  Function of RSC

  
	
   

  	
   

  	
  5.1.1

  	
  Membership

  
	
   

  	
   

  	
  5.1.2

  	
  Chair

  
	
   

  	
   

  	
  5.1.3

  	
  Minutes

  
	
   

  	
   

  	
  5.1.4

  	
  Responsibilities of the RSC

  
	
   

  	
   

  	
  5.1.5

  	
  RSC
  Dispute Resolution

  
	
   

  	
  5.2

  	
  Establishment
  and Function of Management Team

  
	
   

  	
   

  	
  5.2.1

  	
  Membership

  
	
   

  	
   

  	
  5.2.2

  	
  Chair

  
	
   

  	
   

  	
  5.2.3

  	
  Minutes

  
	
   

  	
   

  	
  5.2.4

  	
  Responsibilities of
  Management Team

  
	
   

  	
   

  	
  5.2.5

  	
  Management Team
  Dispute Resolution

  
								

 

i

 

	 
	
   

  	
  5.3

  	
  Establishment of
  Project Team(s)

  
	 
	
   

  	
   

  	
   

  	
   

  
	 
	
  6.

  	
  DEVELOPMENT
  AND COMMERCIALIZATION OF DEVELOPMENT CANDIDATES

  
	 
	
   

  	
   

  	
   

  	
   

  
	 
	
   

  	
  6.1

  	
  Development
  and Commercialization Obligations

  
	 
	
   

  	
   

  	
  6.1.1

  	
  SCHERING’s
  obligations

  
	 
	
   

  	
   

  	
  6.1.2

  	
  EPIX’
  obligations

  
	 
	
   

  	
  6.2

  	
  Progress
  Reports

  
	 
	
   

  	
  6.3

  	
  Clinical Development by
  EPIX

  
	 
	
   

  	
  6.4

  	
  Record Keeping

  
	 
	
   

  	
   

  	
   

  
	 
	
  7.

  	
  LICENSE GRANTS; ROYALTIES

  
	 
	
   

  	
   

  	
   

  	
   

  
	 
	
   

  	
  7.1

  	
  Research
  Licenses

  
	 
	
   

  	
   

  	
  7.1.1

  	
  License
  to SCHERING

  
	 
	
   

  	
   

  	
  7.1.2

  	
  License to EPIX

  
	 
	
   

  	
  7.2

  	
  Development
  and Commercialization Licenses

  
	 
	
   

  	
   

  	
  7.2.1

  	
  Licenses
  to SCHERING

  
	 
	
   

  	
   

  	
  7.2.2

  	
  Licenses to
  EPIX

  
	 
	
   

  	
   

  	
  7.2.3

  	
  License Term

  
	 
	
   

  	
  7.3

  	
  Payments of
  EPIX

  
	 
	
   

  	
   

  	
  7.3.1

  	
  Milestones

  
	 
	
   

  	
   

  	
  7.3.2

  	
  Royalties
  by EPIX

  
	 
	
   

  	
  7.4

  	
  Royalties
  by SCHERING; Buy-up Option Epix

  
	 
	
   

  	
   

  	
  7.4.1

  	
  Royalty Rates

  
	 
	
   

  	
   

  	
  7.4.2

  	
  Buy-up Option Epix

  
	 
	
   

  	
   

  	
  7.4.3

  	
  Payments of EPIX
  under Buy-up Option

  
	 
	
   

  	
   

  	
  7.4.4

  	
  Sublicense
  Income

  
	 
	
   

  	
  7.5

  	
  General License Conditions

  
	 
	
   

  	
   

  	
  7.5.1

  	
  Payment Dates and Reports

  
	 
	
   

  	
   

  	
  7.5.2

  	
  Payments; Currency
  Conversion

  
	 
	
   

  	
   

  	
  7.5.3

  	
  Records; Audit Rights;
  Disputes

  
	 
	
   

  	
   

  	
  7.5.4

  	
  Taxes

  
	 
	
   

  	
   

  	
  7.5.5

  	
  Retained Rights

  
	
   

  	
   

  
	
  8.

  	
  TERMINATION

  
	
   

  	
   

  
	
   

  	
  8.1

  	
  Term

  
	
   

  	
  8.2

  	
  Termination By Either Party

  
	
   

  	
   

  	
  8.2.1

  	
  Termination
  for Breach

  
	
   

  	
   

  	
  8.2.2

  	
  Termination for Insolvency

  
	
   

  	
   

  	
  8.2.3

  	
  Termination for Convenience

  
	
   

  	
  8.3

  	
  Consequences of Termination

  
	
   

  	
  8.4

  	
  Surviving
  Provisions

  
	
   

  	
   

  	
   

  
	
  9.

  	
  INTELLECTUAL PROPERTY
  RIGHTS

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  9.1

  	
  Disclosure
  of Inventions

  
						

 

ii

 

	
   

  	
  9.2

  	
  Ownership

  
	
   

  	
   

  	
  9.2.1

  	
  EPIX Background Technology

  
	
   

  	
   

  	
  9.2.2

  	
  SCHERING Background
  Technology

  
	
   

  	
   

  	
  9.2.3

  	
  Joint
  Technology

  
	
   

  	
  9.3

  	
  Patent
  Coordinators

  
	
   

  	
  9.4

  	
  Patent Filing,
  Prosecution and Maintenance

  
	
   

  	
   

  	
  9.4.1

  	
  Patent Filing,
  Prosecution and Maintenance of Joint Patent Rights

  
	
   

  	
   

  	
  9.4.2

  	
  Patent Filing,
  Prosecution and Maintenance by EPIX

  
	
   

  	
   

  	
  9.4.3

  	
  Patent Filing,
  Prosecution and Maintenance by SCHERING

  
	
   

  	
  9.5

  	
  Infringement of Patent
  Rights

  
	
   

  	
   

  	
  9.5.1

  	
  Infringement of
  Joint Patent Rights

  
	
   

  	
   

  	
  9.5.2

  	
  Infringement of EPIX
  Patent Rights

  
	
   

  	
   

  	
  9.5.3

  	
  Infringement of
  SCHERING Patent Rights

  
	
   

  	
   

  	
  9.5.4

  	
  Notice
  of Infringement

  
	
   

  	
   

  	
  9.5.5

  	
  Infringement
  of Know-How

  
	
   

  	
  9.6

  	
  Cooperation

  
	
   

  	
  9.7

  	
  Patent Management

  
	
   

  	
   

  	
   

  
	
  10.

  	
  CONFIDENTIALITY

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  10.1

  	
  Nondisclosure Obligations

  
	
   

  	
   

  	
  10.1.1

  	
  General

  
	
   

  	
   

  	
  10.1.2

  	
  Limitations

  
	
   

  	
   

  	
  10.1.3

  	
  Terms
  of this Agreement

  
	
   

  	
  10.2

  	
  Injunctive
  Relief

  
	
   

  	
   

  	
   

  
	
  11.

  	
  REPRESENTATIONS AND WARRANTIES

  
	
   

  	
   

  
	
   

  	
  11.1

  	
  Representations and
  Warranties

  
	
   

  	
  11.2

  	
  Organization

  
	
   

  	
  11.3

  	
  Authorization

  
	
   

  	
  11.4

  	
  No Inconsistent Obligation

  
	
   

  	
  11.5

  	
  Warranty
  Disclaimer

  
	
   

  	
   

  	
   

  
	
  12.

  	
  INDEMNITY

  
	
   

  	
   

  
	
   

  	
  12.1

  	
  Claim

  
	
   

  	
  12.2

  	
  SCHERING
  Indemnity Obligations

  
	
   

  	
  12.3

  	
  EPIX Indemnity Obligations

  
	
   

  	
  12.4

  	
  Procedure

  
	
   

  	
  12.5

  	
  Limited
  Liability

  
	
   

  	
   

  	
   

  
	
  13.

  	
  MISCELLANEOUS

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  13.1

  	
  Force Majeure

  
	
   

  	
  13.2

  	
  Assignment

  
	
   

  	
  13.3

  	
  Severability

  
	
   

  	
  13.4 

  	
  Notices

  
	
   

  	
  13.5

  	
  Applicable Law

  

 

iii

 

	
   

  	
  13.6

  	
  General Dispute Resolution

  
	
   

  	
   

  	
  13.6.1

  	
  Negotiation

  
	
   

  	
   

  	
  13.6.2

  	
  Arbitration

  
	
   

  	
  13.7

  	
  Public
  Announcements

  
	
   

  	
  13.8

  	
  Entire Agreement; Amendment

  
	
   

  	
  13.9

  	
  Headings

  
	
   

  	
  13.10

  	
  Agreement Not to
  Solicit Employees

  
	
   

  	
  13.11

  	
  Exports

  
	
   

  	
  13.12

  	
  Waiver

  
	
   

  	
  13.13

  	
  Counterparts

  
	
   

  	
  13.14

  	
  Independent
  Contractors; Negation of Partnership

  
	
   

  	
  13.15

  	
  Ambiguities

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Exhibit 1.13

  	
   

  	
  EPIX Patent Rights

  
	
   

  	
  Exhibit 1.15

  	
   

  	
  Products in Development or Commercialized

  
	
   

  	
  Exhibit 1.49

  	
   

  	
  SCHERING Patent Rights

  
	
   

  	
  Exhibit 2.4A

  	
   

  	
  Criteria for Lead Compounds

  
	
   

  	
  Exhibit 2.4B

  	
   

  	
  Criteria for Development Candidates

  
	
   

  	
  Exhibit 3.2A

  	
   

  	
  Copy of Loan Agreement

  
	
   

  	
  Exhibit 3.2B

  	
   

  	
  Copy of Security
  Agreement

  

 

iv

 

COLLABORATIVE RESEARCH AGREEMENT

 

This COLLABORATIVE RESEARCH AGREEMENT (this
“Agreement”) is entered into as of May 26, 2003 (the “Effective Date”), by and
between Epix Medical, Inc., a Delaware corporation having its principal place
of business at 71 Rogers Street, Cambridge, MA 02142-1118 USA (“EPIX”), and
Schering Aktiengesellschaft, a German corporation having its principal place of
business at 13342, Berlin, Germany (“SCHERING”).  Each of SCHERING, EPIX and their respective Affiliates is
sometimes referred to individually herein as a “Party” and collectively as the
“Parties”.

 

WHEREAS, EPIX has
expertise and proprietary technology related to the discovery, development and
commercialization of products for use in magnetic resonance imaging;

 

WHEREAS, SCHERING has expertise and proprietary
technology related to the discovery, development and commercialization of
products for use in magnetic resonance imaging;

 

WHEREAS, EPIX and
SCHERING desire to bring their collective expertise, proprietary technology and
other resources together in a collaborative effort to discover new technology
and products for use in magnetic resonance imaging; and

 

WHEREAS, EPIX and SCHERING
further desire to provide for a series of rights and obligations pertaining to
the commercialization of new products arising from their collaborative efforts
as set forth herein.

 

NOW, THEREFORE, in
consideration of the mutual covenants contained herein, and for other good and
valuable consideration, the Parties hereto, intending to be legally bound,
hereby agree as follows:

 

1.                                       DEFINITIONS

 

Whenever used in this
Agreement with an initial capital letter, the terms defined in this
Section 1 shall have the meanings specified.

 

1.1                                 “Affiliate”
means any corporation, firm, partnership or other entity which directly or
indirectly controls or is controlled by or is under common control with a Party
to this Agreement. For purposes of this definition, “control” means ownership,
directly or through one or more Affiliates, of fifty percent (50%) or more of
the shares of stock entitled to vote for the election of directors, in the case
of a corporation, or fifty percent (50%) or more of the equity interests in the
case of any other type of legal entity, status as a general partner in any
partnership, or any other arrangement whereby a Party controls or has the right
to control the Board of Directors or equivalent governing body of a corporation
or other entity.

 

1.2                                 “Audit
Disagreement” has the meaning set forth in Section 7.5.3 (b).

 

1

 

1.3                                 “Confidential
Information” means (a) all tangible embodiments of Technology
produced or discovered by either Party or jointly by the Parties under the
Research Program, the prosecution files pertaining to any Joint Patent Rights
and all information concerning the terms of this Agreement and (b) with respect
to a Party (the “Receiving Party”), all information, Technology and Proprietary
Materials which is disclosed by the other Party (the “Disclosing Party”) to the
Receiving Party hereunder or to any of its employees, consultants, Affiliates,
licensees or Sublicensees, except to the extent that the information described
in this Section 1.3(b), (i) as of the date of disclosure is demonstrably known
to the Receiving Party or its Affiliates, as shown by written documentation,
other than by virtue of a prior confidential disclosure to such Party or its
Affiliates; (ii) as of the date of disclosure is in, or subsequently enters,
the public domain, through no fault or omission of the Receiving Party; (iii)
is obtained from a Third Party having a lawful right to make such disclosure
free from any obligation of confidentiality to the Disclosing Party; or (iv) is
independently developed by or for the Receiving Party without reference to or
reliance upon any Confidential Information of the Disclosing Party as
demonstrated by competent written records.

 

1.4                                 “Control”
or “Controlled” means (a) with respect to Know-How (other than
Proprietary Materials) and/or Patent Rights, the possession by a Party of the
ability to grant a license or sublicense of such Know-How and/or Patent Rights
as provided herein without violating the terms of any agreement or arrangement
between such Party and any Third Party and (b) with respect to Proprietary
Materials, the possession by a Party of the ability to supply such Proprietary
Materials to the other Party as provided herein without violating the terms of
any agreement or arrangement between such Party and any Third Party.

 

1.5                                 “Cost”
or “Costs”
shall mean expenses incurred by the Parties, determined in a reasonable manner
in accordance with GAAP in case of EPIX and IAS in case of SCHERING, and
consistent with each Party’s accounting practice.

 

1.6                                 “Cost of
Goods Sold”  shall mean the cost for
manufacturing the Licensed Product, using SCHERING’s standard accounting
procedures computed in accordance with IAS applied on a consistent basis. Such
cost shall include, but not be limited to, the fully burdened cost of all raw
materials, auxiliaries and other ingredients, labor and overhead, depreciation,
maintenance and repair, destroyed material, production variance, imputed
interest on safety stocks and capacity cost for dedicated equipment, for the
synthesis, formulation, filling, finishing, labeling, packaging, storing,
testing and quality control, and assurance activities, and shall also include
reasonable expenses for services and transportation charges and any royalties
paid to Third Parties in connection with the manufacturing process or materials
used. “Cost of Goods” shall not include general and
administrative expenses, sales and marketing costs or costs associated with
meeting the chemistry manufacturing and control requirements of the FDA or
other regulatory authorities.

 

1.7                                 “Designation
Notice” has the  meaning
set forth in Section 2.4.

 

1.8                                 “Development
Candidates” shall mean Lead Compounds in the Field that progress
successfully through the lead optimization process and that are designated
according to

 

2

 

the criteria in Exhibit
2.4 as “Development Candidates” as well as any modifications thereof during any
development process thereafter.

 

1.9                                 “Development
Costs” shall mean all internal (direct and indirect) and Third
Party expenses incurred by EPIX in connection with the Research Program, or by
SCHERING following exercise of the SCHERING Option, determined in a reasonable
manner in accordance with GAAP.  Such
expenses include, but are not limited to (i) direct labor (salaries, wages,
incentive awards and employee benefits but excluding any employee benefits
associated with equity incentive plans); (ii) materials and supplies; (iii)
allocated Costs for building space directly dedicated to the development of the
Lead Compounds, Development Candidates and/or Licensed Products (including
rent, depreciation, amortization and maintenance) but excluding expenses
relating to unused capacity, development of other products, and amortization of
property, plant and equipment not directly related to development of Lead
Compounds, Development Candidates and/or Licensed Products; (iv) Third Party
contracts and consulting expenses incurred for services in connection with the development
of Lead Compounds, Development Candidates and/or Licensed Products; (v)
allocated Costs for information technology directly dedicated to the
development of the Lead Compounds, Development Candidates and/or Licensed
Products; and (vi) travel and entertainment, telephone, recruiting, training
(both internal and external), clinical trial insurance, software, personal
computer equipment and support Costs and freight and delivery expenses. Such
Costs shall not include General and Administrative Expenses or expenses
incurred from departments that are not directly engaged in the development of
the Lead Compounds, Development Candidates and/or Licensed Products including,
but not limited to, finance and procurement, corporate administration, legal
(both external and internal expenses), human resources, business development
and licensing, sales and marketing except for Costs of investor relations.

 

Development
activities for which Development Costs are incurred include but are not limited
to pre-clinical and clinical work (Phase I-IV trials (such Phase IV trials to
be intended to support approval of an NDA, MAA or a supplement or amendment
thereto, required as a condition of approval of an NDA, MAA or a supplement or
amendment thereto, or required to support continued approval of an NDA, MAA or
a supplement or amendment thereto), regulatory filings, Cost of compound for
pre-clinical and clinical work (Phase I-IV trials, as described above in this
sentence), and all Costs of Lead Compounds, Development Candidates and/or
Licensed Products related to regulatory filings in the Territory including CMC
Costs.

 

1.10                           “Effective
Date” has the meaning set forth in the introductory paragraph.

 

1.11                           “EPIX
Background Technology” means collectively all EPIX Patent Rights
and EPIX Know-How.

 

1.12                           “EPIX
Option” has the meaning set forth in Section 4.2.

 

1.13                           “EPIX
Patent Rights” means the Patent Rights, Controlled by EPIX and
having claims covering EPIX Know-How, which are already in existence prior to
the Effective Date, as identified on Exhibit 1.13 hereto or filed thereafter.

 

3

 

1.14                           “EPIX
Know-How” means all Know-How useful in the Field that is: (a)
Controlled by EPIX immediately prior to the Effective Date, or (b) developed or
conceived by EPIX on or after the Effective Date in the conduct of activities
outside of the Research Program.

 

1.15                           “Field”
means the diagnosis or characterization of diseases or conditions in humans
through the use of magnetic resonance imaging; provided, however,
that the Field shall not include: (i) any products that are subject to a
license granted under the Thrombus Development Agreement entered into by and
between the Parties as of the Effective Date or the Strategic Collaboration
Agreement between EPIX and SCHERING dated June 9, 2000, or (ii) any products
already commercialized or in preclinical or clinical development prior to the
Effective Date as set forth on Exhibit 1.15 , 
or (iii) any product, compound or Technology being subject to a contract
or collaboration with a Third Party which is already in existence prior to the
Effective Date, or any extension or amendment thereof, except for those
contracts as to be determined by the RSC.

 

1.16                           “FDA”
means the United States Food and Drug Administration or any successor agency.

 

1.17                           “First
Commercial Sale” means the date of the first sale of a Licensed
Product in the ordinary course of business in any country by a Party or an
Affiliate or Sublicensee of such Party after all marketing, pricing and/or
reimbursement approvals of the competent health authority(ies) of such country
required for sale of such product in such country have been obtained.

 

1.18                           “Full Time
Equivalent”  or “FTE” means one (1) or more qualified
employee(s), contractor(s) or agent(s) of a Party who, collectively, spend time
and effort working on a specific project or task equivalent to the time and
effort of one (1) full-time employee for one (1) year.

 

1.19                           “General
and Administrative Expenses” shall mean all direct and indirect
expenses incurred by SCHERING and EPIX in connection with departmental units
that are not directly engaged in the research, development, manufacturing, or
sales and marketing of Joint Technology, Lead Compounds, Development Candidates
and Licensed Products.  General and
Administrative Expenses shall include, but not be limited to, charges falling
within the following, groups: finance, procurement, order entry, corporate
administration, legal (both external and internal expenses), human resources,
business development and licensing and investor relations.  “General and Administrative Expenses” shall
exclude the following groups of charges: clinical trial insurance Costs,
facilities and information technology. 
Such expenses shall be determined in accordance with GAAP, consistently
applied.

 

1.20                           “IND”  means
an Investigational New Drug application, as defined in the United States Food,
Drug and Cosmetic Act and applicable regulations promulgated thereunder, or the
equivalent in any other country.

 

1.21                           “Indemnitee”
has the meaning set forth in Section 12.4.

 

4

 

1.22                           “Indemnitor”
has the meaning set forth in Section 12.4.

 

1.23                           “Joint
Know-How” means all Know-How that is: (a) developed or conceived
by EPIX and/or SCHERING after the Effective Date in the conduct of activities
within the Research Program, and/or (b) Controlled jointly by EPIX and
SCHERING.

 

1.24                           “Joint
Patent Rights” means Patent Rights Controlled by SCHERING and
EPIX and having claims covering Joint Know-How, which are filed after the
Effective Date.

 

1.25                           “Joint
Technology” means collectively all Joint Patent Rights and Joint
Know-How.

 

1.26                           “Know-How”
means and includes all present and future know-how, inventions, trade secrets,
copyrights, data, regulatory submissions and other intellectual property of any
kind, whether patentable or not, including Proprietary Materials.

 

1.27                           “Lead
Compounds” means compounds that will be the subject of research
optimization efforts in the Research Program and that are designated, as
provided in Section 2.4, to be “Lead Compounds.”

 

1.28                           “Licensed
Product(s)” means any product based upon, derived from or
incorporating a Development Candidate or Joint Technology licensed by either
SCHERING or EPIX under this Agreement.

 

1.29                           “License
Term” has the meaning set forth in Section 7.2.3 of this
Agreement.

 

1.30                           “Management
Team” means the organizational body for the Research Program as
set forth in Section 5.2.

 

1.31                           “MAA”
means an application for Regulatory Approval to sell a Product in the European
Union.

 

1.32                           “NDA”  means
a New Drug Application, as defined in the United States Food, Drug and Cosmetic
Act and applicable regulations promulgated thereunder.

 

1.33                           “Net Sales”
shall meanthe amount invoiced by the selling Party, its Affiliates or
sublicensees for sales of a Licensed Product to unaffiliated Third Parties less
the following deductions applicable to the Licensed Product for:

 

(i)                                     transportation
charges and insurance charges paid by the selling Party;

 

(ii)                                  sales
and excise taxes or customs duties paid by the selling Party or any other
governmental charges imposed upon the sale of the Licensed Product and paid by
the selling Party exclusive of taxes on the income of the selling Party;

 

5

 

(iii)                               fees
paid to distributors, consignees or agents in connection with the sale of the
Licensed Product;

 

(iv)                              rebates
and premiums granted in connection with the sale of a Licensed Product;

 

(v)                                 credits
to customers on account of governmental requirements, price differences,
rejection, outdating, returns or recalls of the Licensed Product;

 

(vi)                              quantity
discounts, cash discounts or chargebacks granted in connection with the sale of
the Licensed Product;

 

(vii)                           provisions
for price reductions; and

 

(viii)                        selling
Party’s standard allowance as demonstrated to the other Party’s reasonable
satisfaction, and in no case in excess of [*****].

 

For the purpose of
calculating Net Sales, the Parties recognize that (a) the selling Party’s
customers may include persons in the chain of commerce who enter into
agreements with the selling Party as to price even though title to the Licensed
Product does not pass directly from the selling Party to such customers and
even though payment for such Licensed Product is not made by such customers
directly to the selling Party and (b) in such cases, chargebacks paid by the
selling Party to or through a Third Party (such as a wholesaler) can be
deducted by the selling Party from gross revenue in order to calculate Net
Sales. Any deductions above which involve a payment by the selling Party shall
be taken as a deduction against aggregate sales for the period in which the
payment or deduction is made.

 

In the event a Licensed
Product is sold in the form of a combination product containing one or more
active ingredients in addition to a Licensed Product, Net Sales for such
combination product will be adjusted by multiplying actual Net Sales of such
combination product by the fraction A / (A+B) where A is the invoice price of
the Licensed Product, if sold separately, and B is the invoice price of any
other active ingredient or ingredients in the combination, if sold
separately.  If, on a country-by-country
basis, the other active ingredient or ingredients in the combination are not
sold separately in that country, Net Sales shall be calculated by multiplying
actual Net Sales of such combination product by the fraction A / C where A is
the invoice price of the Licensed Product if sold separately, and C is the
invoice price of the combination product. 
If, on a country by country basis, neither the Licensed Product nor the
other active component or components of the combination product is sold
separately in said country, Net Sales shall be determined between the Parties in
good faith. 

 

1.34                           “Part or
Parts of the Agreement” means either all terms relating to the
Research Program or all terms relating to a license granted or optioned under
this Agreement, depending on which terms are involved.

 

6

 

1.35                           “Other
Schering Patent(s)” means any patent filed by SCHERING after the
Effective Date which incorporates Technology arising out of research activities
at SCHERING outside the Field and outside the scope of this Collaboration.

 

1.36                           “Patent
Rights” means the rights and interests in and to issued patents
and pending patent applications (which for purposes of this Agreement shall be
deemed to include certificates of invention and applications for certificates
of invention and priority rights) in any country, including all provisional
applications, substitutions, continuations, continuations-in-part, divisionals,
and renewals, all letters patent granted thereon, and all reissues,
reexaminations and extensions thereof, Controlled by a Party.

 

1.37                           “Phase
III Clinical Trial” means a pivotal human clinical trial in any
country the results of which could be used to establish safety and efficacy of
a Product as a basis for a marketing approval application submitted to the FDA,
or that would otherwise satisfy requirements of U.S. Statute 21 CFR 312.21(c),
or its foreign equivalent.

 

1.38                           “Project
Team(s)” means the working group(s) conducting the work in the
various research projects under the Research Plan(s) and established in
accordance with Section 5.3.

 

1.39                           “Proprietary
Materials” means any tangible chemical, biological or physical
research materials that are furnished by or on behalf of one Party to the other
Party in connection with this Agreement, regardless of whether such materials
are specifically designated as proprietary by the transferring Party.

 

1.40                           “[*****]”
means the use of [*****] to a [*****] for the purpose of imaging in [*****] or
[*****] or for [*****].

 

1.41                           “Regulatory
Approval”  means any approval, product and establishment
license, registration or authorization of any national, federal, state or local
regulatory agency, department, bureau or other governmental entity necessary
for the manufacture, use, storage, importation, export, transport or sale by a
Party of a Licensed Product in a regulatory jurisdiction.

 

1.42                           “Research
Plan(s)” means the written plan(s) and description(s) of  each research project to be conducted under
this Agreement, as to be determined by the RSC.

 

1.43                           “Research
Program” means the collaborative research  program to be conducted pursuant to this
Agreement as reflected in the Research Plan(s), focusing initially in the
following three areas; (a) inflammation (including plaque) imaging with
magnetic resonance imaging contrast media (including gadofluorines), (b)
cardiac perfusion imaging, and (c) high-sensitivity magnetic resonance imaging
contrast media.

 

1.44                           “Research
Program Term” has the meaning set forth in Section 2.1.

 

7

 

1.45                           “Research
Steering Committee” or  “RSC” means the committee of EPIX and
SCHERING representatives established pursuant to Section 5.1 hereof to
administer the affairs of the Collaboration.

 

1.46                           “SCHERING
Background Technology” means collectively all SCHERING Patent
Rights and SCHERING Know-How.

 

1.47                           “SCHERING
Know-How” means all Know-How useful in the Field that is: (a)
Controlled by SCHERING immediately prior to the Effective Date, or (b)
developed or conceived by SCHERING on or after the Effective Date in the
conduct of activities outside of the Research Program.

 

1.48                           “SCHERING
Option” has the meaning set forth in Section 4.1.

 

1.49                           “SCHERING
Patent Rights” means the Patent Rights, Controlled by SCHERING
and having claims covering SCHERING Know-How, which are already in existence
prior to the Effective Date, as identified on Exhibit 1.49 hereto or filed
thereafter.

 

1.50                           “Sublicense
Income” means all payments received by a Party from a
sublicensee in connection with the grant of a sublicense under a development
and a commercial license in accordance with Section 4.4  or Section 7.2, including without limitation,
royalties, up-fronts, technology access fees, milestones and fifty percent
(50%) of the premium over fair market value paid to such Party  in connection with  the issuance of securities of such Party where fair market value
is based on the number of securities issued multiplied by the average closing
price of the stock as quoted on the stock exchange (NASDAQ or Deutsche Boerse
XETRA, respectively), such average based on a twenty (20) business day period,
but excluding (a) payments made to support or fund research and development
activities and (c) payments made for other rights or tangible property to the
extent not in excess of the fair market value of such other rights or tangible
property.

 

1.51                           “Term”
has the meaning set forth in Section 8.1.

 

1.52                           “Territory”
means all countries of the world.

 

1.53                           “Third
Party” means any person or entity other than SCHERING and EPIX
and their respective Affiliates.

 

2.                                       RESEARCH
PROGRAM

 

2.1                                 Objectives of the Research Program; Term;
Exclusivity.  The
objectives of the Research Program shall be the discovery and optimization of
compounds that may become Licensed Products and Joint Technology that is useful
in the Field.  The Research Program
shall commence on the Effective Date and shall continue for a period of three
(3) years, with an option to extend the Program for two (2) additional years
upon mutual agreement of both Parties no

 

8

 

later than ninety
(90) days prior to the expiration of the initial term (the “Research Program
Term”).  Neither Party shall perform any
research, in the Field during the Research Program Term outside of this collaboration.

 

2.2                                 Obligations of the Parties.

 

2.2.1                        Research Plan(s).  The work under the Research Program will be
organized into various research projects to be conducted in accordance with a
Research Plan, which may be amended from time-to-time during the Research
Program Term.  The initial Research Plan
will be determined at the first meeting of the RSC.  The Parties will execute each Research Plan in accordance with
the requirements set forth herein (for example, with the diligence specified in
Section 2.2.2). For each of the research projects one of the Parties shall be
designated by the Management Team as being primarily responsible for the
various tasks under the relevant Research Plan. Each Research Plan may be
modified upon proposal for such modification by the Project Team to the Management
Team, which shall discuss and decide about such modifications.

 

2.2.2                        Due Diligence; Commitment of FTE’s.  Each Party will use commercially reasonable
efforts to perform all aspects of its obligations under the relevant Research
Plan(s) consistent with the efforts it devotes to its other collaborations with
commercial entities, and in accordance with all applicable laws, ordinances,
rules, regulations, orders, licenses and other requirements now or hereafter in
effect.  Each Party shall devote  [*****] FTE’s exclusively to the performance
of its obligations under the Research Program. The Management Team shall
allocate the actual number of FTE’s for each research project.  [*****] [*****] months after the Effective
Date EPIX may start to reduce its number of FTE’s to a [*****].  After such reduction of FTE’s [*****] the
[*****].  The individuals whom each
Party commits to the performance of the Research Program shall have the
training and experience required to perform the tasks assigned to him or her by
each Party in a manner consistent with this standards set forth in this Section
2.2.2.  Each Party will maintain a list
of the individuals it commits to the performance of the Research Program and
shall share such list with the other Party solely to facilitate the performance
of the Research Program and to allow each Party to monitor the other Party’s
compliance with this Section.  The list
of individuals each Party shall commit to the performance of the Research Program
shall be determined and exchanged at the first meeting of the RSC.

 

2.2.3                        Information Exchange; Reports.  The Party responsible for a research project
shall keep the Management Team fully informed about the status of the  Research Plan for which it is responsible.  In addition, each Project Team shall submit
a written report, describing the progress of the work done by it under the
relevant Research Plan in reasonable detail, to the Research Steering Committee
(RSC) at least seven (7) days prior to each meeting of the RSC. The Parties expect
that the exchange of information and materials may involve on-site visits and
longer exchange visits by scientists of one Party to the facilities of the
other Party. Such visits will have defined purposes, include a reasonable
number of participants and be scheduled reasonably in advance.

 

9

 

2.2.4                        Supply of Proprietary Materials.  From time-to-time during the Term of this
Agreement, a Party (the “Transferor”) may supply the other Party (the
“Recipient”) with its Proprietary Materials for use in the Research Program or
for any additional development activities agreed upon by the Parties.  In connection therewith, the Recipient
hereby agrees that: (a) it shall not use Proprietary Materials for any purpose
other than exercising any rights granted to it or reserved by it hereunder, (b)
it shall use the Proprietary Materials only in compliance with all applicable,
federal, state, and local laws and regulations, (c) it shall not transfer any
Proprietary Materials to any Third Party without the prior written consent of
the Transferor, except as expressly permitted hereby, (d) the Transferor shall
retain full ownership of all such Proprietary Materials and (e) upon the
expiration or termination of this Agreement, the Recipient shall at the
instruction of the Transferor either destroy or return any Proprietary
Materials which are not the subject of the grant of a continuing license
hereunder.

 

2.3                                 Contract Services and Goods.  The Research Program indicates the Parties’
currently anticipated needs for contracted services and goods.  The decision on contracting any goods and
services from Third Parties shall be made by the Management Team. SCHERING
shall be responsible for funding such contracted services and goods if needed
and as indicated in one of the Research Plan(s) on a case-by-case basis up to a
maximum of $[*****] for each full calendar year, such amount to be reduced
ratably for any partial year.  The cost
of any other contracted goods and services as are provided for in the Research
Plan(s) shall be shared equally by the Parties.  As is set forth in more detail in Section 2.2.2, the Parties
shall commit [*****] FTE’s each to the performance of the Research Program.  In the event EPIX in fact commits less than
[*****] FTE’s to the performance of the Research Program, then the funding for
contracted goods and services set forth herein shall be reduced ratably over
such period of time unless the RSC shall determine otherwise. With regard to
all contracts already executed prior to the Effective Date for which the
Parties may agree to include them in the Field and, therefore, this Agreement,
all payments due under those contracts for the calendar year 2003 shall be paid
pro rata under this Section 2.3 as of the Effective Date. It is understood
between the Parties that the inclusion of any such Third Party contract may
only be included in this Agreement upon the Third Party’s consent. [*****] the
Parties agree [*****] of [*****] does [*****], Epix and Schering [*****] of
[*****] contract as [*****] or [*****]

 

2.4                                 Discovery of Lead Compounds.  The initial work under the Research Program
will be focused on the discovery of compounds meeting criteria set forth in
Exhibit 2.4A.   Upon proposal of the
relevant Project Team the Management Team shall submit the most promising
compounds to the RSC for designation as “Lead Compounds” in accordance with the
criteria set forth in Exhibit 2.4 A. 
Lead Compounds will undergo additional lead optimization efforts in
order to meet the criteria identified on Exhibit 2.4 B. Upon proposal of the
relevant Project Team, the Management Team shall decide upon submission of a
Lead Compound to the RSC for designation as a Development Candidate. If it has
been submitted by the Management Team and the RSC has positively decided to
designate the Lead Compound as a Development Candidate, the RSC shall provide
written notice to SCHERING and EPIX with its decision (the “Designation
Notice”).  It is understood that the
SCHERING members on the RSC have the authority to render any decision hereunder
only after an internal review and approval process for

 

10

 

any Lead Compound
or Development Candidate at SCHERING. Such review process shall be initiated by
a SCHERING RSC or Management Team member as soon as possible and shall in any
case be finished within ninety (90) days after submission of a Lead Compound or
Development Candidate to the RSC by the Management Team.

 

3.                                       RESEARCH FUNDING

 

3.1                                 Payments by SCHERING.  In 
consideration of the performance by EPIX of the Research Program,
SCHERING shall make  payments to EPIX in
the aggregate amount of $[*****] (= $[*****] per FTE) for each twelve (12)
month period during the Research Program Term. 
Such annual payment shall be made in equal quarterly installments with
the first such payment being due and payable within ten (10) business days of
the Effective Date and with subsequent payments becoming due and payable every
three (3) months thereafter during the Research Program Term.  The annual payment shall be reduced
accordingly if and whenever EPIX reduces its committed FTEs in accordance with
Section 2.2.2.

 

3.2                                 Loan by SCHERING to EPIX.  SCHERING shall provide a loan of
up to $15,000,000 to EPIX in accordance with the terms and conditions set forth
in the Loan Agreement and the Security Agreement, copies of which are attached
hereto as Exhibit 3.2A and Exhibit 3.2B respectively.

 

4.                                       OPTION RIGHTS FOR DEVELOPMENT
CANDIDATES AND JOINT TECHNOLOGY

 

4.1                                 SCHERING License Option.

 

4.1.1                        Option Grant.  EPIX hereby grants to SCHERING the exclusive
right and option (the “SCHERING Option”) to obtain an exclusive license under
the terms set forth in Section 7 to develop and commercialize products based
upon, derived from or incorporating a Development Candidate with the right to
sublicense (the “SCHERING Option”).

 

4.1.2                        Exercise of SCHERING Option.  Upon the delivery by the RSC to SCHERING and
EPIX of a Designation Notice, SCHERING will have a period of [*****] [*****] to
determine whether to exercise the SCHERING Option with respect to the
Development Candidate identified in such notice.  SCHERING shall notify EPIX of its decision within such [*****]
period.  If no notice is provided to
EPIX within such [*****] period, the SCHERING Option for such Development
Candidate shall expire.

 

4.2                                 Failure to Exercise; EPIX License Option.  For all Development Candidates for which
SCHERING fails to exercise the SCHERING Option, SCHERING hereby grants to EPIX
the exclusive right and option (the “EPIX Option”) to obtain an exclusive
license under the terms set forth in Section 7 and to further develop and
commercialize products based upon, derived from or incorporating such
Development Candidate, with the right to sublicense.  Each EPIX

 

11

 

Option shall
commence upon the expiration of the corresponding SCHERING Option and shall be
exercised within [*****] upon notification to SCHERING. If no notice is
provided by EPIX within such [*****] period, the EPIX Option for such
Development Candidate shall expire.

 

4.3                                 Failure to Exercise the Option by both Parties.  In case that neither SCHERING nor EPIX
exercise their respective option for the relevant Development Candidate during
the period set forth in Section 4.1 or Section 4.2 as applicable, both the EPIX
Option and the SCHERING Option shall again become operative and either Party
may thereafter exercise its option by written notice to the other Party.  Options shall then be exercisable on a
first-come, first-served basis.

 

4.4                                 Joint Technology Option.  Each Party hereby grants to the other the
right and option  to obtain an
exclusive, worldwide, royalty-bearing license, with the right to grant
sublicenses, under such Party’s interest in the Joint Technology, to the extent
required to permit such other Party to develop, make, have made, use, sell,
promote, have sold, and import a product based upon, derived from or
incorporating Joint Technology for use in [*****] the [*****].  The Joint Technology option shall not apply
to Development Candidates.  This option
shall commence upon the expiration of the Research Program and shall continue
in full force and effect until the [*****] anniversary of the termination of
the Research Program.  The Joint Technology
option shall be exercisable by written notice from one Party to the other Party
and on a first-come, first-served basis. For all exclusive licenses optioned
under this Section 4.4 the royalty rate of Section 7.2.1 (b) (royalties for
[*****] shall apply as well as Section 7.2.3 and Section 7.5. Notwithstanding
any rights which the Parties may have at law or otherwise as joint owners of
the Joint Technology, the Parties hereby agree that neither of them will
practice any Joint Technology, except as provided in this Section 4.4 or in
their performance hereunder, without the express written consent of the other
Party during the Term and for a period of [*****] years thereafter.

 

5.                                       ADMINISTRATION OF THE COLLABORATION

 

5.1                                 Establishment and Function of RSC.  EPIX and SCHERING hereby establish a
“Research Steering Committee” (or “RSC”) to oversee the Research Program.  The RSC shall have the responsibilities as
set forth in Section 5.1.4.

 

5.1.1                        Membership.

 

(a)                                  The
RSC shall be comprised of two (2) named representatives of SCHERING and two (2)
named representatives of EPIX.  The RSC
representatives shall be appointed as soon as possible after the Effective Date
and shall meet as needed but not less than twice annually.  Such meetings shall be at times and places
or in such form as the members of the RSC shall agree, and may take place by
conference call or videoconference. 
Each Party shall have the right to have other employees of the same
Party (or consultants to such Party, with the advance permission of the other
Party) present at and participating in any RSC meeting provided that the names,
titles, and subject matter to be addressed by such additional attendees are

 

12

 

submitted in
writing to the other Party at least three (3) business days in advance of the
meeting, and that neither Party has more than five (5) attendees at a meeting
without the advance permission of the other Party.

 

(b)                                 A
Party may change its representative to the RSC at any time. Members of the RSC
may be represented at any meeting by an authorized designee. In making any
approval, determination or taking any other action delegated to the RSC,
SCHERING and EPIX shall each have one vote on the RSC, regardless of how many
representatives each Party may have in attendance at any RSC meeting.

 

5.1.2                        Chair.  The RSC shall initially be chaired by the
EPIX representative (the “Chair”) and thereafter the Chair shall alternate from
meeting to meeting between the representative of SCHERING and the representative
of EPIX.

 

5.1.3                        Minutes.  The RSC shall keep accurate minutes of its
deliberations, which record all proposed decisions and all material actions
recommended or taken.  The Chair shall
be responsible for the preparation of draft minutes.  Draft minutes shall be sent to the other member of the RSC within
ten (10) working days after each meeting. 
The draft minutes shall be edited by the Chair based on comments from
the other member of the RSC to be provided within ten (10) working days and
shall be distributed to the other member by the Chair within thirty (30)
working days after the meeting, and in any case no later than one (1) week
prior to the next meeting.  All minutes
of the RSC shall at all times be available to both Parties.

 

5.1.4                        Responsibilities of the RSC.  The RSC shall be responsible for making
strategic decisions relating to the overall Research Program, including without
limitation, the following matters:

 

(a)                                  determination
of a Research Plan and any amendments thereto or changes thereof;

 

(b)                                 monitoring
the progress of the Research Program based upon information from the Management
Team;

 

(c)                                  approving
resource allocation and approving priorities within the Research Program with
regard to each Research Plan;

 

(d)                                 determination
of potential Lead Compounds;

 

(e)                                  determination
of potential Development Candidates; and

 

(f)                                    dispute
resolution for disputes among Management Team.

 

5.1.5                        RSC Dispute Resolution.  In the event that the RSC shall not be able
to reach a decision or take an action on any matter that is reserved to the RSC
hereunder, then such RSC decisions shall first be referred for resolution to
the Chief Executive Officer  of EPIX and the Head of Corporate Research
of SCHERING for attempted resolution by good faith negotiation.  Such good faith negotiation may include the
appointment by either Party of an

 

13

 

unaffiliated
expert chosen on the basis of such person’s experience and expertise in the
particular type of issue that is unresolved, in order to advise such officers
on the matter.  If such officers are
unable to resolve the matter within ninety (90) days, then SCHERING shall have
authority to make the decision.

 

5.2                                 Establishment and Function of
Management Team. 
EPIX and SCHERING hereby establish a “Management Team” to plan and
administer the execution of the various projects composing the Research Program
and reflected by the Research Plan(s). 
The Management Team shall have the responsibilities as set forth in
Section 5.2.4.

 

5.2.1                        Membership.

 

(a)                                  The
Management Team shall be comprised of two (2) named representatives of SCHERING
and two (2) named representatives of EPIX. 
Each such representative shall be appointed as soon as possible after
the Effective Date and shall meet as needed but not less than four times
annually.  Such meetings shall be at
times and places or in such form as the members of the Management Team shall
agree, and may take place by conference call or videoconference.  Each Party shall have the right to have
other employees of the same Party (or consultants to such Party, with the
advance permission of the other Party) present at and participating in any
Management Team meeting provided that the names, titles, and subject matter to
be addressed by such additional attendees are submitted in writing to the other
Party at least three (3) business days in advance of the meeting, and that
neither Party has more than three (3) attendees at a meeting without the
advance permission of the other Party.

 

(b)                                 A
Party may change its representatives to the Management Team at any time.  Members of the Management Team may be
represented at any meeting by an authorized designee.  In making any approval, determination or taking any other action
delegated to the Management Team, SCHERING and EPIX shall each have one vote on
the Management Team, regardless of how many representatives each Party may have
in attendance at any Management Team meeting.

 

5.2.2                        Chair. 
The  Team shall initially be
chaired by one of the EPIX representatives (the “Chair”) and thereafter the
Chair shall alternate from meeting to meeting between one of the
representatives of SCHERING and one of the representatives of EPIX.

 

5.2.3                        Minutes. 
The Management Team shall keep accurate minutes of its deliberations,
which record all proposed decisions and all actions recommended or taken.  The Chair shall be responsible for the
preparation of draft minutes.  Draft
minutes shall be sent to the other member of the Management Team within ten
(10) working days after each meeting. 
The draft minutes shall be edited by the Chair based on comments from
the other member of the Management Team to be provided within ten (10) working
days and shall be distributed to the other member by the Chair within thirty
(30) days after the meeting, but in no case later than one (1) week prior to
the next meeting of the Management Team. All records of the Management Team
shall at all times be available to both Parties.

 

14

 

5.2.4                        Responsibilities of Management Team.  The Management Team shall be responsible for
making decisions that are relevant to the individual research projects within
the Research Program, including without limitation, the following matters:

 

(a)                                  allocating
FTE’s and resources to the research projects (to be approved by RSC)

 

(b)                                 choosing
project management tools;

 

(c)                                  monitoring
the progress of each research project and providing information to the RSC

 

(d)                                 selection
of contract service providers

 

(e)                                  proposing
potential Lead Compounds to RSC;

 

(f)                                    proposing
potential Development Candidates to RSC.

 

5.2.5                        Management Team Dispute Resolution.  In the event that the Management Team shall
not be able to reach a decision or take an action on any matter that is
reserved to the Management Team hereunder, then such dispute shall first be
referred for resolution to the RSC. If the RSC can not agree on the solution
for the dispute, Section 5.1.5 shall apply accordingly.

 

5.3                                 Establishment of Project Team(s).  Upon consultation with the Party primarily
responsible for the relevant research project, the Management Team shall
determine and nominate a Project Team consisting of all FTE’s working on that
research project.

 

6.                                       DEVELOPMENT AND COMMERCIALIZATION
OF DEVELOPMENT CANDIDATES

 

6.1                                   Development and Commercialization
Obligations.

 

6.1.1                        SCHERING’s obligations.  SCHERING shall use diligent efforts to
undertake the development and commercialization of each Licensed Product
licensed hereunder in the Field, using the level of resources and effort which
are consistent with those which it would apply to a product of comparable
potential resulting from its own research programs.

 

6.1.2                        EPIX’ obligations.  EPIX shall use diligent efforts to undertake
the development and commercialization of each Licensed Product licensed
hereunder in the Field, using the level of resources and effort which are
consistent with those which it would apply to a product of comparable potential
resulting from its own research programs.

 

6.2                                 Progress Reports.    The developing Party shall keep the other
Party regularly informed on all development activities for a Licensed Product,
at least by annual up-date reports.

 

15

 

6.3                                 Clinical Development by EPIX.  In the event that  SCHERING desires for EPIX to perform additional development work
on a licensed Development Candidate, including without limitation, clinical
trials, then EPIX and SCHERING shall agree on a development plan to advance
such Development Candidate through to completion of a proof-of-concept clinical
trial.  Such development plan will
include a protocol for such proof-of-concept clinical trial and estimated
Development Cost for such proof-of-concept clinical trial.  SCHERING shall deliver the development plan
to EPIX upon its completion.  EPIX will
then have a period of thirty (30) days to determine, in its sole discretion,
whether to accept the obligation to undertake the additional work described in
the development plan.  In the event that
EPIX agrees to perform such work, EPIX will so notify SCHERING in writing and
EPIX will perform the work, in accordance with the diligence standards provided
hereunder.  Such additional work shall
not be deemed to be part of the Research Program  and EPIX shall not be permitted to count the efforts it makes
under such development plan as work performed under the Research Program for
purposes of determining whether it has met the requirement that it commit
[*****] to the work under the Research Program.  SCHERING shall reimburse, on a monthly basis, one hundred percent
(100%) of all Development Costs incurred by EPIX in performing such development
work.  EPIX shall invoice SCHERING for
such amounts at the end of each calendar month and shall provide sufficient
detail of the costs and expenses incurred.

 

6.4                                 Record Keeping.  EPIX and SCHERING shall each maintain
records in sufficient detail and in accordance with commonly accepted industry
standards which will document in a manner appropriate for purposes of
supporting the filing of potential patent applications, all work done and
results achieved in the performance of the Research Program (including all data
in the form required under any applicable governmental regulations). Subject to
Article 10 hereof, EPIX and SCHERING shall each provide the other the right to
inspect and copy such records to the extent reasonably required for the
performance of its obligations under this Agreement and shall not use such
records or information except to the extent otherwise permitted by this
Agreement.

 

7.                                       LICENSE GRANTS; ROYALTIES

 

7.1                                 Research Licenses.

 

7.1.1                        License to SCHERING.   EPIX hereby grants to SCHERING and its
Affiliates a fully paid-up, non-exclusive, royalty-free, worldwide license in
the Field, without the right to grant sublicenses, under EPIX Background
Technology, for the sole purpose of conducting the activities required in the
performance of its obligations hereunder as part of the Research Program,
during the Research Program Term.

 

7.1.2                        License to EPIX.  SCHERING hereby grants to EPIX and its
Affiliates a paid-up, non-exclusive, royalty-free, worldwide license in the
Field, without the right to grant sublicenses under SCHERING Background
Technology for the sole purpose of conducting the activities required in the
performance of its obligations hereunder as part of the Research Program,
during the Research Program Term.

 

16

 

7.2                                 Development and Commercialization
Licenses.

 

7.2.1                        Licenses to SCHERING

 

(a)                                  Subject
to SCHERING’s exercise of the SCHERING Option, EPIX hereby grants to SCHERING
an exclusive, worldwide, royalty-bearing license, with the right to grant
sublicenses under the EPIX Background Technology and EPIX’ interest in the
Joint Technology to the extent required to permit SCHERING  to develop, make, have made, use, promote,
sell, have sold and import Licensed Products, for use in the Field, in the
Territory during the License Term.

 

(b)                                 EPIX
hereby grants to SCHERING an exclusive, worldwide, royalty-bearing license,
with the right to grant sublicenses under EPIX’ interest in the Joint
Technology to permit SCHERING to develop, make, have made, use, promote, sell,
have sold and import products for use in the  [*****]
during the License Term.  Anything to
the contrary herein notwithstanding, products which are developed, made, used,
promoted, sold or imported under this license shall be “Licensed Products” for
all purposes under this Agreement except that the following Sections shall not
apply to such products: Section 6.1.1, 6.2, 7.2.3(b) and Section 7.4. SCHERING
shall pay a royalty on products under this Section equal to [*****] [*****] of
Net Sales. SCHERING shall inform EPIX about the First Commercial Sale of any
product under this license. For the sake of clarity the Parties agree that any
royalty obligation under this Section expires upon the expiration of the last
to expire of the relevant Patent Rights in the country covering the product.

 

7.2.2                        Licenses to EPIX

 

(a)                                  Subject
to EPIX’s exercise of the EPIX Option, SCHERING hereby grants to EPIX an
exclusive, worldwide, royalty-bearing license, with the right to grant
sublicenses under the SCHERING Background Technology and SCHERING’s interest in
the Joint Technology to the extent required to permit EPIX to develop, make,
have made, use, sell, promote, have sold and import Licensed Products, for use
in the Field, in the Territory during the License Term.

 

(b)                                 SCHERING
hereby grants to EPIX a non-exclusive, worldwide, royalty-free license, without
the right to grant sublicenses under Other Schering Patent(s) to the extent
necessary to permit EPIX to develop, make, have made, use, promote, sell, have
sold and import Licensed Products in the Field.

 

7.2.3                        License Term.  The term of any license granted pursuant to
Section 7.2 or Section 4.4 with respect to any Licensed Product, shall commence
(i) in case of a license granted under Section 7.2.1 (a) or 7.2.2 (a) upon the
date the option giving rise to such license is exercised in accordance with
this Agreement, or (ii) in case of a license granted under Section 7.2.1 (b),
7.2.2 (b) or 4.4 upon the existence of the relevant Joint Technology, or Other
Schering Patent(s) and shall continue on a country-by-country and
product-by-product basis until the longer of: (a) the expiration of the last to
expire of the relevant Patent Rights in the country

 

17

 

covering the
Licensed Product and (b) the expiration of [*****] from the First Commercial
Sale in such country of such Licensed Product (the “License Term”).  Upon the expiration of the License Term for
each  Licensed Product, such license
shall convert automatically to a paid up, royalty-free license to develop,
manufacture, use, sale or import such Licensed Product.  The Parties hereby acknowledge that during
the License Term royalties may be payable hereunder for a Licensed Product that
is not covered by any claim in Patent Rights subject to a license granted
hereunder.  Under such circumstances,
royalties shall be payable as set forth herein, but at a reduced rate equal to
fifty percent (50 %) of the royalty rate which would otherwise be payable
hereunder, if the manufacture, use, sale or importation of such Licensed
Product were covered by a claim in Patent Rights subject to a license granted
hereunder.  Such reduced royalties shall
be in consideration of: (i) the commercial advantage and background information
gained from the Research Program, (ii) the contribution of the unpatented
Technology to the successful development of the Licensed Product and (iii) the
exclusivity of the Collaboration.

 

7.3                                 Payments of EPIX

 

7.3.1                        Milestones.  EPIX shall make the following one-time
milestone payments to SCHERING for each EPIX Licensed Product.  Such payments shall be due and payable
within thirty (30) days following the achievement of the corresponding
milestone event.

 

	
  Milestone Event

  	
   

  	
  Milestone
  Payment

  Amount

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  [*****]

  	
   

  	
  $

  	
  [*****]

  	
   

  
	
  [*****]

  	
   

  	
  $

  	
  [*****]

  	
   

  
	
  [*****]

  	
   

  	
  $

  	
  [*****]

  	
   

  
	
  [*****]

  	
   

  	
  $

  	
  [*****]

  	
   

  

 

7.3.2                        Royalties by EPIX.

 

(a)                                  EPIX
shall pay SCHERING a royalty based on total annual Net Sales of each Licensed
Product sold by EPIX and/or its Affiliates during the License Term, at the
following rates:

 

	
  On Annual Net Sales of a

  Licensed Product between:

  	
   

  	
  Royalty
  Rate (%)

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Above
  $ [*****]$ [*****]

  	
   

  	
  [*****]

  	
  %

  
	
   

  	
   

  	
   

  	
   

  
	
  Above
  $ [*****]

  	
   

  	
  [*****]

  	
  %

  

 

(b)                                 EPIX
shall pay SCHERING [*****] of any and all Sublicense Income within thirty (30)
days of receipt by EPIX.

 

18

 

7.4                                 Royalties
by SCHERING; Buy-up Option EPIX.

 

7.4.1                        Royalty Rates.  SCHERING shall pay EPIX a royalty based on
total annual Net Sales of each  Licensed
Product sold by SCHERING and/or its Affiliates during the License Term at the
following rates:

 

	
  On Annual Net Sales of a

  Licensed Product between:

  	
   

  	
  Royalty
  Rate (%)

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Above
  $[*****] and up to $[*****]

  	
   

  	
  [*****]

  	
  %

  
	
   

  	
   

  	
   

  	
   

  
	
  Above
  $[*****]

  	
   

  	
  [*****]

  	
  %

  

 

7.4.2                        Buy-up Option EPIX.  Notwithstanding the foregoing, EPIX shall
have the option of increasing the above royalty rates payable with respect to
each Licensed Product sold by SCHERING by reimbursing SCHERING for a percentage
of all the Development Costs for such Licensed Product incurred by SCHERING as
follows.  For every [*****] of the total
Development Costs incurred by SCHERING after the date SCHERING exercises the
SCHERING Option for a particular Licensed Product that EPIX reimburses SCHERING
for, the royalty rate otherwise payable under the table above will be increased
by [*****] [*****].  This option is
limited such that EPIX cannot reimburse SCHERING for more than [*****] of such
Development Costs for any Licensed Product and so the maximum royalty rates
payable for any SCHERING Licensed Product are [*****] and [*****]; provided,
however, if the [*****] for any Licensed Product is [*****] than [*****] of the
[*****] of [*****], then [*****] this [*****] hereunder.  EPIX must exercise this option with respect
to a  Licensed Product by providing
written notice to SCHERING within [*****] months after the day on which
SCHERING exercises the SCHERING Option relating to such Licensed Product.  If EPIX fails to provide notice within such
[*****] month period, this option shall expire with respect to such Licensed
Product and shall be of no further force or effect.

 

7.4.3                        Payments of EPIX under Buy-up Option.  Within one (1) month from the end of the
calendar quarter in which EPIX has exercised its buy-up option and on a
quarterly basis thereafter, EPIX shall pay its share of the Development Costs
incurred by SCHERING during the relevant calendar quarter, except that the
first such payment shall include reimbursement based on total Development Costs
incurred by SCHERING from the date it exercised the SCHERING Option.  The Development Costs incurred by SCHERING
during each calendar quarter shall be converted from EURO into United States
Dollars by the EURO Foreign Exchange Reference Rate published by the European
Central Bank in Frankfurt/Main on the last day of the applicable calendar
quarter. The
corresponding calculation will be provided by SCHERING to EPIX within fifteen
(15) business days  from the end of the
respective calendar quarter.

 

7.4.4                        Sublicense Income.  SCHERING shall pay EPIX [*****] of any and
all

 

19

 

Sublicense Income within thirty (30) days of receipt by SCHERING.

 

7.5                                 General License Conditions.

 

7.5.1                        Payment Dates and Reports.  All royalty payments on Net Sales shall be
paid within sixty (60) days after the end of each calendar quarter in which
such Net Sales are made.  Such payments
shall be accompanied by a report for the applicable calendar quarter showing
the Net Sales of each Licensed Product sold,   the applicable royalty rate for such Licensed Product, and a
calculation of the amount of royalty due.

 

7.5.2                        Payments; Currency Conversion.

 

(a)                                   Payments.  Payments by either Party to the other Party
under this Agreement shall be made in United States dollars by wire transfer of
immediately available funds to an account at a commercial bank designated by
the receiving Party at least ten (10) Business Days before such payment is due.

 

(b)                                  Royalty
Payments within SCHERING. 
The calculation of royalty payments within SCHERING is based on Euro.
Therefore, where payments are based on Net Sales in countries other than the
member states of the European Monetary Union, the amount of such Net Sales
expressed in the currency of each country shall be converted into Euro at the
Euro Foreign Exchange Reference Rates published by the European Central Bank in
Frankfurt / Main, Germany on the last Business Day of the applicable calendar
quarter. The resulting Euro amount will be converted into United States dollars
again at the Euro Foreign Exchange Reference Rates published by the European
Central Bank in Frankfurt / Main, Germany on the last Business Day of the
applicable calendar quarter. These Euro Foreign Exchange Reference Rates are,
as of the effective date, published on Reuters screen <ECB37>.  If no Euro Foreign Exchange Reference Rate
is determined for the relevant currency the parties shall agree upon another
reference rate.

 

(c)                                   Royalty
Payments within EPIX. 
The calculation of royalty payments within EPIX is based on United
States dollars. Therefore, where payments are based on Net Sales in countries
other than the United States, the amount of such Net Sales expressed in the
currency of each country shall be converted into United States dollars at the
Euro Foreign Exchange Reference Rates published by the European Central Bank in
Frankfurt / Main, Germany on the last Business Day of the applicable calendar
quarter. If no Euro Foreign Exchange Reference Rate is determined for the
relevant currency the parties shall agree upon another reference rate.

 

7.5.3                        Records; Audit Rights; Disputes.

 

(a)                                   Records
of Revenues and Expenses; Audit Rights.  Each Party will maintain complete and
accurate records which are relevant to the determination of Development Costs,
and royalty payments under this Agreement and such records shall be open during
reasonable business hours for a period of two (2) years from creation of
individual records for examination at the other Party’s expense and not more
often than once each calendar year by a

 

20

 

certified public accountant selected by the other Party (subject to the
consent of the Party to be audited, such consent not to be unreasonably
withheld or delayed), or the other Party’s internal accountants (unless the
Party to be audited objects to the use of such internal accountants) for the
sole purpose of verifying for the inspecting Party the correctness of
calculations and classifications of such Development Costs and royalty payments
under this Agreement.  Each Party shall
bear its own Costs related to such audit; provided, that, for any
underpayments greater than [*****] of annual Development Costs and/or royalty
payments (as the case may be) by the audited Party, the audited Party shall pay
the other Party the amount of underpayment, together with interest as provided
herein, from the time the amount was due and the inspecting Party’s
out-of-pocket expenses related to the audit. 
For any underpayments less than [*****] of annual Development Costs
and/or royalty payments (as the case may be), found under this Section, the audited
Party shall pay the inspecting Party the amount of the underpayment.  Any overpayments by the audited Party will
be refunded to the audited Party or credited to future payments by the audited
Party to the inspecting Party, at the audited Party’s election.

 

(b)                                  Resolution
of Payment Disputes. 
Except as set forth in this Section, the provisions of Section 13.6
shall not be applicable to disputes described in this Section.  If there is a dispute between the Parties
following any audit performed pursuant to this Section (an “Audit Disagreement”):
(i) within thirty (30) business days of the identification of the Audit
Disagreement and notice thereof to the other Party, the Parties shall jointly
select a recognized international accounting firm to act as an independent
expert to resolve such Audit Disagreement; (ii) the Audit Disagreement
submitted for resolution shall be described by the Parties to the independent
expert, which description may be in written or oral form, within ten (10)
business days of the selection of such independent expert; (iii) the
independent expert shall render a decision on the matter as soon as
practicable; (iv) the decision of the independent expert shall be final and
binding unless such Audit Disagreement involves alleged fraud, breach of this
Agreement or construction or interpretation of any of the terms and conditions
thereof, which Audit Disagreements shall be resolved as set forth in Section
13.6; and (v) all fees and expenses of the independent expert, including any
Third Party support staff or other costs incurred with respect to carrying out
the procedures specified at the direction of the independent expert in
connection with such Audit Disagreement, shall be borne by each Party in
inverse proportion to the disputed amounts awarded to such Party by the independent
expert through such decision (e.g., EPIX disputes $100; the independent expert
awards EPIX $60; EPIX pays for forty percent (40%) of the independent expert’s
costs, and SCHERING pays for sixty percent (60%) of the independent expert’s
costs.)

 

(c)                                   Payments;
Interest.  Any payments
due under this Agreement shall be due on such date as specified in the
Agreement and, in the event such date is not a business day, then the next
succeeding business day.  Any failure by
a Party to make a payment within ten (10) days after the date when due shall
obligate such Party to pay computed interest, the interest period commencing on
the due date and ending on the payment day, to the receiving Party at a rate
per annum equal [*****].  The interest
shall be computed on the basis of a 365/360 year; interest shall be compounded
annually in arrears.  Such interest
shall be due and payable on the tender of the underlying principle payment.

 

21

 

(d)                                  Financial
Procedures.  Each Party
shall include in any agreement with its Affiliates or sublicensees terms
requiring such party to retain records as required in this Section 7.5.3 and to
permit the such Party to inspect such records as required by this Section
7.5.3.

 

7.5.4                        Taxes.  Each
Party shall pay any and all taxes levied on 
account of signing fees, research and development funding, milestone
payments, royalties or other payments received from the other Party under this
Agreement. If laws or regulations require that taxes be withheld by the paying
Party on any such payments, the paying Party shall: (i) deduct those taxes from
the remittable payment; (ii) timely pay the deducted taxes to the proper taxing
authority; and (iii) send proof of payment to the receiving Party within thirty
(30) days of receipt of confirmation of payment from the relevant taxing
authority.

 

7.5.5                        Retained Rights.  Each Party reserves the right to practice all Know-How and Patent
Rights that it may Control to the extent not expressly subject to a right, license
or option hereunder.  No rights are
granted hereunder by implication or estoppel.

 

8.                                       TERMINATION

 

8.1                                 Term.  The term
of this Agreement shall commence on the Effective Date and shall continue until
the last to occur of the following: (i) the tenth (10th) anniversary
of the expiration or termination of the Research Program Term and (ii) the
expiration or termination of the License Term for the last Licensed Product
(the “Term”).

 

8.2                                 Termination By Either Party.  This Agreement may be terminated partially
or in its entirety at any time by either Party as follows:

 

8.2.1                        Termination for Breach.   If either Party commits a material breach
of this Agreement, the other Party may notify the breaching Party in writing of
such breach, setting forth the nature of the breach in reasonable detail.  If the breaching Party fails to cure such
breach within thirty (30) days (in the case of a payment due under this
Agreement) or sixty (60) days (in the case of any other breach) of the receipt
of the foregoing notice from the non-breaching Party, then, subject to the
terms of this Section 8.2.1, the non-breaching Party may terminate (i) the
respective Part of this Agreement which is impacted by the uncured material
breach, or (ii) if the breach is of a general nature having a material impact
on all Parts, the entire Agreement effective immediately upon a second written
notice to the breaching Party. The right of either Party to terminate this
Agreement as herein above provided shall not be affected in any way by its waiver
of, or failure to take action with respect to any previous default.

 

8.2.2                        Termination for Insolvency.  In the event that either Party files for
protection under bankruptcy laws, makes an assignment for the benefit of
creditors, appoints or suffers appointment of a receiver or trustee over its
property, files a petition under any bankruptcy or insolvency act or has any
such petition filed against it which is not discharged within sixty (60) days
of the filing thereof, then the other Party may terminate this Agreement
effective immediately upon written notice to such Party.

 

22

 

8.2.3                        Termination for Convenience.  Either Party may terminate the Research
Program upon six (6) months prior written notice to the other Party.  Either Party may terminate any license
granted to it hereunder upon written notice to the other Party.  Neither Party may, under this Section 8.2.3,
terminate a license or option granted to the other Party under this Agreement.

 

8.3                                 Consequences of Termination.  In the event of a termination of this
Agreement in part or in its entirety pursuant to Section 8.2 above, all
Proprietary Materials shall be returned by each Party to the Party which
Controls such Proprietary Materials to the extent required by the fact of a
partial or total termination of this Agreement.

 

8.4                                 Surviving Provisions.  Termination and expiration of this Agreement
for any reason shall be without prejudice to:

 

(a)                                   the
rights and obligations of the Parties herein which survive such expiration or
termination by their terms, including without limitation, those provided in
Sections 2.2.4, 4.4, 6.4, 7.3, 7.4, 7.5, 8.3, 8.4, 9.3.2, 13.4, 13.5, 13.6
and Articles 9, 10, 11 and 12, all of which shall survive such expiration or termination;
and

 

(b)                                  any
other rights or remedies provided at law or equity which either Party may
otherwise have against the other.

 

9.                                       INTELLECTUAL PROPERTY RIGHTS

 

9.1                                 Disclosure of Inventions.  Each Party shall promptly inform the other
about all Know-How that is conceived, made or developed in the course of
carrying out the Research Program by employees or agents of either of them or
their Affiliates, alone or jointly with employees or consultants of the other
Party or its Affiliates.

 

9.2                                 Ownership.

 

9.2.1                        EPIX Background Technology.  As between the Parties, EPIX shall have sole
and exclusive ownership of all right, title and interest on a worldwide basis
in and to any and all EPIX Background Technology with full rights to license or
sublicense, subject to the obligations to SCHERING as set forth herein.

 

9.2.2                        SCHERING Background Technology.  As between the Parties, SCHERING shall have
sole and exclusive ownership of all right, title and interest on a worldwide
basis in and to any and all SCHERING Background Technology, with full rights to
license or sublicense, subject to the obligations to EPIX as set forth herein.

 

9.2.3                        Joint Technology  .  SCHERING and EPIX shall jointly own all
Joint Technology, subject to the rights of, and the licenses granted to, each
Party hereunder.

 

9.3                                 Patent Coordinators.  EPIX and SCHERING shall each appoint a
Patent Coordinator, reasonably acceptable to the other Party, who shall serve
as such Party’s primary

 

23

 

liaison with the
other Party on matters relating to patent filing, prosecution, maintenance and
enforcement.  Each Party may replace its
Patent Coordinator at any time by notice in writing to the other Party. The
initial Patent Coordinators shall be:

 

For EPIX:                                                                                            Dr.
Alan McEwen

 

For SCHERING:                                                           Dr.
Norbert Schwarz

 

The Patent Coordinators
will have responsibility for managing all Joint Patent Rights claiming Joint
Know-How as set forth in Section 9.4.1.

 

9.4                                 Patent Filing, Prosecution and Maintenance.

 

9.4.1                        Patent Filing, Prosecution and Maintenance of
Joint Patent Rights.  The
Parties, acting through the Patent Coordinators, shall be jointly responsible
for preparing, filing, prosecuting, obtaining and maintaining all Joint Patent
Rights.  The Parties will share equally
the expense of such efforts; provided, however, that either Party may decide
not to share such expenses, on a country-by-country basis, and thereafter such
Joint Patent Rights, in such country, shall be deemed to be exclusively owned
by the other Party.  The Parties shall
jointly select patent attorneys and agents to assist them in such efforts.

 

9.4.2                        Patent Filing, Prosecution and Maintenance by EPIX.  Subject to the other terms of this
Section 9, EPIX shall be responsible for preparing, filing, prosecuting,
obtaining and maintaining, at its sole cost, expense and discretion, and acting
through patent attorneys or agents of its choice, all EPIX Patent Rights. With
regard to those EPIX Patent Rights relevant to the actual research projects
being conducted during the Research Program Term EPIX: (i) will keep the
Patent Coordinators reasonably informed of the status of such filing,
prosecution and maintenance, including, without limitation: (a) by
providing the Patent Coordinators with copies of all communications received
from or filed in patent office(s) with respect to such filing, and (b) by
providing the Patent Coordinators a reasonable time prior to taking or failing
to take any action that would affect the scope or validity of any such of any
such filing (including the substantially narrowing, cancellation or abandonment
of any claim(s) without retaining the right to pursue such subject matter in a
separate application, or the failure to file or perfect the filing of any
claim(s) in any country), with prior written notice of such proposed action or
inaction so that the Patent Coordinators have a reasonable opportunity to
review and comment.

 

9.4.3                        Patent
Filing, Prosecution and Maintenance by SCHERING. 
Subject to the other terms of this Section 9, SCHERING shall be
responsible for preparing, filing, prosecuting, obtaining and maintaining, at
its sole cost, expense and discretion, and acting through patent attorneys or
agents of its choice, all SCHERING Patent Rights. With regard to those SCHERING
Patent Rights relevant to the actual research projects being conducted during
the Research Program Term SCHERING will keep the Patent Coordinators
reasonably informed of the status of such filing, prosecution and maintenance,
including, without limitation: (a) by

 

24

 

providing the
Patent Coordinators with copies of all communications received from or filed in
patent office(s) with respect to such filing, and (b) by providing the
Patent Coordinators a reasonable time prior to taking or failing to take any
action that would affect the scope or validity of any such of any such filing
(including the substantially narrowing, cancellation or abandonment of any
claim(s) without retaining the right to pursue such subject matter in a
separate application, or the failure to file or perfect the filing of any
claim(s) in any country), with prior written notice of such proposed action or
inaction so that the Patent Coordinators have a reasonable opportunity to
review and comment.

 

9.5                                 Infringement of Patent Rights.

 

9.5.1                        Infringement of Joint Patent Rights.  The Parties shall jointly determine whether
to bring suit (or take other appropriate legal action) against any actual,
alleged or threatened infringement of Joint Patent Rights.  If both Parties desire to take such action,
they shall jointly determine how to share the expense and proceeds, if any, of
the action and they shall jointly choose legal counsel.  If either Party declines to take any such
action, the other Party shall have the right (but not the obligation), at its
own expense, to bring suit (or take other appropriate legal action) against
such actual, alleged or threatened infringement, with legal counsel of its own
choice, but shall not be permitted to settle any such suit without the prior
consent of the other Party, which consent shall not be unreasonably
withheld.  Any damages, monetary awards
or other amounts recovered, whether by judgment or settlement, pursuant to any
suit, proceeding or other legal action taken by a single Party under this
Section shall applied as follows:

 

(a)                                  First,
to reimburse the Party bringing such action for it’s costs and expenses
(including reasonable attorneys’ fees and costs) incurred in prosecuting such
enforcement action;

 

(b)                                 Second,
the remainder shall be divided between the Parties with [*****] to the Party
bringing such action and the remaining [*****] to the other Party.

 

9.5.2                        Infringement of EPIX Patent Rights.  EPIX shall have the first right (but not the
obligation), at its own expense and with legal counsel of its own choice, to
bring suit (or take other appropriate legal action) against any actual, alleged
or threatened infringement of EPIX’ Patent Rights in the Field.  SCHERING shall have the right, at its own
expense, to be represented in any such action by EPIX by counsel of SCHERING’s
own choice; provided, however, that under no circumstances shall
the foregoing affect the right of EPIX to control the suit as described in the
first sentence of this Section.  If EPIX
does not file any action or proceeding against such infringement within six (6)
months after the later of (i) EPIX’s notice to SCHERING under Section
9.5.4, (ii) SCHERING’s notice to EPIX under Section 9.5.4, or (iii) a
written request from SCHERING to take action with respect to such infringement,
then SCHERING shall have the right (but not the obligation), at its own
expense, to bring suit (or take other appropriate legal action) against such
actual, alleged or threatened infringement, with legal counsel of its own
choice, but shall not be permitted to settle any such suit without the prior
consent of EPIX, which consent shall not be unreasonably withheld.  Any damages, monetary awards or other
amounts recovered, whether by judgment or settlement, pursuant to any suit,

 

25

 

proceeding or
other legal action taken under this Section 9.5, shall applied as follows:

 

(a)                                  First,
to reimburse the Parties for their respective costs and expenses (including
reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement
action;

 

(b)                                 Second,
to licensing Party in reimbursement for lost sales (net of royalties)
associated with Licensed Products and to the licensor Party in reimbursement
for lost royalties owing hereunder based on such lost sales;

 

(c)                                  Third,
any amounts remaining shall be allocated as follows: (a) if EPIX is the
Party bringing such suit or proceeding or taking such other legal action, one
hundred percent (100%) to EPIX, (b) if SCHERING is the Party bringing such
suit or proceeding or taking such other legal action, one hundred percent
(100%) to SCHERING, and (c) if the suit is brought jointly, fifty percent (50%)
to each Party.

 

9.5.3                        Infringement of SCHERING Patent Rights.  SCHERING shall have the first right (but not
the obligation), at its own expense and with legal counsel of its own choice,
to bring suit (or take other appropriate legal action) against any actual,
alleged or threatened infringement of SCHERING’s Patent Rights.  EPIX shall have the right, at its own
expense, to be represented in any such action by SCHERING by counsel of EPIX’s
own choice; provided, however, that under no circumstances shall
the foregoing affect the right of SCHERING to control the suit as described in
the first sentence of this Section 9.5.3. 
If SCHERING does not file any action or proceeding against such
infringement within six (6) months after the later of (i) SCHERING’s
notice to EPIX under Section 9.5.4, (ii) EPIX’s notice to SCHERING
under Section 9.5.4, or (iii) a written request from EPIX to take
action with respect to such infringement, then EPIX shall have the right (but
not the obligation), at its own expense, to bring suit (or take other
appropriate legal action) against such actual, alleged or threatened
infringement, with legal counsel of its own choice, but shall not be permitted
to settle any such suit without the prior consent of SCHERING, which consent
shall not be unreasonably withheld.  Any
damages, monetary awards or other amounts recovered, whether by judgment or
settlement, pursuant to any suit, proceeding or other legal action taken under
this Section 9.5, shall applied as follows:

 

(a)                                  First,
to reimburse the Parties for their respective costs and expenses (including
reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement
action;

 

(b)                                 Second,
to licensing Party in reimbursement for lost sales (net of royalties)
associated with Licensed Products and to the licensor Party in reimbursement
for lost royalties owing hereunder based on such lost sales;

 

(c)                                  Third,
any amounts remaining shall be allocated as follows: (a) if SCHERING is
the Party bringing such suit or proceeding or taking such other legal action,
one hundred percent (100%) to SCHERING, (b) if EPIX is the Party bringing
such suit or proceeding

 

26

 

or taking such other legal action, one hundred percent (100%) to EPIX,
and (c) if the suit is brought jointly, fifty percent (50%) to each Party.

 

9.5.4                        Notice of Infringement.  If either Party learns of any actual,
alleged or threatened infringement by a Third Party of any Patent Rights
related to the Research Program or any license granted under this
Agreement(that is EPIX Patent Rights, SCHERING Patent Rights and Joint Patent
Rights), such Party shall promptly notify the other Party and shall provide
such other Party with available evidence of such infringement.

 

9.5.5                        Infringement of Know-How.  Section 9.5 and the principles and
mechanisms set forth therein shall apply accordingly to any infringement of
unpatented Know-How related to the Research Program or any license granted
under this Agreement (that is EPIX Know-How, SCHERING Know-How and Joint
Know-How.

 

9.6                                 Cooperation.  If a Party brings any such action or
proceeding hereunder, the other Party agrees to be joined as party plaintiff if
necessary to prosecute such action or proceeding, and to give the Party
bringing such action or proceeding reasonable assistance and authority to file
and prosecute the suit; provided, however, that neither Party shall be required
to transfer any right, title or interest in or to any property to the other
Party or any Third Party to confer standing on a Party hereunder.

 

9.7                                 Patent Management.  The Parties agree to exercise their respective
rights to manage the filing, prosecution and maintenance of Patent Rights under
this Agreement in a manner, insofar as reasonably possible, that maximizes the
value of such Patent Rights within the Field.

 

10.                                 CONFIDENTIALITY

 

10.1                           Nondisclosure Obligations.

 

10.1.1                  General.  Except as provided in this Article 10,
during the Term and for a period of fifteen (15) years thereafter, both Parties
shall maintain in confidence and use only for purposes specifically authorized
under this Agreement: (i) information and data received from the other Party
resulting from or related to Know-How, the development of Lead Compounds,
Development Candidates and Licensed Products and (ii) all information and data
not described in clause (i) but supplied by the other Party under this
Agreement marked “Confidential.”  For
purposes of this Article10, information and data described in clause (i) or
(ii) shall be referred to as “Information.”

 

10.1.2                  Limitations.  To the extent it is reasonably necessary or
appropriate to fulfill its obligations or exercise its rights under this
Agreement, a Party may disclose Information it is otherwise obligated under
this Section 10.1 not to disclose to its Affiliates, sublicensees, consultants,
outside contractors and clinical investigators, on a need-to-know basis on
condition that such entities or persons enter into written agreements to keep
the Information confidential for the same time periods and to the same extent
as such Party is required to keep

 

27

 

the Information
confidential. In addition a Party or its Affiliates or sublicensees may
disclose such Information to government or other regulatory authorities to the
extent that such disclosure is reasonably necessary to obtain patents or authorizations
to conduct clinical trials of, and to commercially market Licensed
Products.  However, for the avoidance of
doubt, the Parties state that neither SCHERING nor EPIX shall disclose
pre-clinical or clinical data of the contents or pre-clinical or clinical
study, reports derived from studies of Licensed Products that has been received
from the other Party to advertising agencies, marketing research consultants,
customers, healthcare professionals, consumers or regulatory agencies without
the prior written approval of the other Party.

 

The obligation not to
disclose Information shall not apply to any part of such Information that: (i)
is or becomes part of the public domain other than by unauthorized acts of the
Party obligated not to disclose such Information or those of its Affiliates or
Sublicensees; (ii) can be shown by competent evidence to have been disclosed to
the receiving Party or its or Sublicensees by a Third Party, provided, that
such Information was not obtained by such Third Party directly or indirectly
from the other Party under this Agreement pursuant to a confidentiality
agreement; (iii) can be shown by competent evidence, prior to disclosure under
this Agreement, to already have been in the possession of the receiving Party
or its Affiliates or Sublicensees, provided, that such Information was not
obtained directly or indirectly from the other Party under this Agreement
pursuant to a confidentiality agreement; (iv) can be shown by competent
evidence to have been independently developed by the receiving Party or its
Affiliates without breach of any of the provisions of this Agreement; or (v) is
disclosed by the receiving Party pursuant to interrogatories, requests for
information or documents, subpoena, civil investigative demand issued by a
court or governmental agency or as otherwise required by law; provided, that,
the receiving Party notifies the other Party immediately upon receipt thereof
so that such other Party (with the cooperation of the receiving Party) can seek
a protective order or other order limiting or preventing disclosure; and provided,
further, that the disclosing Party furnishes only that portion of the
Information which it is advised by counsel is legally required under the
circumstances.

 

10.1.3                  Terms of this Agreement.  Except as provided in Section 10.1.2 hereof,
EPIX and SCHERING each agree not to disclose any terms or conditions of this
Agreement to any Third Party without the prior written consent of the other
Party, except as required by applicable law. 
If either Party determines that it is required to file this Agreement
with the Securities and Exchange Commission or other governmental agency for
any reason, such Party shall request confidential treatment of such portions of
this Agreement as the Parties shall together determine is appropriate.  Notwithstanding the foregoing, prior to
execution of this Agreement, EPIX and SCHERING have agreed upon the substance
of information that can be used as a routine reference in the usual course of
business to describe the terms of this transaction, and EPIX and SCHERING may
disclose such information, as modified by mutual agreement from time to time,
without the other Party’s consent as may be necessary from time to time.

 

10.2                           Injunctive Relief.  The Parties hereto understand and agree that
remedies at law may be inadequate to protect against any breach of any of the
provisions of this Article 10 by

 

28

 

either Party or
their employees, agents, officers or directors or any other person acting in
concert with it or on its behalf. 
Accordingly, each Party shall be entitled to the granting of injunctive
relief or other equitable relief by a court of Competent jurisdiction against
any action that constitutes any such breach of this Article 10, in addition to
any monetary damages to which a Party may be entitled.

 

11.                                 REPRESENTATIONS AND WARRANTIES

 

11.1                           Representations and Warranties.  EPIX and SCHERING each represent and warrant
to the other, as of the Effective Date as follows:

 

11.2                           Organization.  It is a corporation duly organized, validly
existing and is in good standing under the laws of the jurisdiction of its
organization, is qualified to do business and is in good standing as a foreign
corporation in each jurisdiction in which the performance of its obligations
hereunder requires such qualification and has all requisite power and
authority, corporate or otherwise, to conduct its business as now being
conducted, to own, lease and operate its properties and to execute, deliver and
perform this Agreement.

 

11.3                           Authorization.  The execution, delivery and performance by
it of this Agreement: (a) have been duly authorized by all necessary corporate
action and (b) do not and will not violate any provision of any agreement, law,
rule, regulation, order, writ, judgment, injunction, decree, determination or
award presently in effect having applicability to it or any provision of its
charter documents.

 

11.4                           No Inconsistent Obligation.  It is not under any obligation to any
person, or entity, contractual or otherwise, that is conflicting or
inconsistent in any respect with the terms of this Agreement or that would
impede the diligent and complete fulfillment of its obligations hereunder and
that it has all power and authority under all instruments or agreements to
which it is a Party to enter into this Agreement and to perform its obligations
hereunder.

 

11.5                           Warranty Disclaimer.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY
TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT
AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

 

12.                                 INDEMNITY

 

12.1                           Claim.  For
purposes of this Article 12 “Claim” shall mean any and all Third Party suits,
actions, claims, demands, liabilities, expenses, and/or losses, including
without limitation reasonable attorneys fees, based upon, arising in connection
with, or resulting from the development, clinical study in humans, or
commercialization of Lead Compounds, Development Candidates and Licensed
Products excluding any suits, actions, claims, demands, liabilities, expenses,
and/or losses based upon, arising in connection with, or resulting from
infringement of

 

29

 

the intellectual property rights (including without limitation patent
rights) of any Third Party or Third Parties.

 

12.2                           SCHERING Indemnity
Obligations.  Subject to
the provisions of Sections 12.3 and 12.4, SCHERING agrees to defend, indemnify
and hold EPIX, its Affiliates and their respective directors, officers,
employees and agents harmless from all Claims against EPIX, its Affiliates or
their respective directors, officers, employees or agents solely based upon,
arising in connection with or resulting from (a) actual or asserted violations
of any applicable law or regulation by SCHERING, its Affiliates, sublicensees,
or agents by virtue of which any Lead Compound, Development Candidate, or
Licensed Product is developed, distributed or sold by SCHERING shall be alleged
or determined to be adulterated, misbranded, mislabeled or otherwise not in
compliance with such applicable law or regulation, (b) the manufacture, use,
sale or promotion of Lead Compounds, Development Candidates or Licensed
Products by SCHERING; (c) any negligent or willful or intentional act or
omission to act by SCHERING, its Affiliates, sublicensees, or agents in any
manner in connection with performance hereunder; or (d) the breach of any
representation or warranty of SCHERING in this Agreement.

 

12.3                           EPIX Indemnity Obligations.  Subject to the provisions of Sections 12.2
and 12.4, EPIX agrees to defend, indemnify and hold SCHERING, its Affiliates
and their respective directors, officers, employees and agents harmless from
all Claims against SCHERING, its Affiliates or their respective directors,
officers, employees or agents solely based upon, arising in connection with or
resulting from (a) actual or asserted violations of any applicable law or
regulation by EPIX, its Affiliates, sublicensees, or agents by virtue of which
any Lead Compound, Development Candidate, or Licensed Product is developed,
distributed or sold by EPIX shall be alleged or determined to be adulterated,
misbranded, mislabeled or otherwise not in compliance with such applicable law
or regulation, (a) the manufacture, use, sale or promotion of Lead Compounds,
Development Candidates or Licensed Products; (b) any negligent or willful or
intentional act or omission to act by EPIX, its Affiliates, sublicensees or
agents in any manner in connection with performance hereunder; or (c) the
breach of any representation or warranty of EPIX in this Agreement.

 

12.4                           Procedure.  A Party or any of its Affiliates (the
“Indemnitee”) that intends to claim indemnification under this Sections 12.2 or
12.3 shall promptly notify the other Party (the “Indemnitor”) of the Claim in
respect of which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall assume the defense thereof with counsel mutually ‘satisfactory
to the Parties; provided, however, that an Indemnitee shall have
the right to retain its own counsel, with the fees and expenses to be paid by
the Indemnitor, if representation of such Indemnitee by the counsel retained by
the Indemnitor,  would be inappropriate
due to actual or potential differing interests between such Indemnitee and any
other Party represented by such counsel in such proceedings. An Indemnitee
shall not be entitled to indemnification under Sections 12.2 or 12.3 if any
settlement or compromise of a Claim is effected by the Indemnitee without the
consent of the Indemnitor, which consent shall not be unreasonably withheld or
delayed.  The failure to deliver notice
to the Indemnitor within a reasonable time after notice of a Claim, if
prejudicial to its ability to defend such action, shall relieve such Indemnitor
of any

 

30

 

liability to the
Indemnitee under Sections 12.2 or 12.3. 
The Indemnitee under Sections 12.2 or 12.3, its employees and agents
(and those of any indemnified Affiliates or other Indemnitees), shall cooperate
fully with the Indemnitor and its legal representatives in the investigation
and defense of the Claim covered by this indemnification.  Any Costs paid by an Indemnitor shall be
without prejudice to the Indemnitor’s right to contest the Indemnitee’s right
to be indemnified, and subject to refund in the event that the Indemnitor is
ultimately held not to be obligated to indemnify the Indemnitee.

 

12.5                           Limited Liability.  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN
THIS AGREEMENT, NEITHER EPIX NOR SCHERING WILL BE LIABLE WITH RESPECT TO ANY
SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR LOST PROFITS.

 

13.                                 MISCELLANEOUS

 

13.1                           Force Majeure.  Neither Party shall be held liable or
responsible to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any
term of this Agreement when such failure or delay is caused by or results from
causes beyond the reasonable control of the affected Party, including but not
limited to fire, floods, embargoes, war, acts of war (whether war is declared
or not), insurrections, riots, civil commotions, strikes, lockouts or other
labor disturbances, acts of God or acts, omissions or delays in acting by any
governmental authority; provided, however, that the Party so affected shall use
reasonable commercial efforts to avoid or remove such causes of nonperformance,
and shall continue performance hereunder with reasonable dispatch whenever such
causes are removed. Either Party shall provide the other Party with prompt
written notice of any delay or failure to perform that occurs by reason of
force majeure.  The Parties shall
mutually seek a resolution of the delay or the failure to perform as noted
above.

 

13.2                           Assignment.  This Agreement may not be assigned or
otherwise transferred by either Party without the prior written consent of the
other Party; provided, however, that either EPIX or SCHERING may,
without such consent, assign its rights and obligations under this agreement:
(i) to any Affiliate, or (ii) in connection with a merger, consolidation or
sale of substantially all of such Party’s assets to an unrelated Third Party; provided,
however, with respect to this Subsection (ii), that the other Party has
the right to terminate with immediate effect the Research Program Term under
this Agreement; provided, further, with respect to this
Subsection (ii), that such Party’s rights and obligations under this Agreement
shall be assumed in writing by its successor in interest in any such
transaction and shall not be transferred separately from all or substantially
all of its diagnostic imaging business assets. 
Any purported assignment in violation of the preceding sentence shall be
void.  Any permitted assignee shall
assume all obligations of its assignor under this Agreement.

 

13.3                           Severability.  Each Party hereby agrees that it does not
intend, by its execution hereof, to violate any public policy, statutory or
common laws, rules, regulations, treaty or

 

31

 

decision of any
government agency or executive body thereof of any country or community or
association of countries.  Should one or
more provisions of this Agreement be or become invalid, the Parties hereto
shall substitute, by mutual consent, valid provisions for such invalid provisions
which valid provisions in their economic and other effects are sufficiently
similar to the invalid provisions that it can be reasonably assumed that the
Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be
agreed upon, the invalidity of one or several provisions of this Agreement
shall not affect the validity of this Agreement as a whole or the validity of
any portions hereof, unless the invalid provisions are of such essential
importance to this Agreement that it is to be reasonably assumed that the
Parties would not have entered into this Agreement without the invalid
provisions.

 

13.4                           Notices.  Any
consent, notice or report required or permitted to be given or made under this
Agreement by one of the Parties hereto to the other shall be in writing,
delivered personally or by courier, postage prepaid (where applicable),
addressed to such other Party at its address indicated below, or to such other
address as the addressee shall have last furnished in writing to the addressor
and shall be effective upon receipt by the addressee.

 

If to
EPIX:                                                                                         EPIX
Medical, Inc.

71
Rogers Street

Cambridge,
Massachusetts 02142-1118

Attention:  Chief Executive Officer

 

with a
copy to:                                                                 Mintz
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One
Financial Center

Boston,
Massachusetts 02111

Attention:  William T. Whelan, Esq.

 

If to
SCHERING:                   SCHERING
Aktiengesellschaft

13342
Berlin

Germany

Attention:  Head of Corporate Research

 

with a
copy to:                                                                 SCHERING
Aktiengesellschaft

13342
Berlin

Germany

Attention:  Legal Department

 

13.5                           Applicable Law.  This Agreement shall be governed by and
construed in accordance with the laws of the State of New York, without giving
effect to the choice of laws provisions thereof.

 

13.6                           General Dispute Resolution.

 

13.6.1                  Negotiation.  Subject to any other dispute resolution
principles and mechanisms set forth in this Agreement, the Parties hereby agree
that they will attempt in good

 

32

 

faith to, resolve any controversy or claim arising out of or relating
to this Agreement promptly by negotiations. 
If a controversy or claim should arise hereunder, the representatives of
the Parties will confer at least once and will attempt to resolve the matter.   If the matter has not been resolved within
fourteen (14) Business Days of their first meeting, the representatives shall
refer the matter to the Chief Executive Officer of EPIX and the Head of
Corporate Research of SCHERING.  If the
matter has not been resolved within thirty (30) Business Days of the first
meeting of the Chief Executive Officer of EPIX and the Head of Corporate
Research of SCHERING (which period may be extended by mutual agreement),
subject to rights to injunctive relief and specific performance, and unless
otherwise specifically provided for herein, any controversy or claim arising
out of or relating to this Agreement, or the breach thereof, will be settled as
set forth in Section 13.6.2, unless provided otherwise in this Agreement.

 

13.6.2                  Arbitration.  All disputes, controversies or differences
which may arise between the Parties out of or in relation to this Agreement or
any default or breach thereof may be resolved by arbitration in accordance with
the commercial arbitration rules (except as otherwise specified herein) of the
American Arbitration Association by three arbitrators, one to be selected by
each of the Parties from a list of arbitrators supplied by the American
Arbitration Association within thirty days of receipt of such list, and a third
to be selected by the first two from such list within a reasonable time. The
arbitrators shall be experienced in the subject matter of the arbitration (for
example, arbitration of a scientific issue would require appointment of
arbitrators with knowledge of the relevant area of science).  The arbitration shall take place in New
York, New York.  Either Party may
initiate an arbitration by written not ice to the other Party, such notice
shall set forth the particulars of the issue to be arbitrated in sufficient
detail to permit the Party receiving the notice to conduct an investigation and
formulate a position (such notice shall not preclude the Parties from
attempting to informally settle their differences).  The arbitrators shall select one of their number to serve as
presiding arbitrator, with the responsibility for handling administrative
matters relating to the arbitration. 
Within sixty days of written notice to the Parties of the selection of
the third arbitrator, each Party shall contemporaneously submit in writing to
the presiding arbitrator and the other Party its position for the resolution of
the issue that is the subject matter of the arbitration.  At the request of either Party, to be submitted
to the presiding arbitrator and the other Party within sixty days receipt of
the written position of the other Party, the arbitrators shall schedule
in-person presentations of the Parties (at which both parties and all three
arbitrators shall be present), which may include the presentation of witnesses,
oral argument, or both, at the discretion of each of the Parties, and which
shall not exceed five hours for each of the Parties.  The in-person presentations shall be scheduled by the arbitrators
at their convenience and the reasonable convenience of the Parties, but shall
be held within ninety and one hundred fifty days of receipt by the presiding
arbitrator of the first request for an in-person presentation.  If neither Party makes a request for an in person
presentation, then the decision of the arbitrators shall be based solely on the
written positions of the Parties.  The
arbitrators shall have the power only to select one of the Party’s positions,
and the decision of any two of the arbitrators shall be the result of the
arbitration.  The non-prevailing Party
shall bear the costs of the arbitration. 
The decision resulting from the arbitration provided for herein shall be
final and binding on the Parties hereto. 
Notwithstanding the above, without resort to arbitration in the first
instance, either Party has the right to bring suit against the other Party for:

 

33

 

(i) any breach of
such other Party’s duties of confidentiality pursuant to Article 10 of this
Agreement and (ii) any infringement of its own proprietary rights by the other
Party.  Judgment upon the arbitrators’
award may be entered in any court of competent jurisdiction.  The Parties agree not to institute any
litigation or proceedings against each other in connection with this Agreement
unless they have complied with the provisions of this Section 13.6.2, as they
may be applicable, unless otherwise provided herein.

 

13.7                           Public Announcements.  Anything in Article 10 to the contrary
notwithstanding, the Parties agree that press releases and other announcements
to be made by either of them in relation to this Agreement shall be subject to
the written consent of the other Party, which consent shall not be unreasonably
withheld or delayed, except to the extent that any such press release is
required to be made by law or the rules of any national stock exchange and the
consent of the other Party is not obtained after reasonable efforts to do
so.  The Parties will agree to issue a
joint press release immediately following the execution of this Agreement, the
form and content of which shall be reasonably satisfactory to both Parties.

 

13.8                           Entire Agreement; Amendment.  This Agreement, together with the exhibits
hereto, contain the entire understanding of the Parties with respect to the
subject matter hereof.  All express or
implied agreements and understandings, either oral or written, heretofore made
are expressly merged in and made a part of this Agreement and the other
agreements described in this Section. 
This Agreement may be amended, or any term hereof modified, only by a
written instrument duly executed by both Parties hereto.

 

13.9                           Headings.  The captions to the several Articles and Sections hereof are not
a part of this Agreement, but are merely guides or labels to assist in locating
and reading the several Articles and Sections hereof.

 

13.10                     Agreement Not to Solicit Employees.  During the Term and for a period of two (2)
years following the expiration or termination of this Agreement, EPIX and
SCHERING agree not to seek to persuade or induce any employee of the other
company to discontinue his or her employment with that company in order to
become employed by or associated with any business, enterprise or effort that
is associated with its own business.

 

13.11                     Exports.  The
Parties acknowledge that the export of technical data, materials or products is
subject to the exporting Party receiving any necessary export licenses and that
the Parties cannot be responsible for any delays attributable to export
controls which are beyond the reasonable control of either Party.  EPIX and SCHERING agree not to export or
re-export, directly or indirectly, any information, technical data, the direct
product of such data, samples or equipment received or generated under this
Agreement in violation of any applicable export control laws or governmental
regulations.  EPIX and SCHERING agree to
obtain similar covenants from their licensees, Sublicensees and contractors
with respect to the subject matter of this Section 13.11.

 

13.12                     Waiver.  The
waiver by either Party hereto of any right hereunder shall not be

 

34

 

deemed a waiver of
any other right hereunder whether of a similar nature or otherwise.

 

13.13                     Counterparts.  This Agreement may be executed in two or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

13.14                     Independent Contractors; Negation
of Partnership.  The
relationship of EPIX and SCHERING established by this Agreement is that of
independent contractors, and nothing contained in this Agreement shall be
construed to give either Party the power to direct or control the day-to-day
activities of the other, or allow one Party to create or assume an obligation
on behalf of the other Party for any purpose whatsoever.  This Agreement is not intended to create a
partnership between EPIX and SCHERING for United States federal income tax
purposes (as defined in Section 761 of the Internal Revenue Code), for any
state or local jurisdiction in the United States, of for any country other than
the United States.  Therefore, there is
no requirement in the United States to file Form 1065, United States
Partnership Return of Income, or any similar state or local income tax return
in any political subdivision of the United States, or any similar tax document
in any country other than the United States, in regard to the contractual
relationship described in this Agreement.

 

13.15                     Ambiguities.  The Parties acknowledge and agree that: (i)
each Party and its counsel reviewed and negotiated the terms and provisions of
this Agreement and have contributed to its revision; (ii) the rule of
construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement;
and (iii) the terms and provisions of this Agreement shall be construed fairly
as to all Parties hereto and not in a favor of or against any Party, regardless
of which Party was generally responsible for the preparation of this Agreement.

 

 

IN WITNESS WHEREOF, the
Parties have executed this Agreement as of the date first set forth above.

 

	
  EPIX MEDICAL, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
   

  	
  Michael D. Webb

  
	
   

  	
  Chief Executive Officer

  

 

35

 

	
  SCHERING
  AKTIENGESELLSCHAFT

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Prof. Dr. Günter Stock

  
	
   

  	
  Member of the Vorstand

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Prof. Dr. Björn
  Wallmark

  
	
   

  	
  Head of Corporate
  Research

  

 

36

 

Exhibit 1.13

 

EPIX Patent Rights

The following patent
families constitute existing utility applications assigned to EPIX or in the
case of the MET-1 patent family exclusively licensed from The General Hospital
Corporation of Boston, Massachusetts (Agreement of March 24, 1992 amended July
10, 1995).  MET-9 is assigned to Dyax
and EPIX with EPIX having exclusive rights to MRI applications (Agreement of
June 20, 1997 amended March 17, 2003).

 

	
  MET-1

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  US-CIP

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  CANADA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  HONG KONG

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  LATVIA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-3

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-4

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  ISRAEL

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  SOUTH AFRICA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  SWAZILAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  TAIWAN

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-5

  	
   

  	
  US CON Publication

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  CHINA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  ISRAEL

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-6

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  

 

37

 

	
   

  	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-7

  	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-8

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-9

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-10

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-11

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-12

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-14

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-15

  	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-16

  	
   

  	
  US Publication

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  PCT

  	
   

  	
  [*****]

  

 

38

 

Exhibit
1.15

 

Products of SCHERING in Development or Commercialized

 

1.              Commercialized
Products

 

Magnevist (gadopentetate
dimeglumine)

Gadovist  (gadobutrol)

Resovist (ferucarbotran)

Feridex (ferumoxide)

Teslascan (mangafodipir
trisodium)

 

2. Products in Development

[*****]

 

39

 

Exhibit 1.49

 

Schering Patent Rights

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  02346A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/FEB/2003

  
	
  02346A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  NO

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/FEB/2003

  
	
  02346A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/SEP/2004

  
	
  02346A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  31/DEC/2007

  
	
  02346A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/FEB/2003

  
	
  02346A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  21/JUN/2005

  
	
  02346A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/FEB/2003

  
	
  02346A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/FEB/2003

  
	
  02346A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2001

  
	
  02346A

  	
   

  	
  DE 0071564

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  02346A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/SEP/2003

  
	
  02346A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/FEB/2003

  
	
  02346A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/AUG/2005

  
	
  02346A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  02346A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/JUL/2007

  
	
  02346A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/JUL/2002

  
	
  02346A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  22/JUL/2002

  
	
  02346A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/FEB/2003

  
	
  02346A

  	
   

  	
  CA

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  03/MAR/2004

  
	
  02346A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  
	
  02346A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2002

  
	
  02346A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  23/JUL/2002

  

 

40

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/OCT/2013

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/JUN/2008

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/MAR/2004

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/MAR/2004

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/NOV/2011

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/MAR/2004

  
	
  02491A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  SG

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  02491A

  	
   

  	
  IT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/MAR/2004

  
	
  02491A

  	
   

  	
  SG

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  GB

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  10/JAN/2004

  
	
  02491A

  	
   

  	
  NL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JAN/2004

  
	
  02491A

  	
   

  	
  LU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  BE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/JAN/2004

  
	
  02491A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  GR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  GB

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  AT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  15/SEP/2011

  
	
  02491A

  	
   

  	
  ES

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/NOV/2004

  
	
  02491A

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  CH

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2006

  
	
  02491A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2004

  
	
  02491A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  09/APR/2004

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02491A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUN/2008

  
	
  02491A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JAN/2004

  

 

41

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  02491A

  	
   

  	
  SG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JAN/2004

  
	
  02491A

  	
   

  	
  SG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JAN/2004

  
	
  02575A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  11/JAN/2004

  
	
  02575A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  11/JAN/2004

  
	
  02969A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUL/2007

  
	
  02969A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  30/JAN/2018

  
	
  02969A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2006

  
	
  02969A

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2007

  
	
  02969A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2007

  
	
  02969A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2007

  
	
  02969A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/JUL/2007

  
	
  02969A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2007

  
	
  02969A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/DEC/2007

  
	
  02969A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2007

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/FEB/2016

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02969A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  02969A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUL/2007

  
	
  03035A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/NOV/2007

  
	
  03035A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  03035A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  14/SEP/2010

  
	
  03035A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/NOV/2006

  
	
  03035A

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/NOV/2007

  
	
  03035A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/NOV/2007

  
	
  03035A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/NOV/2007

  
	
  03035A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/NOV/2007

  

 

42

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  03035A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/NOV/2007

  
	
  03035A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/NOV/2007

  
	
  03035A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  06/MAR/2008

  
	
  03035A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  23/NOV/2007

  
	
  03035A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/MAR/2009

  
	
  03035A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  03035A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/MAR/2016

  
	
  03035A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  30/NOV/2007

  
	
  03035A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  03035A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/NOV/2007

  
	
  03193A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/FEB/2009

  
	
  03193A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  03193A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/OCT/2014

  
	
  03193A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/OCT/2014

  
	
  03226A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/MAR/2009

  
	
  03226A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/FEB/2011

  
	
  03226A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50116A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  11/AUG/2009

  
	
  50116A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/JAN/2011

  
	
  50235A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2013

  
	
  50235A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/JUN/2010

  
	
  50235A

  	
   

  	
  DD

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2008

  
	
  50235A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/JUN/2010

  
	
  50235A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/JUN/2010

  
	
  50235A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50235A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/JUN/2010

  
	
  50235A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/NOV/2011

  
	
  50235A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  

 

43

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  50235A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2010

  
	
  50235A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/JUN/2010

  
	
  50235A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/NOV/2010

  
	
  50235A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/JUN/2010

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/AUG/2015

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/MAR/2017

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  09/DEC/2014

  
	
  50235A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50235A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUN/2010

  
	
  50298A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/NOV/2010

  
	
  50298A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/SEP/2014

  
	
  50298A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/JUL/2014

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  15/NOV/2011

  
	
  50298A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/NOV/2010

  
	
  50298A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  21/NOV/2010

  
	
  50340A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2016

  
	
  50340A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  

 

44

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  50340A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JAN/2015

  
	
  50340A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2013

  
	
  50340A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/JAN/2015

  
	
  50340A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/MAR/2016

  
	
  50340A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/MAR/2016

  
	
  50340A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  GR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/MAR/2016

  
	
  50340A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2016

  
	
  50340A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/MAR/2016

  
	
  50340A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  50340A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24/FEB/2017

  
	
  50340A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2011

  
	
  50340A

  	
   

  	
  SE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  18/MAR/2016

  
	
  50340A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  09/NOV/2016

  
	
  50340A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/MAR/2011

  
	
  50340A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50340A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50340A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50351A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/APR/2011

  
	
  50351A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/APR/2011

  
	
  50351A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/APR/2011

  
	
  50351A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/APR/2011

  
	
  50351A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/APR/2011

  
	
  50351A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/APR/2011

  
	
  50351A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/APR/2011

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  12/JAN/2016

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/APR/2011

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/DEC/2015

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/APR/2011

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

45

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  50351A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/APR/2011

  
	
  50384A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/NOV/2011

  
	
  50384A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
   

  
	
  50384A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JAN/2014

  
	
  50384A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  07/NOV/2011

  
	
  50384A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/NOV/2011

  
	
  50396B

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/DEC/2011

  
	
  50396B

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  IL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  06/DEC/2012

  
	
  50396B

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/DEC/2012

  
	
  50396B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2012

  
	
  50396B

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  06/DEC/2012

  
	
  50396B

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50396B

  	
   

  	
  AT

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  BE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  DK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  FR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  LU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  NL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  ES

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  CH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  GR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  GB

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  SE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  PT

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  MC

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  IT

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/2012

  
	
  50396B

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/DEC/2012

  

 

46

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  50449A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  11/MAY/2012

  
	
  50449A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  13/MAY/2012

  
	
  50449A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  IE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/MAY/2012

  
	
  50449A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/MAY/2012

  
	
  50449A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2012

  
	
  50449A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/MAY/2012

  
	
  50449A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/MAY/2012

  
	
  50449A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  13/APR/2012

  
	
  50449A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  27/JUN/2012

  
	
  50449A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  07/MAY/2012

  
	
  50479A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUN/2012

  
	
  50479A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/MAY/2013

  
	
  50479A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50479A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  

 

47

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  50479A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  07/DEC/2012

  
	
  50479A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50580A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/SEP/2013

  
	
  50580A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/SEP/2012

  
	
  50580A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/SEP/2013

  
	
  50580A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/SEP/2013

  
	
  50580A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/SEP/2013

  
	
  50580A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  15/DEC/2015

  
	
  50580A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/SEP/2013

  
	
  50658A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  24/JAN/2014

  
	
  50658A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  ID

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  10/MAR/2014

  
	
  50658A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2014

  
	
  50658A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  MY

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  31/JUL/2015

  
	
  50658A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50658A

  	
   

  	
  TH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24/JAN/2014

  
	
  50658A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  11/MAR/2014

  
	
  50658A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/AUG/2014

  
	
  50658A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/JAN/2014

  
	
  50659A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/NOV/2014

  
	
  50659A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/NOV/2014

  
	
  50659A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/NOV/2014

  
	
  50659A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/NOV/2014

  
	
  50735A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/NOV/2013

  
	
  50735A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  

 

48

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  50735A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  06/NOV/2012

  
	
  50735A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/OCT/2013

  
	
  50735A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50735A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/NOV/2013

  
	
  50784A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/JAN/2014

  
	
  50856A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/APR/2014

  
	
  50856A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2013

  
	
  50856A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  50856A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/MAY/2015

  
	
  51041A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2014

  
	
  51041A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2014

  
	
  51041A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2014

  
	
  51041A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2014

  
	
  51041A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2014

  
	
  51041A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51041A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/JUN/2015

  
	
  51081A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/JAN/2015

  
	
  51081A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/JAN/2015

  
	
  51081A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51108A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  

 

49

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51108A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/JUL/2014

  
	
  51108A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2015

  
	
  51108A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51108A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/JUN/2015

  
	
  51108A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/JUN/2015

  
	
  51121A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/JUN/2015

  
	
  51121A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/JUN/2015

  
	
  51126A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/JUN/2015

  
	
  51130A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2018

  
	
  51130A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  02/JUN/2017

  
	
  51130A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2018

  
	
  51130A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2012

  
	
  51130A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2018

  
	
  51130A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2018

  
	
  51130A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  28/MAY/2018

  
	
  51130A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  01/JUN/2018

  
	
  51130A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/JUN/2018

  
	
  51130A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51130A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/JUN/2018

  
	
  51142A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  09/JUL/2016

  
	
  51142A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51142A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51142A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/JUN/2017

  
	
  51152A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  21/FEB/2015

  
	
  51152A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  07/JUN/2015

  
	
  51155A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  01/MAR/2015

  
	
  51155A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  

 

50

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51155A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/FEB/2016

  
	
  51155A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/FEB/2016

  
	
  51155A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/MAR/2010

  
	
  51155A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/MAR/2016

  
	
  51156A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  27/JAN/2015

  
	
  51156A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  FI

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  HK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/JAN/2016

  
	
  51156A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  

 

51

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51156A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JAN/2016

  
	
  51156A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/JAN/2016

  
	
  51164A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/AUG/2014

  
	
  51164A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2015

  
	
  51164A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/JUL/2015

  
	
  51164A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  10/JUL/2015

  
	
  51164A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUL/2015

  
	
  51201A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  08/MAY/2015

  
	
  51201A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  08/MAY/2015

  
	
  51201A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  08/MAY/2015

  
	
  51201A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  08/MAY/2015

  
	
  51201A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  08/MAY/2015

  
	
  51229A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/FEB/2016

  
	
  51237A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  07/JUN/2015

  
	
  51246A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/NOV/2016

  
	
  51246A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/NOV/2016

  
	
  51246A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/NOV/2016

  
	
  51246A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/NOV/2016

  
	
  51246A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51263A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/APR/2016

  
	
  51282A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  04/JUL/2015

  
	
  51282A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  

 

52

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51282A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  PK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/FEB/2018

  
	
  51282A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  RU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/SEP/2011

  
	
  51282A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUL/2016

  
	
  51282A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51282A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/JUL/2010

  
	
  51282A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/JUL/2016

  
	
  51282A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51282A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/JUN/2016

  
	
  51285A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2016

  
	
  51285A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  

 

53

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51285A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51285A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  25/FEB/2017

  
	
  51285A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/DEC/1997

  
	
  51285A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51285A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/FEB/2017

  
	
  51315A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  04/JAN/2016

  
	
  51315A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51315A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  

 

54

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51322A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JAN/2016

  
	
  51322A

  	
   

  	
  EE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  IS

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  PK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/FEB/2018

  
	
  51322A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  RU

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/JAN/2012

  
	
  51322A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  17/JAN/2017

  
	
  51322A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/JAN/2017

  
	
  51322A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/JAN/2017

  
	
  51322A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/JAN/2017

  
	
  51322A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/FEB/1997

  
	
  51322A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51322A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  17/JAN/2017

  
	
  51322A

  	
   

  	
  LV

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  LT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  RO

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  16/JAN/2017

  
	
  51322A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  16/JAN/2017

  
	
  51358A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  

 

55

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51358A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  22/DEC/2015

  
	
  51358A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  RU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  20/DEC/2011

  
	
  51358A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51358A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/JAN/1997

  
	
  51358A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51358A

  	
   

  	
  VN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51358A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51358A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/DEC/2016

  
	
  51358A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  LI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51358A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/NOV/2016

  
	
  51378A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  26/SEP/2017

  
	
  51378A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/SEP/2018

  
	
  51378A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/OCT/1998

  

 

56

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  51378A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51378A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  CY

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51378A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  17/AUG/2018

  
	
  51412B

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  BA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  MK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  RO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  SI

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  SK 2

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  TR

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51412B

  	
   

  	
  YU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  

 

57

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  51412B

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51412B

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2018

  
	
  51433A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/AUG/2017

  
	
  51433A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2007

  
	
  51433A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  NZ

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  29/JUL/2017

  
	
  51433A

  	
   

  	
  TH

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  04/AUG/2017

  
	
  51433A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/AUG/2012

  
	
  51433A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/AUG/2017

  
	
  51433A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51433A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  05/AUG/2017

  
	
  51433A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  01/AUG/2017

  
	
  51437A

  	
   

  	
  AU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  04/DEC/2016

  
	
  51437A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  

 

58

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  51437A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51437A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/NOV/2017

  
	
  51437A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2017

  
	
  51437A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51437A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  04/DEC/2017

  
	
  51457A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  04/DEC/2016

  
	
  51457A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51457A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/NOV/2017

  
	
  51457A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/NOV/2017

  
	
  51457A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  25/NOV/2017

  
	
  51457A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2017

  
	
  51457A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51457A

  	
   

  	
  ZA

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  04/DEC/2017

  
	
  51479A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/JUL/1998

  
	
  51502A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  03/JUL/2017

  
	
  51502A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  28/MAY/2018

  
	
  51502A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAY/2018

  
	
  51502A

  	
   

  	
  TW

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  02/JUL/2013

  
	
  51502A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUN/2018

  
	
  51502A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/JUN/2018

  
	
  51502A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/JUL/1998

  
	
  51502A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51502A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  03/JUL/2018

  
	
  51502A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/OCT/2022

  
	
  51519A

  	
   

  	
  KP

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/SEP/2013

  
	
  51521A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  10/MAR/2020

  
	
  51521A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  22/FEB/2021

  
	
  51521A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  08/MAR/2021

  
	
  51521A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/SEP/2001

  
	
  51521A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51521A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  22/FEB/2021

  
	
  51521A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  22/FEB/2021

  
	
  51538A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24/SEP/2018

  
	
  51538A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51538A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  26/SEP/2017

  
	
  51538A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51538A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51538A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2018

  
	
  51538A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  24/SEP/2018

  
	
  51538A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/OCT/1998

  
	
  51538A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51545A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/MAR/2019

  
	
  51545A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  

 

59

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51545A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2014

  
	
  51545A

  	
   

  	
  JP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/MAR/2020

  
	
  51545A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/APR/2000

  
	
  51545A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51545A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51545A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/MAR/2020

  
	
  51547A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/DEC/2017

  
	
  51547A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/DEC/2018

  
	
  51547A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/DEC/2018

  
	
  51547A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/DEC/2018

  
	
  51547A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/JAN/1999

  
	
  51547A

  	
   

  	
  WO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51549A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51562A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/1999

  
	
  51562A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51563A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/DEC/1999

  
	
  51563A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51564A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51590A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  03/APR/2018

  
	
  51613A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  24/JUL/2018

  
	
  51613A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/JUL/2019

  
	
  51613A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/JUL/2019

  
	
  51613A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/JUL/2019

  
	
  51613A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  02/JUL/2014

  
	
  51613A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  23/JUL/2019

  
	
  51613A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  30/OCT/1999

  
	
  51613A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51614A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  22/SEP/2018

  
	
  51614A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  21/SEP/2019

  
	
  51614A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/NOV/1999

  
	
  51614A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51614A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  

 

60

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51614A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  CY

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51614A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  20/AUG/2019

  
	
  51645A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  CN

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  A 17/NOV/2019

  
	
  51645A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  02/DEC/2018

  
	
  51645A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  HK

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/NOV/2019

  
	
  51645A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  01/DEC/2019

  
	
  51645A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/JAN/2000

  
	
  51645A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51645A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  17/NOV/2019

  
	
  51658A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/SEP/2018

  
	
  51669A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/SEP/2019

  
	
  51669A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  28/SEP/2020

  
	
  51669A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29/SEP/2020

  
	
  51669A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/OCT/2000

  
	
  51684A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51729A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  29/SEP/2019

  
	
  51729A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  28/SEP/2020

  
	
  51729A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  29/SEP/2020

  
	
  51729A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/OCT/2000

  
	
  51729A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/JUL/2022

  
	
  51734A

  	
   

  	
  PE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51734A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JUL/2021

  
	
  51734A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734A

  	
   

  	
  UY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/JUL/2022

  
	
  51734A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51734A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51734B

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734B

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51734B

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  20/JUL/2021

  
	
  51734B

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  

 

61

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51734B

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51734B

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51734B

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51734B

  	
   

  	
  UY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/JUL/2022

  
	
  51734B

  	
   

  	
  PE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2022

  
	
  51735A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  08/OCT/2000

  
	
  51752A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/AUG/2019

  
	
  51752A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  25/JUL/2020

  
	
  51752A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  25/JUL/2020

  
	
  51752A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/AUG/2020

  
	
  51752A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/AUG/2000

  
	
  51752A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51760A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  11/AUG/2020

  
	
  51760A

  	
   

  	
  PH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51760A

  	
   

  	
  TH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51760A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2016

  
	
  51760A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51760A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/SEP/2001

  
	
  51760A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  HR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  YU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  HK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51760A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  EE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2015

  
	
  51760A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  CO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51760A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  

 

62

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51761A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  HR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51761A

  	
   

  	
  EE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  KR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  YU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2015

  
	
  51761A

  	
   

  	
  HK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51761A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  CO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51761A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51761A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51761A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  11/AUG/2020

  
	
  51761A

  	
   

  	
  PH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51761A

  	
   

  	
  TH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51761A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2016

  
	
  51761A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51761A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/SEP/2001

  
	
  51761A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51761A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51762A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  11/AUG/2020

  
	
  51762A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17/AUG/2016

  
	
  51762A

  	
   

  	
  US

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  10/AUG/2021

  
	
  51762A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26/SEP/2001

  
	
  51762A

  	
   

  	
  UY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/AUG/2021

  
	
  51762A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  BG

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  CO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  

 

63

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51762A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2015

  
	
  51762A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  YU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  BR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  HK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  EE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  HU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51762A

  	
   

  	
  HR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51762A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23/JUL/2021

  
	
  51766A

  	
   

  	
  AE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2015

  
	
  51766A

  	
   

  	
  AT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  AU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  BE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  BG

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  BR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  BY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  CA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  CH

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  CN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  CY

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  CZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  DK

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  EE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  EP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  ES

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  FI

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  FR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  GB

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  GR

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  HR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51766A

  	
   

  	
  HU

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  ID

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  IE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  IL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  IN

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2014

  
	
  51766A

  	
   

  	
  IT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  JP

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  KR

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  

 

64

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant
  number

  	
   

  	
  Expiry

  
	
  51766A

  	
   

  	
  LU

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  MC

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  MX

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  NL

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  NZ

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  PL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  PT

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  RU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  SE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  09/SEP/2019

  
	
  51766A

  	
   

  	
  SK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/SEP/2015

  
	
  51766A

  	
   

  	
  UA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/SEP/2019

  
	
  51766A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/SEP/2020

  
	
  51766A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51766A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51766A

  	
   

  	
  YU

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  ZA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/SEP/2020

  
	
  51766A

  	
   

  	
  HK

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51766A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/SEP/2020

  
	
  51768A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JAN/2022

  
	
  51768A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  26/JAN/2021

  
	
  51768A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/JAN/2022

  
	
  51768A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13/FEB/2002

  
	
  51768A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51769A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  06/APR/2021

  
	
  51769A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24/APR/2002

  
	
  51772A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/MAR/2017

  
	
  51780A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/OCT/2019

  
	
  51800A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
  [*****]

  	
   

  	
  13/JAN/2020

  
	
  51800A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  27/JAN/2001

  
	
  51800A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51832A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  20/DEC/2022

  
	
  51834A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/DEC/2021

  
	
  51834A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14/DEC/2021

  
	
  51834A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51834A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  15/DEC/2020

  
	
  51834A

  	
   

  	
  JO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  02/JUL/2022

  
	
  51834A

  	
   

  	
  PE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13/DEC/2021

  
	
  51834A

  	
   

  	
  SA

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51834A

  	
   

  	
  TH

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14/DEC/2021

  
	
  51834A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/NOV/2016

  
	
  51834A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13/DEC/2021

  
	
  51834A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/DEC/2001

  
	
  51834A

  	
   

  	
  UY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/DEC/2021

  
	
  51834A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  51834A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51954A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  15/SEP/2020

  

 

65

 

	
  File number

  	
   

  	
  Country C

  	
   

  	
  Publication
  number

  	
   

  	
  Grant number

  	
   

  	
  Expiry

  
	
  51954A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14/SEP/2016

  
	
  51954A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14/SEP/2021

  
	
  51954A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  27/SEP/2001

  
	
  51954A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  51954A

  	
   

  	
  EP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/SEP/2021

  
	
  51954A

  	
   

  	
  JP

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/SEP/2021

  
	
  51954A

  	
   

  	
  NO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  05/SEP/2021

  
	
  52024A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/MAR/2022

  
	
  52024A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52024A

  	
   

  	
  WO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15/NOV/2022

  
	
  52024A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52162A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  18/JUN/2021

  
	
  52163A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
  [*****]

  	
   

  	
  19/JUN/2021

  
	
  52163A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUN/2022

  
	
  52163A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  52164A

  	
   

  	
  DE

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
  11/JUL/2021

  
	
  52164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/JUL/2022

  
	
  52164A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18/JUL/2002

  
	
  52164A

  	
   

  	
  WO

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52165A

  	
   

  	
  AR

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2022

  
	
  52165A

  	
   

  	
  CL

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52165A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2021

  
	
  52165A

  	
   

  	
  PE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2022

  
	
  52165A

  	
   

  	
  TW

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  09/JUL/2022

  
	
  52165A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  07/OCT/2022

  
	
  52165A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/JUL/2002

  
	
  52165A

  	
   

  	
  VE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52165A

  	
   

  	
  WO

  	
   

  	
  [*****]

  	
   

  	
   

  	
   

  	
   

  
	
  52165A

  	
   

  	
  UY

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  28/JUN/2022

  
	
  52207A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  22/OCT/2002

  
	
  52231A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/APR/2023

  
	
  52231A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  52307A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16/JUL/2003

  
	
  52307A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10/JUL/2022

  
	
  52308A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13/DEC/2022

  
	
  52308A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/FEB/2004

  
	
  52309A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19/FEB/2023

  
	
  52309A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  06/MAR/2004

  
	
  52335A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/APR/2023

  
	
  52335A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  11/APR/2004

  
	
  53061A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/FEB/2023

  
	
  53061A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/FEB/2004

  
	
  53063A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  03/APR/2023

  
	
  53063A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  53072A

  	
   

  	
  DE

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  04/FEB/2023

  
	
  53072A

  	
   

  	
  US

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  12/FEB/2004

  

 

66

 

Exhibit
2.4 A

 

Lead Compound
Criteria for a Small Molecule

 

In general, these are not “exclusion criteria” but are intended to
provide the project team with a clear set of optimization variables that are
the basis for the decision-making process and will be investigated in the lead
compound optimization phase of the project.

 

Target:

The target has been
validated [*****], and [*****], etc.)

 

Approaches without defined target:

For compounds [*****] an
[*****] of [*****] in [*****] the [*****] of [*****] to [*****].  If possible, [*****].

 

The lead compound:

•                  Has
[*****], i.e., [*****] and [*****] the [*****].

•                  Has
shown [*****].

•                  For
projects with a [*****], the [*****] at [*****]

•                  For
projects [*****], the [*****] at [*****].

•                  Has
a [*****] plan. [*****].

•                  [*****]
have been [*****].

•                                          [*****]:
[*****] using [*****] as well as [*****].

•                                          [*****]:
[*****], [*****] and [*****].

•                  If
[*****], an [*****] of the [*****] is [*****].

•                  [*****]
for [*****] has been [*****].

•                  [*****]
such as [*****] as well as [*****].

•                  Allows
for [*****].

 

Biological
screening models

 

If possible, the [*****]
and [*****] should have been [*****] or [*****] in the [*****].  If [*****] these should also [*****].  The [*****] should be [*****], allow [*****]
[*****] and be [*****]  The [*****]
should have [*****] or [*****].  In
particular, the [*****] for [*****]  If
available, [*****]
should be included in the [*****].

 

Extract from:

[*****]

 

67

 

Exhibit
2.4 B

 

Criteria needed to
make a Development Candidate decision

 

The development candidate
decision [*****] [*****] resulting in the [*****]

 

The development candidate compound should fulfill the criteria listed
below, which should serve as reference points rather than as strict rules:
there will be cases where some criteria are not applicable or where deviations
are justified. In general, the following criteria should be met:

 

•                  [*****]

•                  [*****]
and expected [*****]

•                  [*****]
on third party [*****]

•                  [*****],
[*****] and [*****] for the [*****] in [*****]

•                  if
possible, information available on [*****] with [*****] and [*****]

•                  appropriate
[*****]   [*****]   relevant to the [*****] at [*****], where [*****] and [*****]

•                  expectation
of [*****] for the [*****] based on [*****]
and [*****])

•                  expectation
of [*****] in relation to [*****] for the [*****]

 

Extract from :

[*****]

 

68EXHIBIT
10.3

 

CONFIDENTIAL TREATMENT

EPIX Medical, Inc. has requested that the
marked portions of this document be accorded confidential

treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.

 

Final
Version

 

 

LOAN AGREEMENT

 

By and Between

 

EPIX MEDICAL, INC.

 

AND

 

SCHERING AKTIENGESELLSCHAFT

 

dated as of May 26, 2003

 

 

 

TABLE OF CONTENTS

 

	
  1.

  	
  DEFINITIONS

  
	
   

  
	
  1.1

  	
  DEFINED TERMS

  
	
  1.2

  	
  OTHER DEFINITIONAL PROVISIONS

  
	
   

  
	
  2.

  	
  THE LOANS; PAYMENT OF PRINCIPAL AND
  INTEREST; RELATED MATTERS

  
	
   

  
	
  2.1

  	
  MAXIMUM PRINCIPAL AMOUNT OF LOANS; OTHER
  PROVISIONS RE: THE LOANS

  
	
  2.2

  	
  PROCEDURES FOR DISBURSEMENTS OF FUNDS

  
	
  2.3

  	
  INTEREST CALCULATIONS

  
	
  2.4

  	
  PAYMENT OF PRINCIPAL AND INTEREST

  
	
  2.5

  	
  OTHER PROVISIONS

  
	
  2.6

  	
  PAYMENTS BY EPIX

  
	
  2.7

  	
  TERMINATION

  
	
   

  
	
  3.

  	
  CONDITIONS PRECEDENT

  
	
   

  
	
  3.1

  	
  CONDITIONS PRECEDENT TO THE INITIAL LOAN

  
	
  3.2

  	
  CONDITIONS PRECEDENT TO ALL LOANS

  
	
   

  
	
  4.

  	
  REPRESENTATIONS AND WARRANTIES

  
	
   

  
	
  4.1

  	
  ORGANIZATION AND QUALIFICATION

  
	
  4.2

  	
  DUE AUTHORIZATION

  
	
  4.3

  	
  NO DEFAULT; COMPLIANCE WITH LAWS

  
	
  4.4

  	
  NO REQUIRED GOVERNMENTAL AUTHORIZATIONS

  
	
  4.5

  	
  COMMISSION FILINGS; NASDAQ LISTING

  
	
  4.6

  	
  INTELLECTUAL PROPERTY

  
	
  4.7

  	
  NO MATERIAL ADVERSE EFFECT

  
	
  4.8

  	
  PERFECTED FIRST PRIORITY LIENS

  
	
  4.9

  	
  TITLE; ABSENCE OF LIENS

  
	
  4.10

  	
  COMPLIANCE WITH LAWS

  
	
  4.11

  	
  NO PROCEEDINGS

  
	
  4.12

  	
  DELIVERY OF DOCUMENTS

  
	
  4.13

  	
  NO VIOLATIONS; TAXES AND ASSESSMENTS

  
	
  4.14

  	
  ENVIRONMENTAL MATTERS

  
	
  4.15

  	
  OTHER REPRESENTATIONS

  
	
  4.16

  	
  REPRESENTATIONS AND WARRANTIES APPLICABLE
  TO SUBSIDIARIES

  
	
  4.17

  	
  REAFFIRMATION

  
	
   

  
	
  5.

  	
  AFFIRMATIVE COVENANTS

  
	
   

  
	
  5.1

  	
  MAINTENANCE

  
	
  5.2

  	
  CONDITION OF COLLATERAL; NO LIENS;
  MAINTENANCE OF CERTAIN COLLATERAL

  
	
  5.3

  	
  COMPLIANCE WITH LAWS

  
	
  5.4

  	
  AFFIRMATIVE FINANCIAL COVENANTS

  
	
  5.5

  	
  NASDAQ LISTING

  
					

 

1

 

	
  5.6

  	
  NOTICE OF ADVERSE EVENTS

  
	
  5.7

  	
  FINANCIAL STATEMENTS AND OTHER INFORMATION

  
	
  5.8

  	
  OTHER
  PROVISIONS

  
	
   

  
	
  6.

  	
  NEGATIVE COVENANTS

  
	
   

  
	
  6.1

  	
  AMENDMENTS OF DOCUMENTS

  
	
  6.2

  	
  CONSOLIDATION, MERGER, OR ACQUISITIONS;
  LIQUIDATION

  
	
  6.3

  	
  OTHER LIENS

  
	
  6.4

  	
  DISPOSITION OF ASSETS OR COLLATERAL

  
	
  6.5

  	
  OTHER LIABILITIES

  
	
  6.6

  	
  LOANS OR INVESTMENTS

  
	
  6.7

  	
  GUARANTIES; CONTINGENT LIABILITIES

  
	
  6.8

  	
  DIVIDENDS AND OTHER DISTRIBUTIONS

  
	
  6.9

  	
  TRANSACTIONS WITH AFFILIATES

  
	
  6.10

  	
  OTHER COVENANTS

  
	
  6.11

  	
  SUBSIDIARIES

  
	
   

  
	
  7.

  	
  EVENTS OF DEFAULT

  
	
   

  
	
  7.1

  	
  FAILURE TO PAY

  
	
  7.2

  	
  FAILURE TO PERFORM OR OBSERVE COVENANTS

  
	
  7.3

  	
  SECURITY

  
	
  7.4

  	
  TRANSACTION DOCUMENTS

  
	
  7.5

  	
  FALSE REPRESENTATION OR WARRANTY

  
	
  7.6

  	
  TERMINATION OF THE RESEARCH AGREEMENT

  
	
  7.7

  	
  DEFAULT ON OTHER DEBT

  
	
  7.8

  	
  CESSATION OF BUSINESS

  
	
  7.9

  	
  NON-APPROVABLE LETTER FOR MS-325

  
	
  7.10

  	
  INABILITY TO PAY DEBTS; BANKRUPTCY OR
  INSOLVENCY

  
	
  7.11

  	
  CERTAIN JUDGMENTS

  
	
  7.12

  	
  CHANGE OF CONTROL

  
	
   

  
	
  8.

  	
  REMEDIES

  
	
   

  
	
  8.1

  	
  RIGHTS UNDER TRANSACTION DOCUMENTS

  
	
  8.2

  	
  RIGHTS IN GENERAL

  
	
  8.3

  	
  SETOFF RIGHTS

  
	
  8.4

  	
  ADDITIONAL RIGHTS TO TERMINATE THIS
  AGREEMENT

  
	
  8.5

  	
  CUMULATIVE REMEDIES; NO WAIVER BY SCHERING

  
	
  8.6

  	
  WAIVERS AND CONSENTS RELATING TO REMEDIES

  
	
  8.7

  	
  POWERS OF ATTORNEY

  
	
   

  
	
  9.

  	
  COSTS, EXPENSES AND TAXES; INDEMNIFICATION;
  LIMITATIONS ON SCHERING’S LIABILITY

  
	
   

  
	
  9.1

  	
  COSTS AND EXPENSES

  
	
  9.2

  	
  INDEMNIFICATION BY EPIX

  
	
  9.3

  	
  LIMITATIONS ON SCHERING’S LIABILITY

  
					

 

2

 

	
  10.

  	
  OTHER PROVISIONS

  
	
   

  
	
  10.1

  	
  ENTIRE AGREEMENT; AMENDMENTS; SCHERING’S
  CONSENT

  
	
  10.2

  	
  SPECIFIC PERFORMANCE

  
	
  10.3

  	
  NOTICES

  
	
  10.4

  	
  NO THIRD PARTY BENEFICIARIES

  
	
  10.5

  	
  JOINT EFFORTS

  
	
  10.6

  	
  GOVERNING LAW

  
	
  10.7

  	
  OTHER PROVISIONS

  
	
  10.8

  	
  NO AGENCY RELATIONSHIP

  
	
  10.9

  	
  FURTHER ACKNOWLEDGMENTS AND AGREEMENTS OF
  EPIX AND SCHERING

  
			

 

3

 

EXHIBITS

 

	
  Exhibit
  A

  	
   

  	
  Research Agreement

  
	
  Exhibit
  B

  	
   

  	
  Note

  
	
  Exhibit
  C

  	
   

  	
  Security Agreement

  
	
  Exhibit
  D

  	
   

  	
  Epix Investment Policy and Guidelines

  
	
   

  
	
  SCHEDULES

  
	
   

  
	
  Schedule

  	
   

  	
  4.5

  	
  Material
  Contingent Liabilities

  
	
  Schedule

  	
   

  	
  A

  	
  Loans

  

 

4

 

LOAN AGREEMENT

 

This Loan Agreement (this “Agreement”)
is made as of May 26, 2003 between Epix Medical, Inc. (“Epix”) and
Schering Aktiengesellschaft, Berlin, Germany (“Schering”).

 

WITNESSETH:

 

WHEREAS, Schering has agreed, subject to the
terms and conditions contained in this Agreement, to provide certain loans to
Epix in the maximum principal amount of Fifteen Million Dollars ($15,000,000).

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants herein contained, the parties hereto (the “Parties”)
hereby agree as follows:

 

1.               Definitions

 

1.1            Defined Terms. 
As used herein, the following terms shall have the following meanings
(such meanings to be equally applicable to both the singular and plural forms
of the terms defined):

 

“Advance” means
the making of any Loan by or on behalf of Schering hereunder.

 

“Affiliate” means any corporation,
firm, partnership or other entity which directly or indirectly controls or is
controlled by or is under common control with a Party to this Agreement. For
purposes of this definition, “control” means ownership, directly or through one
or more Affiliates, of fifty percent (50%) or more of the shares of the stock
entitled to vote for the election of directors, in the case of a corporation,
or fifty percent (50%) or more of the equity interests in the case of any other
type of legal entity, status as a general partner in any partnership, or any
other arrangement whereby a Party controls or has the right to control the
Board of Directors or equivalent governing body of a corporation or other
entity.

 

“Agreement” means this Loan Agreement,
as amended, supplemented, restated or otherwise modified from time to time  in writing by the Parties.

 

“Collateral” or “Secured Assets”
means all of the assets in which Epix has granted or does grant Schering a Lien
pursuant to the Security Agreement and/or any other Loan Document.

 

“Default Rate” means a rate of
interest equal to [*****] percent [*****] per annum in excess of the interest
rate or interest rates otherwise applicable at any time to any Loan.

 

“Document” means any contract, other
agreement, instrument, undertaking, other paper or writing or other document of
any kind or nature whatsoever.

 

5

 

“Equity
Interests” means any stock or other equity interest of any kind or nature
whatsoever.

 

“Exhibit” means all Exhibits attached
hereto and made a part hereof as if fully set forth herein.

 

“GAAP” means United States generally
accepted accounting principles as defined by controlling pronouncements of the
Financial Accounting Standards Board, as from time to time supplemented and
amended.

 

“Governmental Authority” means any
United States or foreign federal, national, state or local governmental authority,
agency, department or instrumentality or other regulatory body of any kind or
nature whatsoever, including any (i) court and (ii) that has jurisdiction in
whole or in part relating to the Products, including the right to issue,
condition, otherwise modify, withdraw or otherwise affect any Governmental
Authorization.

 

“Governmental Authorization” means any
permit, authorization, license or other approval of any kind or nature
whatsoever issued or issuable by any Governmental Authority.

 

“including” means “including, without
limitation”, “includes” means “includes, without limitation”, and “include”
means “include, without limitation”.

 

“Intellectual Property” means any
rights of any kind or nature in or to any patents, trademarks, service marks,
copyrights, trade secrets, processes, other proprietary rights, other
inventions, other know-how of any kind or nature whatsoever and other
intellectual property rights of any kind or nature whatsoever (including as to
each of the foregoing any rights obtained as a licensee or sublicensee),
including any applications to or for any of the foregoing.

 

“Interest Rate” means, with respect to
each Loan, the lesser of (a) a fluctuating interest rate per annum equal to
[*****] percent ([*****]) above the Prime Rate with changes in such fluctuating
rate to take effect with each change in the Prime Rate provided that following
the occurrence of an Event of Default, the interest rate applicable to each
Loan shall be immediately increased to the Default Rate and (b) the highest
rate of interest permitted from time to time by applicable law.

 

“Liabilities” means any liabilities,
contractual obligations, common law obligations, obligations arising under Law
or any other obligations of any kind or nature whatsoever, as determined in
accordance with GAAP.

 

“Lien” means any mortgage, security
interest, assignment, pledge, hypothecation, lien, conditional sale or other
title retention agreement, financing lease having substantially the same effect
as any of the foregoing, right, other preferential arrangement or other
encumbrance of any kind or nature whatsoever.

 

“Loan” or “Loans” means any
loan made by or on behalf of Schering to Epix relating to this Agreement.

 

6

 

“Loan Documents” means (i) this
Agreement, (ii) the Security Agreement, (iii) the Note and (iv) any Compliance
Certificates and/or Supplemental Certificates and the initial certificate
referred to in Section 3.1(h) hereof.

 

“Material Adverse Effect” means (i)
any material adverse change in Epix’ business, operations, properties or other
assets, results of operations or condition (financial or otherwise), (ii) any
other material adverse change in, or other material adverse event, occurrence
or other circumstance affecting, the Secured Assets or Schering’s interest
therein or the right or ability of Epix to manufacture or sell the Products, or
(iii) without limiting the generality of clause (i) or clause (ii) the
occurrence of any Order issued enjoining or otherwise prohibiting in any
material respect the manufacture or sale of any material Product or the
consummation of any other material transactions contemplated by the Research
Agreement.

 

“MRI” means magnetic resonance
imaging.

 

“Note” means that certain Promissory
Note of even date herewith, a copy of which is attached hereto as Exhibit B, as
amended, supplemented, restated or otherwise modified from time to time.

 

“Obligations” means (i) all of the
principal of and all of the interest on the Loans and (ii) all other monetary
and non-monetary obligations of Epix to Schering under the terms of this
Agreement and each other Loan Document.

 

“Order” means any injunction, writ, restraining order or other
similar order of any kind or nature of or by any Governmental Authority.

 

“Organizational Documents” means the
Documents related to the creation, organization and internal regulation of any
Person, including the certificate of incorporation or articles of
incorporation, as applicable, and by-laws, of any Person, each as amended and/or
restated.

 

“Person” means an individual, limited
liability company, corporation, partnership, business or other trust,
unincorporated association, joint venture, Governmental Authority or other
entity of any kind or nature whatsoever.

 

“Prime Rate” means the prime rate as
quoted by Bank of America on Reuters screen <USPRIME1> or, if none, by
another nationally recognized source reasonably selected by Schering and
reasonably acceptable to Epix.

 

“Proceeding” means any claim, demand,
proceeding, investigation or other action.

 

“Products” means products using MRI
technology that the Parties desire to sell.

 

“related to” means “arising out of, in
connection with or otherwise related to”, “relates to” means “arises out
of, is in connection with or otherwise relates to” and “relate to” has a
substantially similar meaning.

 

7

 

“Research Agreement” means the
Collaborative Research Agreement in the form of Exhibit A, as amended,
supplemented, restated or otherwise modified from time to time, providing for,
among other things, a joint collaboration by Epix and Schering with respect to
the development and commercialization of new technology and products for use in
magnetic resonance imaging.

 

“SEC” means the Securities and
Exchange Commission.

 

“Security Agreement” means the
Security Agreement in the form of Exhibit C, as amended, supplemented, restated
or otherwise modified from time to time, providing for, among other things, a
grant by Epix to Schering of a first priority Lien in the Secured Assets.

 

“Subsidiary” means any Person in which
Epix directly or indirectly owns fifty percent (50%) or more of (i) the Equity
Interests generally entitled to vote on matters and/or (ii) the Equity
Interests.

 

“Transaction Documents” means this
Agreement, the Research Agreement and all of the other Loan Documents.

 

“UCC” means the Uniform Commercial
Code as in effect from time to time in the State of New York.

 

1.2            Other Definitional Provisions.  The words “hereof”, “herein”, “hereto” and
“hereunder” and words of similar import when used in this Agreement shall refer
to this Agreement as a whole and not to any particular provision of this
Agreement.  Section, Subsection,
Schedule and Exhibit references are to this Agreement unless otherwise
specified.  Amendments and modifications
each include extensions, consolidations, renewals or replacements.  In addition, the following terms are defined
herein.

 

	
  Section

  	
   

  	
  Defined Terms

  
	
  ¶1

  	
   

  	
  Agreement

  
	
  §2.2(c)

  	
   

  	
  Business Day

  
	
  §7.12

  	
   

  	
  Change of Control

  
	
  §4.5

  	
   

  	
  Commission Reports

  
	
  §3.2(b)

  	
   

  	
  Compliance Certificate

  
	
  §4.6

  	
   

  	
  Environmental Laws

  
	
  ¶1

  	
   

  	
  Epix

  
	
  §7

  	
   

  	
  Event of Default

  
	
  §4.5

  	
   

  	
  Exchange Act

  
	
  §2.2(b)

  	
   

  	
  FDA

  
	
  §3.1

  	
   

  	
  Initial Loan

  
	
  §4.3

  	
   

  	
  Law

  
	
   

  	
   

  	
   

  
	
  §2.1

  	
   

  	
  Maximum Principal Amount of Loans

  
	
  §2.2(b)

  	
   

  	
  NDA

  
	
  ¶1

  	
   

  	
  Parties

  

 

8

 

	
  Section

  	
   

  	
  Defined Terms

  
	
  §4.17

  	
   

  	
  Requested Loan

  
	
  ¶1

  	
   

  	
  Schering

  
	
  §2.2(b)

  	
   

  	
  Strategic Collaboration Agreement 

  
	
  §3.2(a)

  	
   

  	
  Supplemental Certificate

  
	
  §7.10

  	
   

  	
  Undismissed

  

 

2.               The Loans; Payment of Principal and
Interest; Related Matters.

 

2.1                                 Maximum Principal Amount of Loans; Other
Provisions Re: the Loans.  Subject
to all of the terms and conditions of this Agreement, including the conditions
precedent hereto, (a) Schering agrees to lend to Epix up to Fifteen Million
Dollars ($15,000,000) (the “Maximum Principal Amount of Loans”) and (b)
the Loans shall be made by Schering to Epix at the times provided for in this
Article II.  The Loans shall be payable
in accordance with the terms of this Agreement and the Note.  Anything to the contrary notwithstanding in
this Agreement, the Parties agree that 
(a) to the extent any Loan is repaid, such amount may be borrowed again
and (b) Schering shall have no obligation to provide any Loans on or after the
earliest of any of the following occur: (A) an Event of Default occurs and/or
(B) the Research Agreement is terminated for any reason, other than as the result of a breach by Schering
pursuant to Section 8.2 of the Research Agreement or an early termination
for convenience
by Schering pursuant to Section 8.2.3 of the Research  Agreement.  Schering shall not be obligated to make Loans
to or on behalf of Epix in amounts which, when aggregated, exceed the Maximum
Principal Amount of Loans.

 

2.2                                 Procedures for Disbursements of
Funds.  Subject to the other
provisions of this Agreement:

 

(a)                                  On
or following the date hereof, Epix may, from time to time, submit to Schering a
written request for a Loan in a principal amount not less than $[*****]
provided that the principal amount outstanding under this Agreement shall not
exceed $7.5 million, except as specified in Section 2.2(b) below.

 

(b)                                 Upon or following
the one (1) year anniversary of the date hereof, Epix may, from time to time,
submit to Schering a written request for a Loan in a principal amount not less
than $[*****] such that the principal amount outstanding under this Agreement
shall not exceed $15 million; provided, however, that Schering shall have no
obligation to make any Loan(s) in excess of the initial $7.5 million and Epix
agrees not to request any such Loan(s) if (i) Epix has received a
“non-fileable” letter relating to its submission of a new drug application
(“NDA”) for Compound MS-325 (as defined in the Strategic Collaboration
Agreement by and between Epix and Schering, dated as of June 9, 2000, as
thereafter amended from time to time (the “Strategic Collaboration Agreement”))
from the U.S. Food and Drug Administration (“FDA”) on or before March 1, 2004,
and (ii) Epix has not, at the time of requesting such Loan, received a
“fileable” letter with respect to such NDA.

 

9

 

(c)                                  Epix
shall be limited to submitting requests for Loans pursuant to Section 2.2(a)
and (b) and to making repayments of Loans pursuant to Section 2.4 hereof an
aggregate number of [*****] times per annum. 
Schering shall, subject to the other provisions of this Agreement, make
the Loan requested by Epix within five (5) Business Days (defined as any day,
other than a Saturday or Sunday, on which federally chartered banks in the
United States and Germany are open for business) after the receipt by Schering
of a request for funds meeting the requirements of this Agreement.  Upon disbursements to Epix by Schering of
any funds under this Agreement, Schering may, at its election, present the Note
to Epix for notation on Schedule A attached hereto of any additional principal
amount outstanding as a consequence of the Loan by Schering.

 

2.3                                 Interest Calculations.

 

(a)                                  The
Loans shall bear interest at the Interest Rate.  Interest shall accrue from the date each such Loan is made.  Interest on the Loans shall be calculated on
a daily basis on the basis of a 360 day year, and on the basis of the actual
days elapsed, upon the outstanding principal balance, including by reason of a
deferred payment because the scheduled or actual payment date is not a Business
Day.

 

(b)                                  Without
limiting the generality of the term Interest Rate, if the interest rate
calculated in accordance with any provision of this Agreement for any Loan
(including any application of the Default Rate) would at any time exceed the
maximum permitted by the law of the State of New York, then for such period as
such rate would exceed the maximum permitted by such Law (and no longer) the
rate of interest payable on any such Loan shall be reduced to the maximum
permitted by the law of the State of New York and any interest payments
received in excess of such maximum rate shall be repaid to Epix.

 

2.4                                 Payment of Principal and Interest.

 

(a)                                  Payment
of Interest.  All interest accruing
under Section 2.3 on any Loan shall be payable to Schering from time to time on
the earliest of each of the following: 
(i) five (5) Business Days after each anniversary of the Note, (ii) on
any day on which any payment of principal by Epix is made in whole or in part
and (iii) on any other day in which any payment of principal is required to be
made in whole or in part, including by reason of any acceleration of the Loans
provided that to the extent that Schering has not accelerated the Loans and
principal is payable, paid or required to be paid in part, then the interest
payable pursuant to this Section 2.4 shall relate only to such principal.

 

(b)                                 Payment
of Principal.  The principal of the
Loans shall be paid to Schering from time to time on the earliest of each of
the following times: (i) (A) principal shall be paid such that the maximum
principal amount outstanding hereunder shall be reduced to $7.5 million  on May 15, 2007 and to zero on May 15,
2008; and (B) notwithstanding clause (A), if the term of the Research Program
under the Research Agreement is extended by mutual written agreement for an
additional two (2) years pursuant to Section 2.1 of the Research Agreement,
principal shall be paid such that the maximum principal amount outstanding
under this Agreement shall instead be reduced to $7.5 million  on May 15, 2009 and to zero on May 15,
2010, respectively, (ii) the

 

10

 

date that Schering declares an acceleration of the Loans pursuant to an
Event of Default and (iii) at such other times as is or may be provided
elsewhere in this Agreement or in the Note. 
Schering shall have the right, but not the obligation, to include as an
Exhibit to the Note a grid which identifies the payments made and any such
indications or other determinations by Schering relating thereto shall
conclusively be deemed correct except to the extent of any manifest error.  Anything to the contrary in this Agreement
notwithstanding, all principal of the Loans and all accrued and unpaid interest
thereon shall be repaid no later than May 15, 2008 (or, if applicable, pursuant
to Section 2.4(b)(i)(B), May 15, 2010). 
Upon any repayment by Epix to Schering from time to time of any Loans
under this Agreement, Schering may, at its election, present the Note to Epix
for notation on Schedule A attached thereto of any reduction in principal
amount outstanding as a consequence of such repayment.

 

(c)                                  Other
Provisions Relating to Payment of Principal and Interest.  All payments of principal and interest shall
be paid in United States dollars and made by wire transfer of immediately
available funds to an account designated from time to time by Schering in
writing.  Notwithstanding any other
provisions of this Agreement to the contrary, all Loans shall be immediately
due and payable, together with all accrued interest thereon, upon the
declaration of an Event of Default by Schering and acceleration of any Loans by
Schering in accordance with the terms of this Agreement.

 

2.5                                 Other Provisions.  If the outstanding principal amount or the accrued interest under
this Agreement are not paid when due by Epix, without demand, presentment or
notice by Schering of any kind (all of which are expressly waived by Epix to
the extent permitted by applicable law), as and when due in accordance with
this Article II and Article VIII, then, in addition to any other rights or
remedies Schering may have in accordance with the terms hereof, Schering shall
have the right, effective upon written notice to Epix, to withhold and retain,
as an offset against principal and interest due hereunder, up to one hundred
percent (100%) of:

 

(a)                                  the
royalty payments due in accordance with Sections 7.7 and 7.8 of the Strategic
Collaboration Agreement, for any given calendar quarter otherwise payable by
Schering to Epix, and

 

(b)                                 of
the operating margin payments in the U.S. in accordance with Section 7.6 of the
Strategic Collaboration Agreement, for any given calendar quarter otherwise
payable by Schering to Epix, until such time as all outstanding amounts of
principal and interest hereunder are completely paid.

 

2.6                                 Payments by Epix.  All payments (including prepayments) to be made by Epix hereunder
on account of principal, interest or otherwise shall be made to Schering
without deduction, set-off or counterclaim of any kind or nature whatsoever,
including any valid or alleged claims of Epix pursuant to the Research
Agreement, unless otherwise agreed to in writing by Schering and except as
otherwise provided in Section 2.5 above. 
Notwithstanding the preceding sentence, Epix may set off any such
amounts to the extent it has obtained a final non-

 

11

 

appealable judgment against Schering for a fixed amount from a court of
competent jurisdiction, it being agreed that Epix may not set off for more than
such fixed amount.

 

2.7                                 Termination.  This Agreement may be terminated by Epix at
any time upon written notice to Schering and repayment of the Obligations in
full in accordance with the terms of this Agreement.  Upon any such termination, Schering agrees to (i) file within
five (5) Business Days of written notice such UCC termination statements as
shall be necessary to terminate any Liens upon the Collateral, and (ii) promptly
return the original Note to Epix marked “cancelled”.

 

3.                                       Conditions Precedent.

 

3.1                                 Conditions Precedent to the Initial
Loan.  The agreement of Schering
to make each Loan, including the first loan to be made after the date hereof
(the “Initial Loan”), is subject to the satisfaction, or written waiver
by Schering, concurrently with the making of each such Loan (except as
otherwise specified herein), of the following conditions precedent:

 

(a)                                   Research
Agreement.  The Parties shall have
executed and delivered the Research Agreement.

 

(b)                                 Security
Agreement, Etc.  Schering shall have
received each of the Security Agreement and the Note, each duly executed and
delivered by, as applicable, a duly authorized officer of Epix.

 

(c)                                  Perfection
of Liens.  All actions reasonably
requested by Schering to assure that it has, and will continue to have, until
the final and indefeasible payment in full of the Loans, a perfected first
priority security interest and Lien  in all of the Collateral shall have been
effected and Schering shall have received evidence reasonably satisfactory to
it that all such actions have been effected in all respects, including the
proper filing and indexing of applicable UCC-1 financing statements covering
the Collateral.

 

(d)                                 Representations
and Warranties.  The representations
and warranties contained in this Agreement and each other Transaction Document
by each Person that is a signatory thereto (other than Schering or any
Affiliate of Schering) shall be true and correct in all material respects (and
as to those representations and warranties containing materiality
qualifications shall be true and correct) on and as of the date the Initial
Loan is provided as if such representations and warranties were made on such
date, unless such representation or warranty specifically refers only to a
prior date or unless such representation or warranty has been affected by an
occurrence which is permitted by the terms of this Agreement, such occurrence
to be notified by Epix to Schering.

 

(e)                                  No
Material Adverse Effect.  As of the
date of execution of this Agreement, since December 31, 2002 there shall not
have occurred any Material Adverse Effect.

 

(f)                                    Receipt
of Other Transaction Documents.  All
of the other Transaction Documents, in form and substance reasonably
satisfactory to Schering, shall have been properly executed by each Party
thereto and delivered to Schering.

 

12

 

(g)                                 Financing
Statement Searches and Similar Searches. 
Schering shall have received UCC-1 financing statement searches and
other searches and such other evidence as Schering reasonably requires to show
that there are no Liens in the Collateral.

 

(h)                                 No
Event of Default or Material Default; Compliance Certificate.  There shall be no Event of Default or
material default, which, with or without notice or the lapse of time or both,
would become an Event of Default, and Schering shall have received a
certificate, in form and substance reasonably satisfactory to Schering, signed
by the chief financial officer of Epix dated as of the making of the Initial
Loan, stating that to his or her actual knowledge (after reading the
Transaction Documents for the purpose of providing such Certificate) (i) all
representations and warranties made by Epix set forth in this Agreement and the
other Transaction Documents are true and correct on and as of such date (unless
such representation or warranty specifically refers to only a prior date or
unless such representation or warranty has been affected by an occurrence which
is permitted by the terms of this Agreement, such occurrence to be notified by
Epix to Schering), (ii) on such date, after giving effect to the Initial Loan,
Epix is in compliance in all material respects with all the terms and
provisions set forth in this Agreement and the other Transaction Documents and
(iii) on such date no Event of Default or other material default, which, with
or without notice or the lapse of time or both, would become an Event of
Default has occurred and is continuing, and such statements shall be true and
correct.

 

(i)                                     No
Order; Status of Collateral.  No
Order shall have been issued by any Governmental Authority enjoining or
otherwise prohibiting, in any material respect, the consummation of the
transactions contemplated by the Research Agreement and/or no material patent
(owned or licensed) constituting Collateral shall be determined to be invalid
in a final nonappealable judgment.

 

(j)                                     Corporate
Documents.  Schering shall have
received with respect to Epix and any other parties to the Transaction
Documents copies of their relevant proceedings relating to the transactions
contemplated hereby and thereby, incumbency certificates, copies of
Organizational Documents, good standing certificates, and similar Documents as Schering
reasonably requests, and all such Documents shall be in form and substance
reasonably satisfactory to Schering.

 

3.2                                 Conditions Precedent to All Loans.  The obligation of Schering to make any Loan
after the Initial Loan is subject to the satisfaction of each of the following
conditions precedent as of the date of the making of each such Loan:

 

(a)                                  Representations
and Warranties.  The representations
and warranties made by Epix in or pursuant to this Agreement and in any other
Transaction Document shall be true and correct in all material respects (and as
to those representations and warranties containing materiality qualifications,
shall be true and correct) on and as of the dates the Loan is requested to be
provided and is provided as fully as if made on and as of each such date (or if
expressly applicable only to an earlier date, such as financial statements, as
of such date or unless such representation or warranty has been affected by an
occurrence which is permitted by the terms of this Agreement, such occurrence
to be notified by Epix to Schering); provided, however, Epix

 

13

 

may provide a supplement that is attached to and cross referenced in
the Compliance Certificate for events occurring after the date hereof that
cause such representations and warranties to not be true (“Supplemental
Certificates”), provided further that the condition in this Section shall
not be deemed satisfied if (i) the items contained in any one or more such
Supplemental Certificates individually or in the aggregate do or will have or,
in Schering’s reasonable good faith judgment may be expected to have, a
Material Adverse Effect or (ii) the events or circumstances relating to any
such items also relate to a material breach or other default by Epix or any
Affiliate of Epix under any Transaction Document.

 

(b)                                 No
Event of Default or Material Default; Compliance Certificate.  There shall be no Event of Default or
material default, which, with notice or the lapse of time or both, would become
an Event of Default, and, in addition, Schering shall have received a
certificate, in form and substance reasonably satisfactory to Schering, signed
by the chief financial officer of Epix, dated as of the making of the Loan (the
“Compliance Certificate”), stating that to his actual knowledge (after
reading the Transaction Documents for the purposes of providing the Compliance
Certificate), (i) all representations and warranties made by Epix in this
Agreement and the other Transaction Documents are true and correct in all
material respects on and as of such date, after giving effect to the
Supplemental Certificate attached thereto, (ii) on such date Epix is in
compliance in all material respects with all the terms and provisions set forth
in this Agreement and the other Transaction Documents and (iii) on such date no
Event of Default or material default, which with or without notice or the
passage of time or both will become an Event of Default, has occurred and is
continuing, and the statements therein shall be true and correct.

 

(c)                                  Research
Agreement.  The Research Agreement
shall have not been terminated as a result of breach by Epix or a termination for convenience by
Epix.

 

(d)                                 No
Order; No Judgment.  No Order shall
have been issued by any Governmental Authority enjoining or otherwise
prohibiting, in any material respect, the manufacture or sale of any material
Product or the consummation of the other transactions contemplated by the
Research Agreement.

 

(e)                                  Status
of Collateral.  No material patent
(owned or licensed) constituting Collateral shall be determined to be invalid
in a final nonappealable judgment.

 

(f)                                    Financing
Statement Searches and Similar Searches. 
Schering shall have received UCC-1 financing statement searches and
other searches and such other evidence as Schering reasonably requires to show
that there are no Liens in the Collateral in favor of any Person other than
Schering.

 

The request by or on behalf of Epix for each
Loan and making of each Loan by Schering hereunder shall constitute a
representation and warranty by Epix as of the date of such request for
borrowing and the date of the making of the Loan that the conditions in
Sections 3.1 (with respect to the Initial Loan) and 3.2 (with respect to each
Loan after the Initial Loan) have been satisfied.

 

14

 

4.               Representations and Warranties.

 

Epix represents and warrants to Schering,
knowing and intending that Schering will rely thereon in making each Loan, that
the following statements are true and accurate:

 

4.1                                 Organization and Qualification.  Epix is a corporation duly organized,
validly existing and in good standing under the laws of the State of
Delaware.  Epix has the power and
authority, and all necessary Governmental Authorizations, to own, lease,
operate and encumber its assets and to carry on its business as now
conducted.  Epix is duly qualified and
in good standing in each jurisdiction where such qualification is required, except
for any qualifications not obtained which would not be reasonably expected to
have a Material Adverse Effect on Epix.

 

4.2                                 Due Authorization.  The execution, delivery and performance by Epix of this Agreement
and the other Transaction Documents are within Epix’s power and authority, and
have been duly authorized by all necessary action on the part of Epix.  Epix has delivered to Schering true and
complete copies of Epix’s resolutions necessary to authorize the transactions
contemplated by this Agreement and the other Transaction Documents and of Epix’s Organizational
Documents in effect on the date of the Initial Loan, all certified by a duly
authorized officer of Epix.

 

4.3                                 No Default; Compliance with Laws.  The execution, delivery and performance by
Epix of this Agreement and the other Transaction Documents do not and will not
(i) violate any of Epix’s
Organizational Documents, and/or any material United States or foreign
federal, state or local regulation, rule, statute, ordinance, judicial decision
or other law of any kind or nature whatsoever, including any Order of any
Governmental Authority applicable
to Epix or its assets (collectively, “Law” or “Laws”),
(ii) constitute a material default
under (including a breach of) any Document filed by Epix with the SEC to
which Epix is a Party or by which Epix or its assets is subject or bound (any
consents required thereby having previously been obtained), after giving effect to any
applicable grace periods thereto, or (iii) result in the
imposition of any Lien, including any restriction on any assets of Epix (except
for the Liens granted to Schering, and the restrictions in favor of Schering,
contained in this Agreement and the other Loan Documents).  Except for defaults which individually or in
the aggregate are not material, Epix is not in default under any Document to
which it is a party or by which it or its assets is otherwise bound or
subject.  This Agreement and each
Transaction Document to which Epix is a party or to which Epix or its assets is
subject or bound has been duly executed and delivered on behalf of Epix and
are, and as to those Transaction Documents to which Epix hereafter becomes a
party, subject or bound will be, legal, valid and binding obligations of Epix,
enforceable against Epix in accordance with their respective terms.

 

4.4                                 No Required Governmental
Authorizations.  No Governmental
Authorization is required by, and no other action is required by, and no notice
or filing is required to be given to or made with, any Governmental Authority
or other Person for the due execution, delivery and performance by Epix of, or
for the validity or enforceability of, this Agreement or any other Transaction
Document.

 

15

 

4.5                                 Commission Filings; NASDAQ
Listing.  Epix has heretofore
delivered to Schering true and complete copies of its (i) Annual Report on Form
10-K for the fiscal year ended December 31, 2002, (ii) Quarterly Report on Form
10-Q for each of the fiscal quarters ended March 31, June 30 and September 30,
2002, (iii) Proxy Statement for the annual meeting of stockholders held in
2002, and (iv) all other reports, filings on Form 8-K and registration
statements filed by Epix with the SEC since December 31, 2001, in
each case as filed with the Commission. 
Epix has filed all required forms, reports and documents with the
Commission since December 31, 2001 (collectively, the “Commission Reports”),
all of which were prepared in accordance with the applicable requirements of
the Securities Act of 1933, as amended, and the rules and regulations
thereunder and the Securities Exchange Act of 1934, as amended together with
the rules and regulations thereunder (the “Exchange Act”) in all
material respects.  Except to the
extent, if any, as may be disclosed in any Commission Report filed subsequent
thereto, as of their respective dates, the Commission Reports, including any
financial statements or schedules included therein, did not contain any untrue
statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, and complied as to
form and substance in all material respects with all applicable Laws.  Each of the financial statements (including,
in each case, any related notes thereto) contained in the Commission Reports
has been prepared in accordance with GAAP (except as may be indicated
in the notes thereto), and each fairly presents in accordance with generally
accepted accounting principles the financial position of Epix as at the
respective dates thereof and the results of its operations and changes in cash
flow for the periods indicated, except as may be indicated in the notes thereto
and/or in any Commission Report subsequent thereto, and except that the
unaudited interim financial statements are subject to normal and recurring
year-end adjustments which were not and are not expected to be material in
amount.  As of the date hereof, except
for Liabilities shown in the balance sheet of Epix as at December 31, 2002,
including the notes thereto (the “2002 Balance Sheet”), or incurred in
the ordinary course of business since the date of such Balance Sheet, Epix does
not have any material Liabilities.  Epix
does not have any material contingent Liabilities, except as set forth on
Schedule 4.5 hereof.

 

4.6                                 Intellectual Property.  The representations and warranties of EPIX
set forth in the Security Agreement are true and complete, and are incorporated
herein by reference in their entirety.

 

4.7                                 No Material Adverse Effect.  As of the date of execution of this
Agreement, since December 31, 2002 there has not been, and Epix has not
suffered or otherwise incurred, a Material Adverse Effect.

 

4.8                                 Perfected First Priority Liens.  The security interest and other Liens
granted in the Collateral by Epix constitute first priority Liens in the
Collateral in favor of Schering.  No
Intellectual Property (or any rights thereto) relating to MRI is owned by or
licensed to any Subsidiary or Affiliate of Epix.  No Person other than Schering has any Liens in the Collateral.
Epix acknowledges that any Liens against the Collateral in favor of
any Person other than Schering would constitute a violation of Article VI
hereof.

 

16

 

4.9                                 Title; Absence of Liens.  Epix has good and marketable title to all of
the Collateral.  None of the Collateral
is subject to any prohibition against encumbering, pledging, hypothecating or
assigning the same or requires notice or consent (except where consent has been
previously and properly obtained) in connection therewith.

 

4.10                           Compliance With Laws.  Epix is in compliance in all material
respects with all Laws
applicable to Epix or the conduct of its business or the ownership of the
Collateral.  Epix has not
received any written notice
alleging any violation of any such Laws.

 

4.11                           No Proceedings. 
As of the date of execution of this Agreement, there are no Proceedings
of any kind or nature whatsoever, including any before any arbitrator or
Governmental Authority, pending or, to Epix’s knowledge, threatened against
Epix that may, individually or in the aggregate, be reasonably expected to have a
Material Adverse Effect.  All material
pending or threatened Proceedings are described in Epix’s December 31, 2002
Annual Report on Form 10-K, in the footnotes to the financial statements.

 

4.12                           Delivery of Documents.  All originals or copies of Transaction
Documents and Documents relating to the Secured Assets provided by or on behalf
of Epix to or on behalf of Schering are true, correct and complete.

 

4.13                           No Violations; Taxes and Assessments.  Epix is not in, and no event or condition
has occurred and is continuing which constitutes or results in (in each case
with or without the giving of notice, lapse of time or both), (a) a default
under any term of its Organizational Documents or under any Document filed by Epix with the SEC to
which Epix is a party or by which Epix or any of its assets is subject or
bound, except for defaults which will not have, and could not reasonably be
expected to have, individually or in the aggregate, a Material Adverse Effect,
or (b) the imposition of any Lien or restriction on any Secured Asset.  Epix has filed all material federal, state
and local tax returns and other tax reports it is required to file (or has
obtained valid, written extensions which are in full force and effect as to any
not so filed), except
where the failure to do so would not be reasonably expected to have a Material
Adverse Effect.  Epix
has paid all taxes, assessments and other governmental charges due and payable, except those
contested in good faith and has made adequate provision for the payment of such
taxes, assessments and charges accrued but not yet payable or contested in good
faith.

 

4.14                           Environmental Matters.  Without limiting the generality of the other
provisions of the Agreement, (a) Epix has been and is in compliance with (i)
all Laws relating to environmental conditions or other environmental matters of
any kind or nature (“Environmental Laws”) (including that there has been
no release of any hazardous materials by Epix that has not been in
compliance in all material respects with applicable Environmental Laws)
and (ii) all Governmental Authorizations that are required pursuant to
Environmental Laws and (b) there are no claims relating to any actual or
alleged environmental Liabilities pending against or, to Epix’s knowledge,
threatened against it, except for any non-compliance and/or claims which will
not have or could not be reasonably expected to have, individually or in the
aggregate, a Material Adverse Effect.  To Epix’s knowledge, Epix
is not subject to any material Liability relating to any environmental
condition or other environmental matter of any kind or nature, including any
past or present use, management, transport, treatment, generation, storage,
disposal, release or

 

17

 

other handling of any hazardous materials, which could be reasonably expected
to have a Material Adverse Effect.

 

4.15                           Other Representations.  No part of Epix’s business is conducted
through any unincorporated association or other Person.  Epix has not, within the five (5) years
preceding the date of this Agreement (a) changed its name, (b) used any name
other than Epix Medical, Inc., or (c) merged or consolidated with, or acquired
all or substantially all of the assets of, any other Person or business.  No part of the proceeds of any Loan will be
used, directly or indirectly, to purchase or carry any “margin stock” (as defined
in Regulation U issued by the Board of Governors of the Federal Reserve
System), to extend credit to others for the purpose of purchasing or carrying
any such margin stock, or for any other purpose that violates any provision of
Regulations G, T, U or X issued by the Board of Governors of the Federal
Reserve System.  Epix is not an
“investment company” registered or required to be registered under the
Investment Company Act of 1940, as amended, nor is Epix controlled by any such
entity.

 

4.16                           Representations and Warranties
Applicable to Subsidiaries.  All
of the representations and warranties made, or hereafter reaffirmed or deemed
made or reaffirmed, apply to each then existing Subsidiary of Epix, as fully in
all respects as if each representation or warranty specifically so stated.

 

4.17                           Reaffirmation. 
All of the
representations, warranties and statements made herein shall survive until
the full and final and indefeasible payment of the principal of and interest on
the Loans.  Epix’s requesting any Loan
hereunder (“Requested Loan”) and/or Epix’s acceptance of each Loan under
this Agreement shall each automatically constitute, without any further action
of any kind or nature whatsoever on the part of Epix, a complete reaffirmation,
as of the date of each Requested Loan and/or the making of each such Loan, of
the representations and warranties set forth in this Agreement and in the other
Loan Documents and the Research Agreement (or, as to those representations and
warranties expressly applicable only to any earlier date, such as financial
statements, as of such date) as fully as if all such representations were fully
repeated in all respects.  Schering’s
requiring or not requiring from time to time a Compliance Certificate
confirming same shall not in any manner diminish each such deemed reaffirmation
or otherwise change the effect of the preceding sentence.

 

5.                                       Affirmative Covenants.

 

Epix covenants and agrees that, until the
later of (i) full and final payment of the principal of the Loans and all
interest thereon and all other payment obligations under this Agreement and
(ii) the expiration of any obligation by Schering to make any further Loans to
Epix, Epix shall, and shall cause its Subsidiaries to:

 

5.1                                 Maintenance. 
Maintain and preserve in full force and effect its existence and good
standing and all other rights, powers, franchises, licenses and qualifications
necessary for its ownership, lease or use of its assets and/or the conduct of
its business, shall pay before they become delinquent all taxes, assessments
and governmental charges lawfully imposed upon it or any of its assets or
required to be collected by it, and shall pay, when due, all other Liabilities of

 

18

 

any kind or nature now or hereafter owing by it provided that Epix may
delay the payment of any such
Liabilities contested in good faith by it.

 

5.2                                 Condition of Collateral; No Liens;
Maintenance of Certain Collateral.  Preserve the Collateral from loss, damage, or destruction of any
kind or nature whatsoever, and keep the Collateral free and clear of any Lien,
except the Liens created by the Security Agreement and each other Loan Document and for licenses of the Collateral in
the ordinary course of business.  In addition, Epix shall, to the extent required by the payment
terms herein and/or therein and except as may otherwise be provided for in any
other Loan Document, pay to Schering all Proceeds of Collateral (as defined in
the Security Agreement), whereupon such Proceeds shall become Schering’s sole
property to the extent of the Obligations.

 

5.3                                 Compliance with Laws.  Comply in all material respects with all
applicable Laws.

 

5.4                                 Affirmative Financial Covenants.  Maintain gross cash and cash equivalents
exceeding US$2,000,000 at any time.

 

5.5                                 NASDAQ
Listing.  Maintain listing with
NASDAQ national market as long as any principal or interest under the Loans has
not been repaid.

 

5.6                                 Notice of Adverse Events.  Promptly notify Schering in writing of the
occurrence or existence of any of the following:  (a) any Event of Default, any material default which, with the
giving of notice, lapse of time or both, would become an Event of Default, or
any other event, circumstance or condition which constitutes, or would reasonably be
expected to in the future constitute or cause, a Material Adverse Effect; (b)
any material, adverse
Proceeding that relates to any of the Secured Assets filed or instituted by or
against it, or to its knowledge threatened by or against it, which would be reasonably expected to
have a Material Adverse Effect, and (c) any of the
representations and warranties by it contained in this Agreement or any other
Loan Document ceases to be materially true, correct and complete (or true,
correct and complete as to representations and warranties qualified by
materiality).

 

5.7                                 Financial Statements and Other
Information.  Deliver to
Schering the following documents and information (a) as soon as same is
reasonably available, but not more than forty-five days after the end of each
fiscal quarter (90 days after December 31), its Annual Report on Form
10-K, and its Quarterly Report on Form 10-Q, as each is filed under the
Exchange Act, (b) contemporaneously with its being filed with the SEC, a copy
of all reports on Form 8-K, and (c) as soon as practicable, except as legally
prohibited, copies of all such financial statements and reports as it shall
send to its stockholders, the SEC or any other similar
regulatory authority, to the extent any such reports furnished to any such
regulatory authority are not confidential. 
For purposes
hereof, the written notice to Schering of the filing of any of the foregoing
reports with the SEC shall be deemed delivery to Schering hereunder.  As of their respective
dates, such reports (including the financial statements contained therein),
will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they are made, not
misleading, and will comply in all material respects with all applicable
Laws.  Within fifteen (15) days after
the end of each quarter, and otherwise promptly upon Schering’s request,

 

19

 

Epix shall provide to Schering (a) a certificate executed by an
executive officer of Epix reasonably satisfactory to Schering stating that to
his or her actual knowledge there then exists no Event of Default hereunder,
and no material default or other event, circumstance or condition which, with
the giving of notice or lapse of time or both, would constitute an Event of
Default and/or (b) such other Documents or information as Schering may
reasonably request in connection with the Loans.  At any time and from time to time upon three (3) Business Days
notice by Schering and for the sole purpose of permitting Schering to determine
compliance with the provisions of this Agreement and the other Transaction
Documents and/or to assess the value of the Collateral, Epix shall give
Schering and/or any representative of Schering access during normal business
hours to inspect any of the Collateral and Documents that relate to the
Collateral and to examine, copy and make abstracts from any and all books,
records and Documents relating to the Collateral in the possession of Epix, subject to such confidentiality
covenants as Epix may reasonably require.

 

5.8                                 Other Provisions. 
Epix will from time to time, take such further actions, including the
execution and delivery of such Documents, as Schering may reasonably request in
order to carry out the purposes of this Agreement and the other Transaction
Documents (including to provide Schering with a first priority perfected lien
in the Collateral).  Epix agrees that
(a) Schering may, so long as same is consistent with the Security Agreement,
file UCC-1 financing statements in any office Schering reasonably elects; and
(b) Epix shall maintain complete and accurate books and records in accordance with GAAP
of all its operations and assets, including records of the Collateral.

 

6.                                       Negative Covenants

 

Any of the financial thresholds mentioned in
this Section 6 shall relate in aggregate to Epix including its subsidiaries.

 

Epix covenants and agrees that, until the
later of (i) full and final payment of the principal of the Loans and all
interest thereon and all other payment Obligations under this Agreement and the
other Loan Documents,
and (ii) the expiration of any obligation by Schering to make any further Loans
to Epix, Epix shall not, directly or indirectly, and will not permit any of its
Subsidiaries to, directly or indirectly:

 

6.1                                 Amendments of Documents.  Amend, supplement, restate or otherwise
modify (including terminate) any Document that constitutes a Secured Asset  if such amendment, supplement,
restatement or other modification would be reasonably expected to have a
Material Adverse Effect.

 

6.2                                 Consolidation, Merger, or Acquisitions;
Liquidation.  Enter into any merger,
consolidation, reorganization or recapitalization or sale of all or substantially
all of its assets without the prior written consent of Schering, which will not
be unreasonably withheld, other
than (i) a merger in which Epix is the surviving corporation, or (ii) a merger
in which the surviving corporation (other than Epix) expressly assumes its
obligations under this Agreement and the other Transaction Documents in writing
and agrees to be bound hereby and thereby; provided that the
consummation of such merger mentioned under (i) and (ii) shall not result in a

 

20

 

breach of Sections 6.5 and 6.7 below by the surviving company; and
provided further that it is agreed that Schering may for any reason withhold
its consent to any such transaction that would result in a Change of Control of
Epix (except as
permitted in Section 7.12); or take any steps in
contemplation of dissolution or liquidation.

 

6.3                                 Other
Liens.  Create or permit to
exist any Lien upon or with respect to any of the Collateral, whether now owned
or hereafter acquired.

 

6.4                                 Disposition of Assets or Collateral.  Sell, lease, or in any manner whatsoever
otherwise transfer or dispose of (including by granting any license therein) all or any Collateral
in the Field (as that term is defined in the Strategic Collaboration Agreement)
to any Person, except
upon notice to Schering, licenses of the Collateral in the ordinary course of
business.   Nothing
contained herein shall preclude any grants outside the Field.

 

6.5                                 Other Liabilities.  Incur, create, assume or permit to exist any indebtedness or
other Liability on account of borrowed money except (a) Obligations to
Schering, (b) loans from third parties in order to repay the outstanding
principal under the Loans and interest thereof, provided that such third party
loan amount (including principal and interest) shall not exceed the outstanding
principal and interest under the Loans, (c) accounts payable less than ninety
(90) days and accrued expenses of Epix incurred in the ordinary course of
business, and (d) Liabilities that do not exceed,
individually or in the aggregate, Fifteen Million Dollars ($15,000,000).

 

6.6                                 Loans or Investments.  Make or agree to make any loans, advances (other than prepaid expenses) or
other extensions of credit of any kind or nature to, or any investments of any
kind or nature in, any Person (including any Subsidiary) in an aggregate amount
for all Persons not to exceed [*****] at one or more times for all such loans,
advances and investments, provided that no such advance, loan or
investment shall be made at any time that any Event of Default has occurred and
is continuing, or any material default or other material event or condition
which, with the giving of notice, the lapse of time or both would constitute an
Event of Default, shall have occurred and be continuing.  Notwithstanding the foregoing, Epix may make
short-term investments in instruments consistent with Epix’s Investment Policy in the form
attached as Exhibit D, as the same may be amended, restated or modified from
time to time in form reasonably acceptable to Schering and upon approval of
Epix’s Audit Committee.

 

6.7                                 Guaranties; Contingent Liabilities.  (a) Assume, guarantee, endorse, contingently
agree to purchase or otherwise become liable for the obligations of any Person
other than any Subsidiary, except (i) by the endorsement of
negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business, (ii) guarantees of employee credit cards not to
exceed [*****] in the aggregate at any time, (iii) contingent liabilities
incurred in licensing transactions in the ordinary course of business, (iv)
milestone, development or royalty payments to Schering and/or other third
parties in connection with licensing and other arrangements inside or outside the Field, or
(b) agree to maintain the working capital, net worth or similar position of or
provide any other credit support to any Person.

 

6.8                                 Dividends and Other Distributions.  Except for redemptions of stock from current
or former employees in the ordinary course of business for amounts in the
aggregate not in

 

21

 

excess of [*****] annually or stock dividends or the issuance of preferred
stock as payment-in-kind, declare or pay any dividend or make
any other distribution of any kind or nature on, or redeem, retire or otherwise
acquire, directly or indirectly, any stock, interest or other Equity Interests.

 

6.9                                 Transactions with Affiliates.  Enter into any transaction with any
Affiliate on a basis less favorable to Epix than if such transactions were at
arm’s length transaction with a third-party that is not an Affiliate of Epix.

 

6.10                           Other
Covenants.  (a) Compromise,
settle or adjust any claim relating to any of the Collateral in excess of [*****]without
Schering’s prior written consent, which will not be unreasonably withheld or
delayed; (b) change, alter or modify, or permit any change, alteration or
modification of, its Organizational Documents in a manner materially adversely
affecting Schering; (c) change any of the following prior to giving Schering 15
Business Days written notice: (i) the location stated in Article 4 for the
maintenance of its books and records, principal place of business or chief
executive office, or (ii) the name under which Epix conducts any of its
business or operations; or (d) enter into any agreement or other Document
containing any provision that would be violated by the performance or
observance of any of Epix’s
obligations under this Agreement or any other Transaction Document.

 

6.11                           Subsidiaries.  Permit any Subsidiary to own or acquire any
Intellectual Property that, if owned or acquired by Epix, would be or become a
Secured Asset.

 

7.                                       Events of Default.

 

At such times as any Loans are then outstanding hereunder, the
occurrence of any of the following shall constitute an event of default (“Event
of Default”).

 

7.1                                 Failure to Pay. 
Epix fails to pay within (a) five Business Days of the due date any
principal of or interest on any Loan, whether due pursuant to any principal
payment date, any required prepayment date, any acceleration or otherwise, or
(b) ten (10) Business Days after Schering correctly gives notice that any
monetary Obligation other than principal and interest is due to Schering
pursuant to the terms of any Loan Document.

 

7.2                                 Failure to Perform or Observe
Covenants.  Epix fails to
perform or observe in any material respect any covenant, term, condition or
other non-monetary Obligation of this Agreement or any other Transaction
Document;  provided
that such event shall be an Event of Default only if such default continues for
a period of ten (10)  Business Days
after Schering has given to Epix written notice stating such default has
occurred; provided further, however, that (i) as to a failure by Epix to
perform or observe the covenant set forth in Section 5.5 hereof following the
approval of MS-325 by the FDA, such event shall be deemed an Event of Default
only if such default continues for a period of ninety (90) days, and (ii) as to
a failure by Epix to perform or observe any covenants set forth in Sections
[*****] (prior to the approval of MS-325 by the FDA), [*****], [*****] hereof,
there shall be no notice required and no cure period required to be given, and as to any
non-appealable judgment of the willful and intentional failure by Epix to
perform or observe any covenant, term or condition of this Agreement or any
other

 

22

 

Transaction Document, there shall be no notice required and no cure
period required to be given and (iii) it is understood that such required
notice and such required cure period shall not apply to any default or Event of
Default occurring under any other Section in this Article VII (whether or not
same also occurs under this Section 7.2).

 

7.3                                 Security. 
Schering shall not have as of the date hereof or shall at any time
hereafter cease to have a valid and perfected first priority Lien in all of the
Collateral other than as a
result of any act or omission of Schering, including that (i)
the grant of the Lien in any of the Collateral shall never have been effective
or shall cease to be effective to grant to Schering (or Schering shall
otherwise not have obtained or cease to have) a perfected first priority
security interest and Lien in all of the Collateral or (ii) any material patent
(owned or licensed) constituting Collateral shall in a final non appealable
judgment be determined to be invalid.

 

7.4                                 Transaction Documents.  There is a non-appealable judgment
that this Agreement or any other Transaction Document shall not have been as of
the date hereof, or shall cease
to be, valid, effective and enforceable in any material respect.

 

7.5                                 False Representation or Warranty.  Any representation, warranty or statement by
Epix contained in this Agreement or any other Transaction Document when made,
reaffirmed or hereby deemed made or reaffirmed is or was, when made, reaffirmed
or hereby deemed made or reaffirmed, materially incorrect.

 

7.6                                 Termination of the Research Agreement.  One year following either (i) the termination by Schering
under Section 8.2 of
the Research Agreement by reason of a material breach thereof by Epix, or (ii) termination by Epix under Section
8.2.3 of the Research Agreement  for convenience.

 

7.7                                 Default on Other Debt.  Any payment default or other material
default occurs under any obligations, that individually or in the aggregate
exceeds [*****] of Epix  to any one or
more third parties that entitles such third parties to declare such indebtedness
or other obligation due prior to its date of maturity and such default is not
cured within sixty (60) days,
exclusive of any vendor dispute in the ordinary course of business provided
that Epix had reserved therefor in full.

 

7.8                                 Cessation of Business.  (a) Epix ceases to do business as a going
concern; or (b) the termination, suspension or loss of any Governmental
Authorization or other asset occurs which results in Epix having to cease a
substantial part of its operations by reason of such loss for a period of more
than twenty (20) Business Days; (c) without limiting the generality of Section
7.9, Epix takes any action to authorize its liquidation or dissolution or
suffers any liquidation or dissolution; (d) any Governmental Authority, or
other entity with power to do so, commences proceedings to condemn, seize or
expropriate assets of Epix necessary for the conduct of Epix’s business and such
proceedings remain Undismissed for twenty (20) Business Days, or Epix abandons
such assets or suspends operation thereof for a period of twenty (20) Business
Days.

 

23

 

7.9                                 Non-approvable letter for MS-325.  Epix receives a non-approvable letter for
MS-325 from the FDA and the Parties, or Schering in good faith, consequently
decide to (i) not further proceed with the development of MS-325, or (ii) to
proceed with the development / registration of an indication completely new or
significantly reduced in comparison to the initially filed indication.
Notwithstanding the foregoing, no Event of Default shall be deemed to have
occurred pursuant to this Section for a period of thirty (30) days following
receipt of any such non-approvable letter.

 

7.10                           Inability to Pay Debts; Bankruptcy or
Insolvency.  Any one or more of
the following occur:  (a) Epix shall
commence any Proceeding (i) under any existing or future law of any
jurisdiction, domestic or foreign, relating to bankruptcy, insolvency,
reorganization or other relief of debtors, seeking to have an order for relief
entered with respect to it or seeking to adjudicate it a bankrupt or insolvent,
or seeking reorganization, arrangement, adjustment, winding-up, liquidation,
dissolution, composition with creditors or other similar relief with respect to
it or its debts, or (ii) seeking appointment of a receiver, trustee, custodian
or other similar official for it or for all or any substantial part of its
assets, or Epix shall make a general assignment for the benefit of its
creditors or a bulk sale; (b) there shall be commenced against Epix any
Proceeding of a nature referred to in clause (i) above which (A) results either
in the entry of an Order for relief or an appointment and any such Order or
appointment remains undismissed in a manner reasonably satisfactory to Schering
(“Undismissed”) for a period of twenty (20) Business Days; the foregoing
shall include the commencement against Epix of any Proceeding seeking issuance
of a warrant of attachment, execution, distraint or similar process against all
or any substantial part of its assets which results in the entry of an Order
for any such relief which remains Undismissed in a manner reasonably
satisfactory to Schering for twenty (20) Business Days; or (c) Epix takes any
action substantially in furtherance of, or expressly authorizing or indicating
its consent to, approval of or acquiescence in or expressly proposes to take
any of the acts set forth in clause (a) or (b) above; or (d) Epix shall
generally not be able to or fail to, or shall expressly admit in writing its
inability to, pay its debts generally as they become due.

 

7.11                           Certain Judgments.  (a) One or more judgments or orders for the payment of money
exceeding [*****] in the aggregate are rendered against Epix, and any such
judgment or order continues unsatisfied and not effectively and continuously
stayed within sixty (60) days of such judgment or order; or (b) any substantial
part of the assets of Epix becomes subject to attachment, execution, levy or
like process which shall not have been effectively and continuously stayed
within sixty (60) days of such attachment, etc.

 

7.12                           Change of Control.  There occurs a Change of Control of Epix.  “Change of Control” means any of the
following:  (i) any person (as such term
is used in Sections 13(d) and 14(d)(2) of the Exchange Act) shall become the
beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act),
directly or indirectly, of Epix’s securities representing fifty percent (50%)
or more of the voting power of all then outstanding securities of Epix having
the right under ordinary circumstances to vote in an election of the Board of
Directors (including that any Epix securities that any such person has the
right to acquire pursuant to any agreement, or upon exercise of conversion
rights, warrants or options, or otherwise, shall be deemed beneficially owned
by such person); (ii)
there shall be consummated any corporate transaction,

 

24

 

including
a consolidation or merger, of Epix in which Epix is not the continuing or
surviving corporation or pursuant to which shares of Epix’s capital stock are
converted into cash, securities or other property, other than (x) a
consolidation or merger of Epix in which the holders of Epix’s voting stock
immediately prior to the consolidation or merger shall, upon consummation of
the consolidation or merger, own at least fifty percent (50%) of the voting
stock of the surviving entity after such consolidation or merger or (y) a
consolidation, merger or other corporate transaction, unless the Research
Agreement shall have been terminated by Schering for convenience; or (iii) there shall be
consummated any sale, lease, exchange or transfer (in any single transaction or
series of related transactions) of all or substantially all of the assets or
business of Epix.

 

8.                                       Remedies.

 

8.1                                 Rights Under Transaction Documents.  Epix acknowledges that certain rights and
remedies of Schering upon an Event of Default are provided in the Security
Agreement.  

 

8.2                                 Rights in General.  Upon or at any time after the occurrence of any Event of Default
Schering shall have the option, from time to time, to effect one or more of the
following (to be effected by written notice by Schering), (a) all obligations
of Schering to make any Loans after the occurrence of an Event of Default shall
terminate, (b) the principal and interest of the Loans and all other
Obligations shall become and be immediately due and payable, without
presentment, demand, protest, or further notice of any kind or nature
whatsoever, all of which are, to the maximum extent permitted by applicable
law, hereby expressly waived by Epix, (c) Schering shall have the right, but
not the obligation, to terminate the Research Agreement; and (d) Schering shall
be entitled to exercise forthwith (to the extent and in such order as Schering
may elect, in its sole and absolute discretion) any and/or all rights and
remedies provided to Schering in this Agreement, the Security Agreement, the
Research Agreement and/or any other Transaction Document, all rights and
remedies of Schering under the UCC, and all other rights and remedies that may
otherwise be available to Schering pursuant to any other Document, at law or in
equity.

 

8.3                                 Setoff Rights. 
To the extent that Epix does not timely pay any amounts under this
Agreement or under any other Loan Document, Schering and/or its Affiliates
shall at any time and from time to time have the right to set-off all of its
payment obligations under the Research Agreement against any amounts due
hereunder (including any due by reason of any acceleration) or thereunder.  Upon the occurrence of an Event of Default,
Schering is hereby authorized at any time and from time to time, without notice
to Epix (any such notice being expressly waived by Epix), to set off and apply
(and/or to cause any Affiliate of Schering to set off and apply) any and all
amounts due by Schering and/or any Affiliate of Schering to Epix (including
pursuant to the Research Agreement) against any or all of the Obligations of
Epix now or hereafter existing under this Agreement or any other Loan Document,
irrespective of whether or not (a) Schering and/or such Affiliate shall have
made any demand and (b) any such Obligations may be unmatured.  Epix further agrees that the rights stated
in this Section 8.3 are in addition to other rights and remedies (including
other rights of set-off such as those pursuant to Section 2.5 hereof) that
Schering may have.

 

25

 

8.4                                 Additional Rights to Terminate This
Agreement.  If all of the
conditions precedent to the Initial Loan shall not have been satisfied by
November 15, 2003, Schering shall have the right, at its election, to terminate
this Agreement and/or not make any further Loans pursuant to this
Agreement.  Such termination shall be
treated as an Event of Default for the purposes of this Agreement, including
for the purposes of determining Schering’s rights and remedies pursuant to
Article VIII hereof.

 

8.5                                 Cumulative Remedies; No Waiver by
Schering.  No remedy referred to
in this Agreement is intended to be exclusive, but each shall be cumulative and
in addition to any other remedy referred to in this Agreement or otherwise
available to Schering pursuant to any other Transaction Document, at law or in
equity.  No express or implied waiver by
Schering of any default or Event of Default shall in any way be, or be
construed to be, a waiver of any future or subsequent default or Event of
Default.  Any failure or delay of
Schering in exercising any rights granted it hereunder and/or under any other
Transaction Document, including upon any occurrence of any of the contingencies
set forth herein, shall not constitute a waiver of any such right upon the
continuation or recurrence of any such contingency or similar contingencies,
and any single or partial exercise of any particular right by Schering shall
not exhaust the same or constitute a waiver of any other right.

 

8.6                                 Waivers and Consents Relating to
Remedies.  In connection with
any action or proceeding relating to this Agreement, any of the Loans, any of
the other Transaction Documents, any of the Collateral, or any act or omission
relating to any of the foregoing:  (a)
EPIX AND SCHERING WAIVE THE RIGHT TO TRIAL BY JURY; (b) Epix waives personal
service of any summons, complaint or other process in connection with any such
action or proceeding and agrees that service thereof may be made, as Schering
may elect, by certified mail directed to Epix at the location provided for
notices to Epix under this Agreement or, in the alternative, in any other form
or manner permitted by law; (c) Epix agrees that all of the Collateral
constitutes security for all of the Obligations, and agrees that Schering shall
be entitled to sell, retain or otherwise deal with any or all of the
Collateral, in any order or simultaneously as Schering shall determine in its
sole and absolute discretion; without limiting the generality of the foregoing,
such rights shall be free of any requirement for the marshaling of assets or
any other restriction that, in the absence of this Agreement and/or the Transaction
Documents, may be placed upon Schering in dealing with the Collateral; (d) Epix
agrees that Schering may at Schering’s election proceed directly against Epix
for collection of any or all of the Obligations prior to, during and/or after
selling, retaining or otherwise dealing with any of the Collateral; and (e) to
the fullest extent permitted by law, Epix (i) waives demand, presentment,
notice of dishonor or protest under or related to this Agreement and/or any
other Transaction Document; and (ii) consents to any of the following by
Schering: (A) any extension, postponement of time of payment or other
indulgence, (B) any substitution, exchange or release of or failure to perfect
or failure to continue perfection of Collateral, (C) any addition to, or
release of, any Person primarily or secondarily liable for the Obligations, and
(D) after the occurrence and during the continuance of an Event of Default any
acceptance of partial payments and the settlement, compromise or adjustment
thereof.

 

8.7                                 Powers of Attorney.  Epix hereby constitutes and appoints Schering (and any employee
or agent of Schering, with full power of substitution) its true and lawful
attorney and

 

26

 

agent in fact to take any or all of the actions described below in
Schering’s or Epix’s
name and at Epix’s
expense:

 

(a)                                  Evidence
of Liens.  Schering may prepare
and/or execute such financing statements and other Documents and take such
other actions as Schering deems necessary or proper in order to create, perfect
or continue the security interests and other Liens provided for by this
Agreement and/or any of the other Loan Documents, and Schering may file the
same (or a photocopy) in any appropriate governmental office.

 

(b)                                 Other
Actions.  Schering may take any and
all action that it reasonably deems necessary or appropriate to preserve its
interest in the Collateral; to the extent same relates to any default by Epix
hereunder or under any other Transaction Document, Epix shall reimburse Schering
for same on demand.  All sums payable by
Epix to Schering under Sections 8.7(b) and 8.7(c) shall constitute Obligations,
shall be secured by the Collateral, and shall be payable on ten (10) Business
Days notice with interest at the Interest Rate from the respective dates such
sums are expended.

 

(c)                                  Schering’s
Right to Cure.  In the event Epix fails
to perform any of its Obligations within ten (10) days following notice from
Schering, then Schering may from time to time perform the same but shall not be
obligated to do so (including that Schering shall not be required to perform
any Obligations which are the same type as those which Schering may have at any
time hereafter elected to perform).

 

(d)                                 Collections;
Modification of Terms.  Upon the
occurrence and during the continuance of any Event of Default, Schering may (i)
demand, sue for, collect and give receipts for any money, instruments or
property payable or receivable on account of or in exchange for any of the
Collateral, or make any compromises it deems necessary or proper, including
extending the time of payment, permitting payment in installments, or otherwise
modifying the terms or rights relating to any of the Collateral, all of which
may be effected without notice to or consent by Epix and without otherwise
discharging or affecting the Obligations, the Collateral or the Liens granted
under any of the Loan Documents, and (ii) take any actions Schering reasonably
elects relating to the Collateral, subject to Section 8.1.

 

(e)                                  Irrevocability.
 Except as may be provided to the
contrary in this Section 8.7 with respect to any power, Epix covenants and
agrees [*****].  Epix further covenants
and agrees that the powers of attorney granted by this Section 8.7 are coupled
with an interest and shall be irrevocable until the later of full and final
payment of the principal of the Loans and all interest thereon and all other
payment obligations under this Agreement and the other Loan Documents, that
said powers are granted solely for the protection of Schering’s interest and
Schering shall have no duty to exercise any thereof; that the decision whether
to exercise any of such powers, and the manner of exercise, shall be solely
within Schering’s discretion; and that neither Schering nor any of its directors,
officers, employees or agents shall be liable for any act of omission or
commission, or for any mistake or error of judgment, in connection with any
such powers except any act of commission constituting gross negligence or
willful misconduct.

 

27

 

9.                                       Costs, Expenses and Taxes;
Indemnification; Limitations on Schering’s Liability.

 

9.1                                 Costs and Expenses.  Epix agrees to pay on demand (a) all losses, costs and expenses
(including reasonable fees and expenses of attorneys and accountants, including
any such reasonable fees and expenses of attorneys and accountants incurred to
enforce any rights of Schering or obligations of Epix hereunder or under any
other Loan Document) from time to time incurred by Schering relating to the
enforcement of this Agreement, the Security Agreement and/or any of the other
Loan Documents and/or (b) the preservation of any rights (including remedies)
of Schering under this Agreement, the Security Agreement and/or any other Loan
Document.  With respect to any amount
advanced or expended by Schering and required to be reimbursed by Epix pursuant
to the foregoing provisions of this Section 9.1, Epix shall also pay Schering
interest on such amount at the Interest Rate, such interest to commence from
the date of advance or expenditure. 
Epix’s
obligations under Sections 9.1 and 9.2 shall survive termination of the other
provisions of this Agreement.

 

9.2                                 Indemnification by Epix.  Epix hereby covenants and agrees to
indemnify, defend and hold harmless Schering and its officers, directors,
employees and agents (and hereby releases each such Person) from and against
any and all claims, demands, damages, Liabilities, costs and expenses
(including the reasonable fees and out-of-pocket expenses of counsel), other
Proceedings and losses of any kind or nature whatsoever which may be incurred
or suffered by or asserted against or threatened to be asserted against
Schering or any such other Person relating to this Agreement or any Loan,
including: (a) any Proceeding relating to any of the Collateral in which
Schering or any of its Affiliates has the right to enforce its rights hereunder
or thereunder or any act or omission relating to any of the foregoing, (b) any
taxes, Liabilities, claims or damages relating to the Collateral or Schering’s
Liens thereon; or (c) the correctness, validity or genuineness of any
instruments or other Documents that may be released or endorsed to Epix by
Schering (which shall automatically be deemed to be without recourse to
Schering in any event), except
if the foregoing results from the gross negligence of willful misconduct of
Schering or its employees or agents.  The foregoing provisions of this Section 9.2
shall not constitute a release of Schering from its obligation to make Loans
pursuant to and subject to the terms hereof, to the extent it breaches its
obligation to do so.

 

9.3                                 Limitations on Schering’s Liability.

 

(a)                                  No
Inquiry Obligation of Schering. 
Schering shall not be obligated to inquire into the accuracy, correctness,
or reasonableness of any Document furnished to it in connection with any
Requested Loan.

 

(b)                                 No
Obligation of Schering.  Schering
shall not have any responsibility whatsoever as to use of any Loan.  Anything to the contrary in this Agreement notwithstanding,
any approval or non-approval by Schering of any one or more matters involving
any Transaction Document, any of the work done pursuant thereto or any other
actions contemplated by any such Document shall not create any responsibility
or liability of any kind or nature whatsoever for Schering or in any manner
reduce or otherwise affect its rights to repayment of the Loans.

 

(c)                                  No
Reliance on Schering’s Procedures. 
Epix shall have no right to rely upon any procedure required by Schering
under any Transaction Document, such procedures being for the sole protection
of Schering and no other Person. 
Further, Schering is entitled to

 

28

 

take any discretionary action permitted under any Transaction Document
solely for its own protection.

 

(d)                                 Limitation
on Schering’s Liabilities.  Schering
shall have no liability for [*****].

 

10.                                 Other Provisions.

 

10.1                           Entire Agreement; Amendments; Schering’s
Consent.  This Agreement, the
Security Agreement and the other Loan Documents supersede, with respect to
their subject matter, all prior and contemporaneous agreements, understandings,
inducements or conditions among or between the Parties, whether express or
implied, oral or written, and constitute the entire agreement of the
Parties.  No amendment or waiver of any
provision of this Agreement or any Loan Document, nor consent to any departure
by any Party therefrom, shall in any event be effective unless the same shall be
in writing and signed by the Party against whom enforcement is sought, and then
such waiver or consent shall be effective only in the specific instance and for
the specific purpose for which given. 
To the extent this Agreement and any other Loan Document or the Research
Agreement are actually inconsistent, then this Agreement shall control except
to the extent otherwise expressly provided in this Agreement, any other Loan
Document or the Research Agreement.  If
a Schedule is not attached hereto, or such Schedule does not contain all
information contemplated hereby, then Epix’s disclosure re: same shall for
the purposes of this Agreement be “none” or “no exceptions”.

 

10.2                           Specific Performance.  Subject to the provisions of Section 9.3, in
the event of any breach or threatened breach of any provision of this
Agreement, an aggrieved Party shall have the right, in addition to any other
rights existing in its favor under this Agreement, to enforce its rights and to
enforce the obligations of the breaching Party by an action or actions for
specific performance and/or injunctive or other equitable relief in order to
enforce or prevent any actual or threatened violations of the provisions of
this Agreement.  The exercise of any
such rights shall not require the posting of any bond or other consideration or
the proof of any actual damages.

 

10.3                           Notices.  All
notices and other communications relating to this Agreement or any of the other
Loan Documents to be effective shall be in writing (including by telecopy), and
shall be deemed to have been duly given or made when delivered by hand, or
three Business Days after delivery to a nationally recognized overnight courier
service (against a signed receipt) or, in the case of telecopy notice, when
sent and confirmed as received, addressed to Epix at: 71 Rogers Street,
Cambridge, MA 02142-1118, Attention: Chief Financial Officer; with a copy to:
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center,
Boston, MA 02111, Attention: William T. Whelan, Esquire and to Schering at:
Muellerstrasse 178, 13353 Berlin, Germany, Attention: Finance Department, with
a copy to: Muellerstrasse 178, 13353 Berlin, Germany, Attention: Legal
Department, or to such other address as the respective Party or its successors
or assigns may subsequently designate by proper notice.

 

10.4                           No Third Party Beneficiaries.  The Parties do not intend that any other
Person shall be a third party beneficiary of this Agreement or that this
Agreement shall otherwise inure

 

29

 

to the benefit of any third party, including that the Parties intend
and agree that no other Person shall have the right to enforce any obligation
hereunder.  Without limiting the
generality of the foregoing, Loans that are used to make advances or other
payments directly to any Person other than Epix shall not in any manner create
or be deemed a recognition by Schering of any third party beneficiary status of
any such Person.

 

10.5                           Joint Efforts. 
This Agreement and each of the other Loan Documents shall each be construed
to be the joint efforts of the Parties and shall not be construed more severely
against any one Party.

 

10.6                           Governing Law. 
This Agreement and the other Loan Documents shall be governed by, and
construed in accordance with, the laws of the State of New York (except to the
extent otherwise expressly provided in any other Loan Document) without giving
effect to the principles of conflicts of laws.

 

10.7                           Other Provisions.  Epix shall take all actions, including the execution and delivery
of all Documents, reasonably requested by Schering with respect to the
transactions contemplated hereby. 
Throughout this Agreement, the masculine shall include the feminine and
vice versa and the singular shall include the plural and vice versa, unless the
context of this Agreement indicates otherwise. 
This Agreement shall be binding upon and inure to the benefit of Epix
and Schering and shall not be assignable without the prior written consent of
the other Party, which consent shall not be unreasonably withheld or delayed
(except that Schering may assign this Agreement to an Affiliate without Epix’s
consent and except as
permitted under Section 6.2), except that no assignments
hereof shall relieve any assigning Party of its obligations hereunder and any
such assigning Party shall continue to be a primary obligor as fully as if such
assignment had not occurred.  Any
purported assignment not made in accordance with the terms hereof shall be
void.  This Agreement may be executed by
fax and in any number of counterparts, each of which when so executed shall be
deemed to be an original and all of which taken together shall constitute but
one and the same agreement.  Subject to
Section 7.4 hereof, any provision of this Agreement, the Research Agreement
and/or any of the other Loan Documents that is prohibited or unenforceable in
any jurisdiction shall, as to such jurisdiction, be ineffective to the extent
of such prohibition or unenforceability without invalidating the remaining
provisions of this Agreement, the Research Agreement and/or such other Loan
Documents, as applicable, or affecting the validity or enforceability of such
provision in any other jurisdiction and each provision which is not wholly
unenforceable shall be enforced to the maximum extent permitted by law.  The table of contents, headings and schedule
of defined terms preceding the text of this Agreement are inserted solely for
convenience of reference and shall not constitute a part of this Agreement nor
affect its meaning, construction or effect. 
The phrase “amended, supplemented, restated or otherwise modified” and
other reasonably similar phrases include any change by way of waiver and
includes extensions, renewals, refinancings and replacements.  The terms “default”, “default under any
Document” and similar terms includes any breach of any Document and any
noncompliance with, and any failure to observe, the terms of any Document.  Any brokerage, commission or finder’s fee
payable in connection with the Loans and the transactions contemplated hereby
is payable by the Party incurring same and such Party incurring same shall
indemnify the other Party in respect of same.

 

30

 

10.8                           No Agency Relationship.  The Parties agree that neither Party is in
any respect the agent of the other Party for any purpose of any kind or nature
whatsoever.

 

10.9                           Further Acknowledgments and
Agreements of Epix and Schering.  Epix and Schering acknowledge and agree that they (i) have
independently reviewed and approved the provisions of this Agreement, including
the Exhibits attached hereto and any and all other Documents as they or their
counsel have deemed appropriate, and (ii) have entered into this Agreement and
have executed the other Transaction Documents executed by them voluntarily,
without duress or coercion, and have done all of the above with the advice of
their legal counsel.  Epix acknowledges
and agrees that, to the extent deemed necessary by them or their counsel, they
and their counsel have independently reviewed, investigated and/or have full
knowledge of all aspects of the transactions and the basis for the transactions
contemplated by this Agreement or any other Transaction Documents and/or have
chosen not to so review and investigate (in which case, Epix acknowledges and agrees
that it has knowingly and upon the advice of counsel waived any claim or
defense based on any fact or any aspect of the transaction that any
investigation would have disclosed), including the risks and benefits of the
various waivers of rights contained in this Agreement (including the waiver of
the right to a jury trial).

 

[Signature Lines are on the Next Page]

 

31

 

IN WITNESS WHEREOF, the undersigned have set
their hands and seals or caused these presents to be executed by their proper
officers and sealed with their seal the day and year first above written.

 

	
  (Corporate Seal)

  	
   

  	
  EPIX MEDICAL, INC.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Attest:

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  	
  By: 

  	
   

  	
   

  
	
  Name: 

  	
   

  	
   

  	
   

  	
  Name: 

  	
   

  	
   

  
	
  Title: 

  	
   

  	
   

  	
   

  	
  Title: 

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  SCHERING AKTIENGESELLSCHAFT

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  	
  By: 

  	
   

  	
   

  
	
  Name: 

  	
  Prof. Dr. Günter Stock

  	
   

  	
  Name:  Prof. Dr. Björn
  Wallmark

  
	
  Title: 

  	
  Member of the Vorstand

  	
   

  	
  Title:  Head of Corporate
  Research

  
													

 

32

 

	
  STATE OF

  	
  )

  
	
   

  	
  ), SS:

  
	
  COUNTY OF

  	
  )

  

 

BE IT REMEMBERED, that on this
       day of May, 2003, before me the
subscriber, a Notary Public of the State of
                         ,
personally appeared,
                     ,
the                           of EPIX MEDICAL, INC., a Delaware
corporation, who, I am satisfied, is the person who executed the within
instrument as the
                  
of said company, and he acknowledged that he signed, sealed with the proper
corporate seal and delivered the same as such officer, that the within
instrument is the voluntary act and deed of said company made by virtue of
authority of its board of directors, and that he received a true copy of the
within instrument on behalf of said company.

 

	
   

  	
   

  	
   

  
	
   

  	
  Notary Public to the Commonwealth of Massachusetts

  
	
   

  	
  [Seal]

  
	
   

  	
   

  

 

33

 

EXHIBIT A

 

See
Exhibit 10.2 to this 8-K/A

 

1

 

EXHIBIT
B

 

PROMISSORY NOTE

 

	
  Maximum Principal Balance of

  	
   

  	
  Date:  May 26, 2003

  
	
  US$15,000,000.00

  	
   

  	
  Cambridge, Massachusetts

  

 

This Promissory Note (“Note”) is executed and delivered under and
pursuant to the terms of that certain Loan Agreement dated as of the date
hereof (as amended, restated, supplemented or modified from time to time, the
“Loan Agreement”) by and between EPIX MEDICAL, INC., a Delaware corporation
with a place of business at 71 Rogers Street, Cambridge, Massachusetts
(“Borrower”), and SCHERING AKTIENGESELLSCHAFT, a German corporation (“Lender”).  Capitalized terms not otherwise defined
herein shall have the meanings provided in the Loan Agreement.

 

FOR VALUE RECEIVED, Borrower hereby promises to pay to the order of
Lender, at the office of Lender located at Muellerstrasse 178, 13353 Berlin,
Germany, Attention: Finance Department or at such other place as Lender may
from time to time designate to Borrower in writing:

 

(i)                                     the
principal sum of FIFTEEN MILLION AND 00/100 (US$15,000,000.00) DOLLARS in
currency of the United States of America, or, such lesser amount as shall then
equal the aggregate unpaid principal balance of the Loans as may be due and
owing under the Loan Agreement, payable in accordance with the provisions of
the Loan Agreement, subject to acceleration upon the occurrence of an Event of
Default under the Loan Agreement or earlier termination of the Loan Agreement
pursuant to the terms thereof; and

 

(ii)                                  interest
on the principal amount of this Note from time to time outstanding until such
principal amount is paid in full at the applicable Interest Rate in accordance
with the provisions of the Loan Agreement. 
In no event, however, shall interest exceed the maximum interest rate
permitted by law.  Upon and after the
occurrence of an Event of Default, and during the continuation thereof,
interest shall be payable at the Default Rate.

 

This Note is the Note referred to in the Loan Agreement and is secured
by the liens granted pursuant to the Security Agreement, is entitled to the
benefits of the Loan Agreement and the other Loan Documents and is subject to
all of the agreements, terms and conditions therein contained.  This Note may be prepaid in whole or in part
at any time without premium or penalty.

 

This Note may be assigned only in accordance with the Loan
Agreement.  This Note is not negotiable
by Lender except to an Affiliate.

 

If an Event of Default under Section 7.10 of the Loan Agreement shall
occur, then this Note shall immediately become due and payable, without notice,
together with reasonable

 

1

 

attorneys’ fees if the collection hereof is placed in the hands of an
attorney to obtain or enforce payment hereof. 
If any other Event of Default shall occur under the Loan Agreement or
any of the Loan Documents, then this Note may, as provided in the Loan Agreement,
be declared to be immediately due and payable, without a notice period,
together with reasonable attorneys’ fees, if the collection hereof is placed in
the hands of an attorney to obtain or enforce payment hereof.

 

This Note shall be governed by and construed and enforced in accordance
with the laws of the State of New York.

 

Borrower expressly waives any presentment, demand, protest, notice of
protest, or notice of any kind except as expressly provided in the Loan
Agreement.

 

	
   

  	
   

  	
  EPIX MEDICAL, INC.,

  
	
   

  	
   

  	
  Borrower

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  Name:

  	
   

  
	
   

  	
   

  	
  Title:

  	
   

  	 

							

 

 

	
  STATE
  OF              )

  
	
   

  	
  SS.:

  
	
  COUNTY
  OF          )

  
	
   

  	
   

  
			

 

On the
             day of
                      ,
2003, before me personally came                         ,
to me known, who being by me duly sworn, did depose and say that he/she is the
                                 
of Epix Medical, Inc., the Borrower described in and which executed the
foregoing instrument; and that he/she signed his/her name thereto as the act
and deed of such corporation by order of the board of directors of said
corporation.

 

	
   

  	
   

  	
   

  
	
   

  	
  Notary Public

  	
   

  

 

2

 

EXHIBIT
C

 

Final Version

 

SECURITY AGREEMENT

 

THIS SECURITY AGREEMENT (as amended, supplemented,
restated or otherwise modified, the “Security Agreement”) is entered into as of
May 26, 2003, between EPIX MEDICAL, INC., a Delaware corporation, with its
principal offices in Cambridge, Massachusetts (the “Debtor”), and SCHERING
AKTIENGESELLSCHAFT, a German corporation having its principal offices at 13342
Berlin, Germany (the “Secured Party “).

 

WHEREAS, on and as of the date hereof, the Debtor and
Secured Party have executed and delivered a certain Loan Agreement providing
for a maximum principal amount of loans of Fifteen Million Dollars
($15,000,000); such Loan Agreement, and any and all amendments, modifications,
extensions, restatements, renewals, refinancings and/or replacements thereof
from time to time is hereinafter referred to as the “Loan Agreement”;
and the Debtor has executed and delivered to Secured Party a certain
Non-Negotiable Note (“Note”) with a maximum principal amount of Fifteen Million
Dollars ($15,000,000) (such note, and any and all amendments, modifications,
extensions, restatements, renewals, refinancings and/or replacements thereof
from time to time being herein referred to as the “Note”);

 

WHEREAS, the indebtedness evidenced by the Note is
secured as hereinafter provided; and

 

WHEREAS, Debtor, in consideration of and in order to
induce Secured Party, from time to time and in accordance with and subject to
the provisions set forth in the Loan Agreement, to make advances aggregating to
a maximum principal amount of Fifteen Million Dollars ($15,000,000), has
determined that it is in the best interest of Debtor to execute, deliver and
perform this Security Agreement;

 

NOW, THEREFORE, for valuable consideration, the
sufficiency and receipt of which are hereby acknowledged, the Debtor and the
Secured Party hereby agree as follows:

 

1.                                       Definitions.  As used in this Security Agreement, and in
addition to terms defined elsewhere in this Security Agreement, the following
terms have the following meanings:

 

“Event of
Default”  shall mean (a) a breach or
default by Debtor under this Security Agreement or (b) an Event of Default as
defined in the Loan Agreement.

 

“Proceeds” has the meaning assigned to it under
the Uniform Commercial Code provided
that Proceeds shall also be deemed to include (i) any
and all proceeds of any insurance, indemnity, warranty or guaranty payable to
Debtor from time to time with respect to any of the Secured Assets, and (ii) any and all
payments (in any form whatsoever) made or due and payable to Debtor from time
to time in connection with any requisition, confiscation, condemnation, seizure
or forfeiture of all or any part of the Secured Assets by any Governmental
Authority (or any Person acting under color of Governmental Authority), provided further that with respect to 

 

1

 

whatever is collected on, or distributed on
account of Secured Assets, Proceeds shall mean exclusively
any and all royalties
from time to time paid or payable under or in connection with any of the
Secured Assets after the
date hereof.

 

“relating to” means “arising out of, in connection
with or otherwise relating to”, and “relates to” and “related to” each has a
substantially similar meaning.

 

“Secured Assets” shall mean and include (i) all
of the Debtor’s right, title and interest in and to (a) any and all letters
patent, or other patents, whether issued in the United States or any other
country, and the inventions described and claimed therein relating to magnetic
resonance imaging (“MRI”), including but not limited to those  set forth on Schedule 1 attached
hereto, whether in good standing or expired, whether now existing or
hereinafter arising or created, and whether owned by Debtor singly or jointly
with another Person (including but not limited to the “Joint Patents” as that
term is defined in the Research Agreement (defined below)) or employed by
Debtor pursuant to license or other grant (hereinafter referred to collectively
as the “Patents”); (b) all applications for Patents and any Patent which may be
issued upon any of said applications and any future patent applications of Debtor
and all applications for re-instatement of any expired Patents (hereinafter
referred to collectively as the “Applications”); (c) any reissue, extension,
division or continuation of the Patents or the Applications (such reissues,
extensions, divisions and continuations being herein referred to collectively
as the “Reissued Patents”); (d) all future royalties or other fees paid or
payment or payments made or to be made to the Debtor in respect of the Patents
(the “Royalties”); and (ii) Proceeds of any and all of the foregoing (the
Patents, Applications, Reissued Patents and Royalties and Proceeds being herein
referred to collectively as the “Patent Rights”); (iii) all rights, interests,
claims and demands that the Debtor has or may have in existing and future
profits and damages for past and future infringements of the Patent Rights
(such rights, interests, claims and demands being herein called the “Claims”)
(the Patent Rights and Claims collectively referred to as the “Patent
Collateral”); (iv) all license and other agreements pursuant to which such
Patent Rights were acquired; (v) all other intangible assets, including
know-how, of every kind and description (including rights under any license
agreement pursuant to which such know-how was granted), now owned or hereafter
acquired by the Debtor, and whether now existing or hereafter arising, relating
to any products involving
MRI, and (vi) all books and records relating to the assets described in
clauses (i), (ii), (iii), (iv) and (v), whether in writing or electronic
form.

 

“Uniform Commercial Code” means the Uniform
Commercial Code as the same may from time to time be in effect in the State of Delaware.

 

2.                                       Definitions
Incorporated.  All capitalized terms
used herein, unless otherwise specifically defined, shall have the meaning
ascribed to such terms in the Loan Agreement, in the Note or in the
Collaborative Research Agreement by and between the Debtor and the Secured
Party, dated as of May 26, 2003, as thereafter amended, supplemented, restated
or otherwise modified from time to time (the “Research Agreement”).  It is agreed that in connection therewith,
the Parties shall look first to the Loan Agreement, then to the Note and then
to the Research Agreement.  In the event of
any conflict or inconsistency between the terms of the Loan Agreement, the Note, the Research Agreement and this
Security Agreement, the Loan Agreement shall prevail.

 

2

 

3.                                       Security
Interest.  The Debtor hereby grants
to the Secured Party a security interest in all of the Debtor’s right, title
and interest in and to the Secured Assets to secure (i) the prompt and complete
payment when due of all principal of and interest heretofore or hereafter owing
or outstanding under the Loan Agreement and/or the Note, (ii) the prompt and
complete payment when due by the Debtor of all costs and expenses (including
reasonable attorney’s fees and expenses) incurred by the Secured Party in the
collection of amounts due under and/or in enforcing its rights under the Loan
Agreement, the Note and/or this Security Agreement and (iii) the prompt and
complete performance when due by the Debtor of all its obligations under the
Loan Agreement, the Note and/or this Security Agreement (the obligations listed
in (i), (ii) and (iii) being referred to collectively herein as the
“Obligations”).

 

4.                                       Debtor
Remains Liable.  Anything herein to
the contrary notwithstanding, (i) Debtor shall remain liable under all
contracts and agreements of every kind and nature whatsoever (“contracts and
agreements” or “contracts or agreements”) included in the Secured Assets to the
extent set forth therein to perform all of its duties and obligations
thereunder to the same extent as if this Security Agreement had not been
executed, (ii) the exercise by the Secured Party of any of its rights hereunder
shall not release Debtor from any of its duties or obligations under the
contracts and agreements included in the Secured Assets, and (iii) unless the
Secured Party in its exercise of  any
rights or remedies expressly assumes by written agreement any of the contracts
or agreements, the Secured Party shall not have any obligation or other
Liability under the contracts and agreements included in the Secured Assets
including without limitation to be obligated to perform any of the obligations
or duties of Debtor thereunder or to take any action to collect or enforce any
claim for payment assigned hereunder.

 

5.                                       Records.  Debtor will at all times keep accurate and
complete records of all items included in the Secured Assets, and the Secured
Party shall have the right at all reasonable times, following reasonable
advance notice without material disruption to the business of the Debtor, to
examine and inspect the same and to make copies thereof.

 

6.                                       Representations,
Warranties and Covenants of the Debtor. 
With respect to the Secured Assets, Debtor hereby represents, warrants
and covenants to the Secured Party as follows:

 

(i)                                     (A)                              Debtor
is the sole owner of the Secured Assets, except for the assets listed in Schedule
6(i) attached hereto.  No Subsidiary
or Affiliate of Debtor owns or will own any Patent Rights rights under
contracts or agreements or other rights or assets of any kind or nature
relating to MRI.

 

(B)        The Secured Assets listed
in Schedule 6(i) hereof are licensed to Debtor and pursuant to the
license agreements identified on that Schedule, true and complete copies of
which license agreements have previously been provided to Lender.  Debtor is in material compliance with all of
each such license agreement, and each such license agreement is in full force
and effect, enforceable in accordance with its terms, and has not been varied,
amended or modified in any manner.

 

3

 

(ii)                                  Until
all principal and interest which may be outstanding under the Loan Agreement is
indefeasibly paid in full, Debtor will have such rights of ownership or other
rights to each item of the Secured Assets as Debtor has on and as of the date
hereof; the same will be used solely in connection with the Debtor’s business;
all of the Secured Assets are free and clear of all Liens, including any
security interests or collateral interests of any other party.

 

(iii)                               Debtor
hereby authorizes Secured Party to file all financing statements and amendments
and supplements thereto, if any, including continuation statements with respect to the Secured Assets
reasonably necessary in the judgment of the Secured Party to perfect the
security interest in the Secured Assets granted hereby.  At the written request of the Secured Party,
Debtor will attend to the filing of any and all continuation statements, as may
be reasonably requested by the Secured Party in order to continue the
perfection of the security interests of the Secured Party hereunder.

 

(iv)                              Debtor
shall, from time to time as requested by the Secured Party, take such action,
including without limitation to execute and deliver to the Secured Party all
such instruments, assignments, supplements, further assurances and security or
other agreements, as may be reasonably required or reasonably requested by the
Secured Party in order to perfect and continue the Secured Party’s security
interest in the Secured Assets hereunder and to provide the Secured Party with
the full benefits contemplated by this Agreement.

 

(v)                                 Debtor
agrees to pay, and to hold the Secured Party harmless from, any and all
Liabilities, costs and expenses (including, without limitation, reasonable
legal fees and expenses) except those caused by the willful misconduct or gross
negligence of the Secured Party (1) with respect to, or resulting from, any
delay in paying, any and all withholding or other taxes
which may be payable or determined to be payable with respect to any of the
Secured Assets, and (2) in connection with any of the transactions contemplated
by this Security Agreement.

 

(vi)                              Debtor
will not create, incur or permit to exist, and it will defend the Secured
Assets against, and it will take such other action as is necessary, or
reasonably requested by the Secured Party, to promptly remove, any Lien or
claim on or to the Secured Assets, other than the liens created hereby, and,
subject to the terms of any agreements relating to licensed Secured Assets, it
will defend the right, title and interest of the Secured Party in and to any of
the Secured Assets against the claims and demands of all persons whomsoever.

 

(vii)                           Debtor
will not sell or otherwise transfer in any manner whatsoever any of the Secured
Assets, except upon the advance written consent of the Secured Party  or as otherwise permitted under
the Loan Agreement.

 

(viii)                        Debtor has
the power to execute and deliver this Security Agreement and to perform its
obligations hereunder and has taken all necessary action and has received all
required consents (private and governmental) to authorize such execution,
delivery and performance, and this Security Agreement constitutes the legal,
valid and binding obligation of the Debtor, enforceable against it in
accordance with its terms.  Furthermore,
the execution, delivery and performance of this Security Agreement by Debtor
does not and will not violate any material Law applicable to Debtor in connection with
the transactions contemplated hereby.

 

4

 

(ix)                                The
execution, performance and delivery of this Security Agreement does not violate
or conflict in any material
respect with the terms or provisions of, or the Debtor’s
performance under, any contract or agreement by or to which the Debtor is a
party, bound or subject.

 

(x)                                   Debtor
is not in material default under any contract or agreement by or to which the
Debtor is now or hereafter a party, bound or subject that is part of the
Secured Assets.  Debtor will perform and
comply in all material respects with all obligations under all provisions of
any Document filed by
Debtor with the Securities and Exchange Commission to which
Debtor is a party or by which it or any of its assets is bound that relates to
the Secured Assets, after
giving effect to any applicable grace periods thereto.

 

(xi)                                Debtor
does not transact and has not transacted within the past five (5) years, any
part of its business under any trade names, division names, assumed names or
other names.

 

(xii)                             Debtor
is a Delaware corporation whose chief executive office is located at Cambridge,
Massachusetts.

 

(xiii)                          (a)
Debtor is the true and lawful exclusive owner of the Patent Rights set forth on
Schedule 1 hereto; (b) the Patent Collateral is valid and enforceable;
(c) Debtor has no notice of any suits or actions commenced or threatened
against it, or notice of claims asserted or threatened against it, with
reference to the Patent Rights and the interests granted herein; and (d) the
Patent Rights and all interests granted herein are so granted free from all
liens, charges, claims, options, licenses, pledges and encumbrances of every
kind and character, except for licenses granted by Debtor set forth on Schedule
6(xiii) hereto.

 

(xiv)                         (a) until
all of the Obligations have been satisfied in full, Debtor will not enter into
any agreement, including without limitation, license agreements, which are
inconsistent with Debtor’s obligations under this Security Agreement; and (b)
if Debtor acquires rights to any new Patent Collateral, the provisions of this
Security Agreement shall automatically apply thereto and Debtor shall give the
Lender prompt written notice thereof along with an amended Schedule 1.

 

Notwithstanding anything to the contrary contained
herein, including, without limitation, the provisions of clauses (i), (v) and
(vi) of this Section 6, Debtor may, prior to the occurrence of an Event of
Default, without the consent of the Secured Party, grant licenses to or under
the Secured Assets that are consistent with any existing or future license
granted by the Debtor to the Secured Party or any of its affiliates, and any
payments received by Debtor in connection with the grant of any such license
(whether in the form of license fees, upfront payments, milestone payments,
royalties or otherwise) shall not be considered Proceeds covered by the
security interest granted to the Secured Party hereunder; provided that, all
Proceeds from the grant of any such license that are received by the Debtor or
which the Debtor is entitled to receive subsequent to the occurrence of an Event
of Default shall be considered Proceeds covered by the security interest
granted to the Secured Party hereunder.

 

5

 

7.                                       Maintenance
of Patent and Prosecution of Patent Application.

 

(a)                                  Debtor
shall, at its own expense, diligently maintain all Patents and diligently file
and prosecute all Applications relating to the inventions described and claimed
in the Patent Collateral in the United States Patent and Trademark Office, and
shall pay or cause to be paid in their customary fashion all fees and
disbursements in connection therewith, and shall not abandon any such
Application prior to the exhaustion of all administrative and judicial remedies
or disclaim or dedicate any Patent without the prior written consent of the
Lender.  Debtor shall not abandon any
Patent Collateral without the prior written consent of the Lender, which shall
not be unreasonably withheld.

 

(b)                                 Any
and all fees, costs and expenses, including reasonable attorneys’ fees and
expenses incurred by the Lender in connection with the preparation,
modification, enforcement or termination of this Security Agreement and all
other documents relating hereto and the consummation of this transaction, the
filing and recording of any documents (including all taxes in connection
therewith) in public offices, the payment or discharge of any taxes, counsel
fees, maintenance fees, encumbrances or costs otherwise incurred in defending
or prosecuting any actions or proceedings arising out of or related to the Patent
Collateral shall be paid by Debtor on demand by the Lender.

 

(c)                                  Debtor
shall have the right to bring suit in the name of Debtor to enforce the Patent
Collateral, in which case the Lender may, at the Lender’s sole option, be
joined as a nominal party to such suit if the Lender shall be satisfied that
such joinder is necessary and advisable and that the Lender is not thereby
incurring any risk of liability by such joinder.  Debtor shall promptly, upon demand, reimburse and indemnify,
defend and hold harmless the Lender for all damages, costs and expenses,
including reasonable attorneys’ fees, incurred by the Lender pursuant to this
paragraph and all other actions and conduct of Debtor with respect to the
Patent Rights.

 

8.                                       Secured
Party’s Duties.  The powers
conferred on the Secured Party hereunder are solely to protect its interest in
the Secured Assets and shall not impose any duty of any kind or nature upon it
to exercise any such powers.  Secured
Party shall have no obligation of any kind or nature to preserve rights against
any Person.

 

9.                                       Default
Remedies.

 

(a)                                  Except
as expressly and unambiguously set forth herein, this Security Agreement shall
be deemed absolute and without conditions. 
Upon an Event of Default, the Secured Party may enforce its rights with
respect to the Secured Assets without first being required to attempt
collection of any sums due from the Debtor. 
If an Event of Default shall occur, the Secured Party shall have the
following rights:

 

(i)                                     to
perform any defaulted covenant or agreement of this Security Agreement, the
Loan Agreement and the Research Agreement to such extent as the Secured Party
shall reasonably determine and advance such monies as it shall deem reasonably
advisable for the aforesaid purpose and all monies so advanced, together with

 

6

 

interest thereon from the date advanced until paid at
a rate per annum equal to the rate then in effect on the Note, shall be secured
hereby and shall be repaid promptly after notice of the amount due without
demand; provided, however, that nothing herein contained shall be construed to
require the Secured Party to advance money for any of the aforesaid purposes;

 

(ii)                                  to
notify all account debtors, to the extent permitted by applicable Law, to pay
directly to the Secured Party or otherwise as the Secured Party may specify all
amounts it owes then or thereafter to Debtor until such time as the Secured
Party has received all amounts to which it is entitled under the Note and this
Security Agreement;

 

(iii)                               to
take control of any and all proceeds to which the Secured Party may be entitled
under this Security Agreement, the Loan Agreement, the Note, or under any
applicable laws;

 

(iv)                              without
demand of performance or other demand, advertisement or notice of any kind
(except the notice specified below of time and place of public or private sale)
to or upon Debtor or any other Person (all and each of which demands,
advertisements and/or notices are hereby expressly waived), to take immediate possession
of the Secured Assets, and, with or without taking possession of the Secured
Assets, to sell, lease, collect, receive, appropriate, realize upon or
otherwise dispose of in any manner whatsoever (or contract to do so), any or
all of the Secured Assets or any part thereof, at one or more times, either at
public or private sale, upon commercially reasonable terms  and in accordance with the UCC,
and the Secured Party may become the purchaser thereof at any one or more
public sale or sales and, to the extent permitted by Law, upon any one or more
private sale or sales, free of any right or equity of redemption in Debtor,
such right or equity being hereby released; provided that, any sale may be
adjourned at any time and from time to time to a reasonably specified time and
place by announcement at the time and place of sale or by publication or
otherwise of the time and place of such adjourned sale; provided further that,
the proceeds of any sale shall be applied (1) first to the expenses of taking,
holding and preparing for sale or disposition, and sale or disposition and the
like (including reasonable attorneys’ fees), (2) next to the interest due under
the Loan Agreement and/or the Note, (3) next to the principal due under Loan
Agreement and/or the Note and the other amounts secured under clauses (i) and
(ii) of Section 3 hereof, (4) next to all other amounts secured under Section 3
hereof, (5) next to the holder of any subordinate security interest therein if
written notification of demand therefor is received and verified by the Debtor
before distribution of the proceeds (or, if there is a dispute with respect
thereto, the Secured Party can deposit such amount with a court or an
appropriate third party) and (6) lastly, any surplus to Debtor and Debtor shall
remain liable for any deficiency if the proceeds of any sales or other dispositions
of the Secured Assets are insufficient to pay all amounts to which Secured
Party is entitled, Debtor also being liable for the reasonable fees and
expenses of any attorneys employed by Secured Party to collect such deficiency;
and provided that, any such sale or sales, public or private, may be made on
credit at the sole discretion of the Secured Party;

 

7

 

(v)                                 to
take immediate possession of the Secured Assets and to use or operate the
Secured Assets in order to preserve the same or their value, and collect,
receive and use all of the net profits from such use or operation to pay
indebtedness secured by such Secured Assets; provided that, any continuing
royalties or other similar amounts derived from the commercial sale of any
products developed from the Secured Assets under the Research Agreement (as
opposed to the sale of any products deriving from intellectual property that
may be developed by the Secured Party) shall be allocated between the parties
in accordance with Section 7.4.1 of the Research Agreement; provided further
that, any sale or license by the Secured Party of any intellectual property
included in the Secured Assets to any third party shall be deemed to be solely
for the account of the Secured Party and not in any manner or portion for the
account of Debtor or distributable to Debtor under and pursuant to the terms of
the Research Agreement;

 

(vi)                              to
require Debtor, to the extent practicable, to assemble the Secured Assets and
make them available to the Secured Party at such locations as the Secured Party
shall reasonably designate;

 

(vii)                           to
enter all of the Debtor’s facilities to remove the Secured Assets therefrom and
take possession of the appropriate portions of the Debtor’s books and records
and computer hardware and software, and to use all of the same in a manner the
Secured Party deems appropriate in order to preserve and sell or otherwise
dispose of the Secured Assets;

 

(viii)                        to
(without assuming any obligations or liability or any kind or nature
thereunder), at any time and from time to time, enforce against any licensee or
sublicensee all rights and remedies of the Debtor in, to and under any patent,
know-how and/or other licenses included in the Secured Assets and, in the
exercise of commercial reasonableness, take or refrain from taking any action
under any such licenses, and the Debtor hereby releases the Secured Party free
and harmless from and against any claims arising out of any lawful action so
taken or omitted to be taken under applicable law with respect thereto;

 

(ix)                                to
proceed to protect and enforce its rights under the Loan Agreement, the Note
and this Security Agreement by a suit or suits in equity or at law, whether for
specific performance or observance of any terms, provisions, covenants or
conditions herein or therein contained in aid of the execution of any power
therein or herein granted, for any foreclosure hereunder or thereunder, or for
the enforcement of any other proper legal or equitable remedy;

 

(x)                                   to
exercise any such additional and/or different rights or remedies as are
provided for in the Loan Agreement and/or the Note; and

 

(xi)                                to
act as true and lawful attorney-in-fact of the Debtor, with full power of
substitution, with full irrevocable power and authority in the place and stead
of the Debtor, in the name of the Debtor, or in its own name, for the purpose
of carrying out the terms of this Security Agreement, to take any and all
appropriate action, including, 

 

8

 

without limitation, to execute, deliver, record and
file any and all Documents which may be reasonably necessary or desirable to
accomplish the purposes of this Security Agreement.

 

(b)                                 The
Secured Party shall, in addition, have any and all other rights and remedies
provided by law or equity, including, without limitation, the rights and
remedies of a secured party under the Uniform Commercial Code.  All of the Secured Party’s rights and
remedies will be cumulative, and no waiver of any default will affect any other
subsequent default.  The rights and
remedies provided in this Security Agreement are cumulative, may be exercised
concurrently or separately, may be exercised from time to time and in such
order, without any marshalling, as the Secured Party shall determine.  Debtor expressly acknowledges that the
Secured Party is not obligated to first foreclose its security interest
in the Joint Patents, the decision as to the order in which the Secured Assets
are to be addressed hereunder being in Lender’s sole and absolute
discretion.  To the extent permitted by
applicable Law, Debtor waives all claims, damages and demands against Secured
Party arising out of the repossession, retention, sale or other disposition of
the Secured Assets.  Nothing herein
contained shall be construed as preventing the Secured Party from taking all
reasonable and lawful actions to protect its interest in the event that
liquidation, insolvency, bankruptcy, reorganization or foreclosure proceedings
of any nature whatsoever affecting the property or assets of Debtor are
voluntarily or involuntarily instituted. 
The Secured Party’s sole duty with respect to the Secured Assets,
including, without limitation the custody, safekeeping and physical
preservation of the Secured Assets shall be those duties which are imposed by
the Uniform Commercial Code and cannot, by contract, be waived or otherwise
eliminated.  Neither the Secured Party,
nor any of its respective directors, officers, employees or agents shall be
liable for failure to demand, collect or realize upon all or any part of the
Secured Assets or for any delay in doing so or shall be under any obligation to
sell or otherwise dispose of any Secured Assets upon the request of the Debtor
or otherwise.

 

(c)                                  (i)   The Debtor expressly acknowledges that the
Secured Party may record evidence of this Security Agreement  and the security interest created hereby
with the appropriate government filing/recording office(s) in such countries as
the Secured Party desires in its sole discretion, whether by filing or
recording a Patent Collateral Assignment in the form of Exhibit A
attached hereto or with such other forms as may be customary, necessary and appropriate
for similar use in a particular country. The Debtor agrees to execute and
deliver promptly all such forms presented to it by the Secured Party.

 

(ii)   Contemporaneously herewith,
the Debtor shall execute and deliver to the Secured Party a Patent Assignment
in the form attached hereto as Exhibit B (and such other forms as may be
customary, necessary and appropriate for similar use in a particular country
other than the United States of America that the Secured Party may present to
the Debtor in the future) permanently assigning all Debtor’s rights in the
Patent Collateral to the Secured Party. 
Such assignment document(s) shall be held by the Secured Party in escrow
until the occurrence of an Event of Default hereunder or under the Loan
Documents. After such occurrence, in addition to all other rights and remedies
of the Secured Party set forth herein, the Secured Party may, at its sole
option, record such escrowed documents with the United States Patent and

 

9

 

Trademark Office and with the appropriate government filing/recording
office(s) in such other countries as the Secured Party desires in its sole
discretion.

 

10.                                 General
Provisions.

 

(a)                                  This
Security Agreement and the security interests of the Secured Party in the
Secured Assets created hereby shall cease and terminate only upon final
indefeasible repayment in full of the principal and any accrued interest under
and pursuant to the Loan Agreement.

 

(b)                                 Debtor
hereby waives all demands, notices, presentments, claims, defenses and protests
of any kind, except (if any) as expressly and unambiguously provided herein and
unless not permitted by applicable law.

 

(c)                                  This
Security Agreement shall be construed to be a contract made under and pursuant
to the laws of the State of New York, and all of the terms, covenants and
conditions contained herein shall be governed by and construed in accordance
with such laws, without giving effect to the conflict of laws principles
contained in such laws.

 

(d)                                 This
Security Agreement, all supplements hereto and all amendments hereof, shall
inure to the benefit of and be binding upon the Debtor, the Secured Party, and
their respective successors and assigns, but this Security Agreement may not be
assigned by Debtor or the Secured Party without the advance written consent of
the other party; provided, however, that the Secured Party may assign this
Security Agreement to an Affiliate without the Debtor’s advance consent.

 

(e)                                  No
course of dealing between the Debtor and the Secured Party or any delay on the
part of the Secured Party in exercising any rights hereunder shall affect the
rights of the Secured Party, on any future occasion, to insist on strict
compliance with the terms hereof or to exercise any available remedy.  All consents and waivers shall be in
writing.  No waiver by either party of
any term, provision, covenant or condition contained in this Security
Agreement, or of any breach of any such term, provision, covenant or condition,
shall constitute a waiver by that party of any subsequent breach or justify or
authorize the non-observance by the other party on any other occasion of such
term, provision, covenant or condition contained in this Security Agreement.

 

(f)                                    Subject
to the provisions of Section 7.4 of the Loan Agreement, the invalidity or
unenforceability of any term or condition hereof shall not affect the validity
or enforceability of any other term or condition hereof or of this Security
Agreement as a whole and each such term or condition which is enforceable in
part but not enforceable in whole shall be enforced to the maximum extent
permitted by applicable law.

 

(g)                                 Titles
of Sections and Subsections are for convenience only, and shall not modify
rights and obligations created hereby. 
All references herein to Sections or Subsections shall refer to the
corresponding Sections or Subsections of this Security Agreement unless
specific reference is made to Sections or Subsections of another document.  Use of the words “hereby”, “herein”,
“hereto”, “hereof”, “hereunder” and similar words shall be deemed to refer to
this

 

10

 

Security Agreement in its
entirety and not merely to the Sections or Subsections wherein any such word
may appear unless otherwise specifically herein provided to the contrary.  No one Party shall be deemed or construed as
the drafter of this Security Agreement, and this Security Agreement shall not
be construed more severely against any Party.

 

(h)                                 All
of the terms, covenants and conditions contained in this Security Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns, provided that Debtor’s obligations hereunder
may not be delegated to any other person without the prior consent of Secured
Party and any such attempted delegation without such consent shall be void.

 

(i)                                      DEBTOR
HEREBY WAIVES ANY RIGHT TO TRIAL BY JURY.

 

(j)                                      No
remedy herein conferred upon the Secured Party is intended to be exclusive of
any other remedy and each and every such remedy shall be cumulative and shall
be in addition to every other remedy provided hereunder or now or hereafter
existing at law or in equity.

 

 

[THE REMAINDER OF THIS
PAGE LEFT INTENTIONALLY BLANK]

 

11

 

IN WITNESS WHEREOF, the parties have caused this
Security Agreement to be executed at the time first above written by their
officers thereunto duly authorized.

 

 

	
   

  	
  SCHERING AKTIENGESELLSCHAFT

  
	
   

  	
  (“SECURED PARTY”)

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name: Prof. Dr. Günter Stock

  
	
   

  	
  Title: Member of the Vorstand

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name: Prof. Dr. Björn Wallmark

  
	
   

  	
  Title: Head of Corporate Research

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  EPIX MEDICAL, INC.

  
	
   

  	
  (“DEBTOR”)

  
	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

  
	
   

  	
  Title:

  

 

 

	
  Schedule 1

  	
   

  	
  Certain Patents and
  Patent Applications

  
	
  Schedule 6(i)

  	
   

  	
  Secured Assets that are
  licensed to Debtor

  
	
  Schedule 6(xiii)

  	
   

  	
  License in the Secured
  Assets granted by Debtor

  
	
  Exhibit A

  	
   

  	
  Form of Patent
  Collateral Assignment

  
	
  Exhibit B

  	
   

  	
  Form of U.S. Patent
  Assignment

  

 

12

 

	
  STATE OF

  	
  )

  
	
   

  	
  ), SS:

  
	
  COUNTY OF

  	
  )

  

 

BE IT REMEMBERED, that on this
           day of May, 2003,
before me the subscriber, a Notary Public of the State of
                            ,
personally appeared,
                         ,
the
                         
of EPIX MEDICAL, INC., a Delaware corporation, who, I am satisfied, is the
person who executed the within instrument as the
                    
of said company, and he acknowledged that he signed, sealed with the proper
corporate seal and delivered the same as such officer, that the within
instrument is the voluntary act and deed of said company made by virtue of
authority of its board of directors, and that he received a true copy of the
within instrument on behalf of said company.

 

	
   

  	
   

  	
   

  
	
   

  	
  Notary Public to the Commonwealth of Massachusetts

  
	
   

  	
  [Seal]

  

 

13

 

Schedule
1

Secured
Assets

 

The following patent families constitute existing utility applications
assigned to EPIX or in the case of the MET-1 patent family exclusively licensed
from The General Hospital Corporation of Boston, Massachusetts (Agreement of
March 24, 1992 amended July 10, 1995). 
MET-9 is assigned to Dyax and EPIX with EPIX having exclusive rights to
MRI applications (Agreement of June 20, 1997 amended March 17, 2003).

 

	
  MET-1

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  US-CIP

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
  CANADA

  	
   

  	
  [*****]

  
	
   

  	
  HONG KONG

  	
   

  	
  [*****]

  
	
   

  	
  LATVIA

  	
   

  	
  [*****]

  
	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-3

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-4

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
  ISRAEL

  	
   

  	
  [*****]

  
	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
  SOUTH AFRICA

  	
   

  	
  [*****]

  
	
   

  	
  SWAZILAND

  	
   

  	
  [*****]

  
	
   

  	
  TAIWAN

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-5

  	
  US CON Publication

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
  CHINA

  	
   

  	
  [*****]

  
	
   

  	
  ISRAEL

  	
   

  	
  [*****]

  
	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
  SINGAPORE

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-6

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
  AUSTRALIA

  	
   

  	
  [*****]

  
	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-7

  	
  AUSTRALIA

  	
   

  	
  [*****]

  

 

14

 

	
   

  	
  EPO

  	
   

  	
  [*****]

  
	
   

  	
  NEW ZEALAND

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-8

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-9

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-10

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-11

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-12

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  
	
  MET-14

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-15

  	
  PCT

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  
	
  MET-16

  	
  US Publication

  	
   

  	
  [*****]

  
	
   

  	
  PCT

  	
   

  	
  [*****]

  

 

15

 

Schedule 6(i)

Collateral
not Owned

 

EPIX’ MET-1 family of world patents listed below is
exclusively licensed from The General Hospital Corporation of Boston,
Massachusetts (Agreement of March 24, 1992 amended July 10, 1995).  There are EPO divisional and Japanese
applications being prosecuted by EPIX.

 

	
  MET-1 Patents

  	
   

  	
   

  
	
  US

  	
   

  	
  [*****]

  
	
  US-CIP

  	
   

  	
  [*****]

  
	
  PCT

  	
   

  	
  [*****]

  
	
  EPO

  	
   

  	
  [*****]

  
	
  CANADA

  	
   

  	
  [*****]

  
	
  HONG KONG

  	
   

  	
  [*****]

  
	
  LATVIA

  	
   

  	
  [*****]

  
	
  SINGAPORE

  	
   

  	
  [*****]

  

 

16

 

Schedule
6 (xiii)

 

Licenses Granted by Debtor

 

 

Strategic Collaboration Agreement dated June 9, 2000 with Schering AG

 

Amendment No. 1 to Strategic Collaboration Agreement dated December 22,
2000 with Schering AG

 

Worldwide License Agreement dated September 25, 2001 with Bracco
Imaging SPA

 

Amended and Restated Strategic Collaboration Agreement dated June 9,
2000 with Tyco/Mallinckrodt Inc

 

Development and License Agreement dated March 29, 1996, as amended
October October 4, 1999 with Daiichi Radioisotope Laboratories, Ltd

 

Reacquisition Agreement dated December 22, 2000 with Daiichi
Radioisotope Laboratories, Ltd

 

17

 

EXHIBIT A

 

PATENT
COLLATERAL ASSIGNMENT

 

This Agreement is made on
the           day of
            , 2003
between EPIX MEDICAL, INC. a Delaware corporation having a mailing address at                                 ,
Cambridge, Massachusetts (“Assignor”) and SCHERING AKTIENGESELLSCHAFT, a German
corporation having a mailing address at 13342 Berlin, Germany (“Lender”).

 

BACKGROUND

 

Assignor has executed and delivered its promissory note to the Lender
pursuant to a certain Loan Agreement of even date herewith between Assignor and
the Lender (as amended from time to time, the “Loan Agreement”).  In order to induce the Lender to execute and
deliver the Loan Agreement, Assignor has agreed to collaterally assign to
Lender certain patent rights, all as more fully set forth in that certain
Security Agreement of even date herewith between Assignor and Lender, a true
copy of which is attached hereto as Exhibit A  (the “Security Agreement”).

 

NOW,
THEREFORE, in consideration of the premises, Assignor
hereby agrees with Lender as follows:

 

1.                                       Capitalized
terms not otherwise defined herein shall have the meanings ascribed to them in
the Loan Agreement or the Security Agreement.

 

2.                                       To
secure the complete and timely satisfaction of all Obligations of Assignor to
Lender, Assignor has granted, assigned 
and conveyed to Lender, pursuant to the terms and conditions of the
Security Agreement, a security interest in Assignor’s entire right, title and
interest in and to, among other things, the Patents, Applications, Reissued
Patents, Royalties, Claims and Proceeds thereof, including but not limited to
those Patents and Applications listed in Schedule 1 attached to the
Security Agreement that is attached hereto.

 

3.                                       Assignor
has agreed that, until all of the Obligations shall have been satisfied in
full, it will not enter into any agreement (for example, a license agreement or
patent assignment) which is inconsistent with Assignor’s obligations and
covenants under the Security Agreement.

 

4.                                       Assignor
authorizes Lender to modify this Agreement by amending Schedule 1
attached to the Security Agreement that is attached hereto to include any
future Patents and Applications.

 

5.                                       If
any Event of Default shall have occurred and be continuing, Assignor hereby
authorizes and empowers Lender to make, constitute and appoint any officer or
agent of Lender, as Lender may select in its exclusive discretion, as
Assignor’s true and lawful attorney-in-fact, with the power to endorse
Assignor’s name on all Applications, documents, papers and instruments necessary
for Lender to use the Patents, or to grant or issue any exclusive or
nonexclusive license under the Patents to any third person, or necessary for
Lender to assign,

 

18

 

pledge, convey or otherwise transfer title in or
dispose of the Patents to any third person. 
Assignor hereby ratifies all that such attorney shall lawfully do or
cause to be done by virtue hereof.  This
power of attorney shall be irrevocable for the life of this Agreement.

 

WITNESS the execution hereof under seal as of the day
and year first above written.

 

 

	
  ATTEST:

  	
   

  	
  ASSIGNOR:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  EPIX MEDICAL, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  LENDER:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  SCHERING AKTIENGESELLSCHAFT

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By 

  	
   

  

 

CERTIFICATE
OF ACKNOWLEDGEMENT

 

	
  COMMONWEALTH OR STATE OF
                        

  	
  :

  	
   

  
	
   

  	
  :

  	
  ss

  
	
  COUNTY
  OF                                        

  	
  :

  	
   

  

 

Before me, the undersigned, a Notary Public in and for the country
aforesaid, on this
            day of
                 ,
20       , personally appeared                              
to me known personally, and who, being by me duly sworn, deposes and says that
he/she is the
                       
of
                             ,
and that the seal affixed to the foregoing instrument is the corporate seal of
said corporation, and that said instrument was signed and sealed on behalf of
said corporation by authority of its Board of Directors, and said
                         acknowledged
said instrument to be the free act and deed of said corporation.

 

	
   

  	
   

  	
   

  
	
   

  	
  Notary Public

  	
   

  
	
   

  	
  My commission expires:

  	
   

  

 

19

 

Exhibit
B

 

PATENT
ASSIGNMENT

 

WHEREAS,  EPIX MEDICAL, INC., having a place of
business at 71 Rogers Street, Cambridge, Massachusetts (the “Grantor”)
is the owner of the entire right, title and interest in and to the United
States patents and patent applications listed on Schedule A attached
hereto and made a part hereof, the inventions described therein and all rights
associated therewith (collectively, the “U.S. Patent Collateral”), which are
registered in the United States Patent and Trademark Office or which are the
subject of pending applications in the United States Patent and Trademark
Office; and

 

WHEREAS,
SCHERING AKTIENGESELLSCHAFT, having a place of business
at 13342 Berlin, Germany (the “Grantee”), is desirous of acquiring said
Patent Collateral;

 

WHEREAS,
pursuant to those certain Loan Agreement of even date herewith and Security
Agreement of even date herewith, each between Grantor and Grantee, the Grantee
has a security interest in the assets of the Grantor adequate to carry on the
business of the Grantor with respect to the Patent Collateral; and

 

WHEREAS,
the Security Agreement provides that this Assignment shall become effective
upon the occurrence of an Event of Default as defined in the Security
Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, and intending to be
legally bound hereby, the Grantor, its successors and assigns does hereby
transfer, assign and set over unto Grantee, its successors, transferees and
assigns, all of its present and future right, title and interest in and to the
Patent Collateral and all proceeds thereof and all rights and proceeds
associated therewith.

 

IN
WITNESS WHEREOF, the undersigned has caused this
Patent Assignment to be executed by its duly authorized officer on this 21th
day of May, 2003.

 

	
  ATTEST:

  	
   

  	
  EPIX MEDICAL, INC.

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  (SEAL)

  	
   

  
	
  Print Name:

  	
   

  	
   

  	
   

  	
  Print Name:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
   

  
										

 

20

 

	
  STATE OF

  	
  )

  	
   

  
	
   

  	
  )

  	
  ss:

  
	
  COUNTY OF

  	
  )

  	
   

  

 

On this, the
                 
day of May, 2003, before me, a Notary Public, the undersigned officer,
personally appeared                                                     ,
who acknowledged himself/herself to be the
                                         
of  EPIX MEDICAL, INC. and that
he/she, in such capacity, being authorized to do so, executed the foregoing
instrument for the purposes therein contained by signing on behalf of said
corporation pursuant to a resolution of the board of directors of said
corporation.

 

IN WITNESS WHEREOF, I hereunto set my hand and official seal.

 

	
   

  	
   

  
	
   

  	
  Notary Public

  
	
  My commission expires:

  	
   

  

 

21

 

SCHEDULE
A

 

	
  MET-3

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-4

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-5

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  US CON Publication

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-6

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-7

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-8

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-9

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-10

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-11

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-12

  	
   

  	
  US

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-14a

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-14b

  	
   

  	
  US Application

  	
   

  	
  [*****]

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  MET-16

  	
   

  	
  US Publication

  	
   

  	
  [*****]

  

 

22

 

EXHIBIT D

 

EPIX’ INVESTMENT POLICY and GUIDELINES

 

POLICY

 

Cash is a resource that will be invested if not immediately required to
fund operations.

 

PURPOSE

 

To establish the responsibility, authority and guidelines for the
investment of the Company’s surplus cash. 
“Surplus cash” is cash in corporate accounts not immediately required to
fund operations, debt repayments, working capital, capital investment, or other
outstanding near-term financial obligations.

 

RESPONSIBILITY

 

The Treasury Department, including the CFO and one other person
designated by the CFO, will be responsible for managing and investing the cash
for the Company.  The CFO and designee
will have the authority to: 1) open accounts with banks, brokerage and other
financial institutions; 2) establish safekeeping accounts or other arrangement
for the custody of securities; 3) execute documents as necessary; 4) select or
change investment managers and be responsible for monitoring and reporting the
results of all investment managers to the Board of Directors.

 

The surplus cash of the Company will be invested in accordance with
this policy.  Any exceptions to this
policy will require the written approval of the Chief Financial Officer and the
Chief Executive Officer.

 

INVESTMENT OBJECTIVES

 

The primary objective of the Company’s investment program is safety and
preservation of principal which will be achieved by investing in high-quality,
diversified portfolios.  These investments
will also satisfy the following objectives:

 

Liquidity of investments sufficient to satisfy the Company’s cash flow
requirements.

 

Maximize the return on invested funds, as compared to industry
averages, while adhering to the stated objectives and risk profile.

 

RISK PROFILE

 

The Company will attempt to ensure the safety of its invested funds by
minimizing interest rate, reinvestment and event risk.

 

The risk associated with fluctuating interest rates is a change in the
market value of investments.  Generally,
securities should be purchased with the intention of holding to maturity even
though a sale of securities may be necessary to meet capital requirements.

 

 

Reinvestment risk results from having to reinvest funds at maturity at
rates lower than previously earned. Selecting investments with maturities
consistent with the Company’s needs as reflected on the cash flow plan will
help to limit this risk.

 

Event risk impacts the liquidity of a security.  The Company will invest in safe, high quality
securities and monitor the portfolio and credit markets to respond to a
reduction in the credit rating of any investment issuer, guarantor or
depository.  The portfolio will include
only marketable securities with active secondary or resale markets to ensure
liquidity.

 

LIQUIDITY and MATURITY

 

The
Company will provide a cash flow projection which will serve as the basis for
establishing portfolio maturities. 
These projections will be updated quarterly or more frequently, if
necessary.

 

Excess cash is invested with liquidity in mind, and without any loss of
principal.  Daily liquidity is
essential; restrictions on liquidity are:

 

At least $1 million must be available each business day until 1:30p.m.
Eastern time with no loss of principal.

 

The remainder of the funds is to be invested, consistent with
anticipated cash needs, in securities with maturities no longer than 24
months.  The average maturity of the
portfolio may not exceed 12 months.

 

For securities which have put dates, reset dates, or are traded based
on their average maturity, the put date, reset date, or average maturity will
be used, instead of the final maturity date, for maturity guideline purposes.

 

Repositioning of these securities before their maturity, generating
small gains or losses, is permitted for managing liquidity requirements
only.  Any repositioning of securities
causing a gain or loss must be pre-approved by the Chief Financial Officer for
fiduciary control purposes.

 

INVESTMENT RESTRICTIONS

 

Investments shall be made in the context of the following investment
guidelines:

 

ELIGIBLE INVESTMENTS

 

1.                                        Direct
obligations of the U.S. Treasury, including bills, notes, and bonds.

 

2.                                      Obligations
issued or guaranteed by agencies or instrumentalities of the U.S. government.

 

 

3.                                      Bank obligations,
including certificates of deposit, bank notes, and bankers acceptances.  Investments in these securities is limited
to banks whose long term debt is rated “A” or higher by Moody’s or Standard
& Poor’s and short term obligations are rated “A1” or higher by Moody’s or
“P1” or higher by Standard & Poor’s.

 

4.                                         Corporate
obligations, including intermediate term notes rated “A” or higher by Moody’s
or Standard & Poor’s and Commercial Papers rated “A1” or higher by Moody’s,
or “P1” or higher by Standard & Poor’s.

 

5.                                         Repurchase
agreements collateralized at a minimum of 102% with U.S. Treasury securities or
other securities rated “AAA” or equivalent that would be permitted by this
policy.

 

6.                                         Money market
funds over $1 billion in assets, with an historically constant dollar net asset
value, consisting of eligible investments as stated above are appropriate for
investing, as long as the fund’s manager has been in business over five years,
has name recognition, and has performance that is easily tracked.

 

7.                                         U.S. and
dollar denominated international corporate debt of all types is acceptable as
long as the issuer meets credit rating and marketability guidelines.

 

8.                                         For all
eligible investments the coupon and the maturity value must be known for the
life of the security at the time of purchase. 
Exceptions may be granted on a case by case basis for floating rate
notes by the CFO.

 

CONCENTRATION LIMITS

 

There is no limit to the percentage of the portfolio which may be
maintained in securities issued by the U.S. Treasury or by its agencies and
instrumentalities.  However, no single
government agency shall comprise more than 30% of the total portfolio.

 

No one issuer or group of issuers from the same holding company, is to
exceed 15% of the portfolio at time of purchase, with the exception of
Government securities.  No single
industry shall comprise more the 25% of the total portfolio.

 

U.S. bank and insurance company securities (CDs, commercial papers,
BAs, etc.) must not in total exceed 60% of the portfolio.  Holdings of one issuer cannot exceed
$1,000,000 or 15% of the total portfolio at the time of purchase.

 

UNACCEPTABLE INVESTMENTS

 

No investment will be permitted in common stocks, preferred stocks,
options (put or calls,), commodities, foreign securities, futures or mutual
funds whose underlying securities are ineligible investments according to this
investment policy.

 

The short sales or margin of securities.

 

Securities whose structure could cause it to have an interest rate
adjustment that could cause the current coupon to be reset to zero for any
period.

 

 

Securities that are linked to the fluctuation of currencies, non-U.S.
interest rates, stock indices, levels of inflation or similar market
indicators.

 

INVESTMENT PERFORMANCE

 

The company shall review the performance of Merrill Lynch Investment
Managers on a quarterly basis.  Merrill
Lynch Investment Managers will issue a quarterly investment performance
analysis using time weighted measures. 
A quarterly meeting will be held with the Chief Financial Officer and
her/his designee to review performance figures and any updated liquidity needs.

 

On a monthly basis, Merrill Lynch Investment Managers will provide Epix
Medical, Inc. with the necessary standard and custom reports to satisfy the
company’s accounting and informational needs. 
These reports will be provided to the company within a reasonable period
of time following the close of the company’s fiscal month.

 

CREDIT QUALITY

 

Trends for a given company or industry must be reviewed periodically by
the Investment officer and adjustments in percentage positions made
accordingly.  Should any investment held
in the Epix Medical, Inc. portfolio fall short of prescribed guidelines,
immediate notification must be made to the individual appointed by the board to
oversee fiduciary control.

 

MARKETABILITY

 

All securities are to be purchased through investment banking and
brokerage firms of high quality and reputation, with a history of making
markets for the securities in which we invest. 
In the unlikely even that securities must be sold before their maturity,
the securities must be easily remarketed. 
To accomplish this, the securities must be conventional “products” with
strong name recognition.

 

TRADING GUIDELINES

 

Normal investing practice is to reinvest the funds on the day a
security matures, to minimize lost interest. 
A daily transaction log is to be maintained and available for review at
any time.  All trading firms must
generate a hard copy document for each transaction which is mailed to us on a
timely basis, and then matched to the transaction log.  Quarterly summaries of our investment
holdings and cash usage are to be made available for board review.

 

SAFEKEEPING

 

Assets are to be held in a segregated bank custody account with
separate fiduciary account documents executed by the bank.  Assets shall not be held by any investment
manager.

 

 

FIDUCIARY DISCRETION

 

The Chief Financial Officer or other individual appointed by the Board
and her/his authorized employees are responsible for securing and managing
investments and cash for operations. 
These individuals have full discretion to invest any excess capital
subject to strict adherence to these guidelines.  These guidelines are to be reviewed periodically with the Chief
Financial Officer or Chief Executive Officer and revisions made consistent with
objectives set forth herein.

 

 

Schedule 4.5

 

Material Contingent Liabilities as of May 14, 2003

 

Facility Lease as amended May 21, 2002 of 22,950 square feet at 71
Rogers Street and adjacent locations through December 31, 2007, Cambridge, MA

 

Facility Sublease as amended December 31, 2002 of 13,310 square feet at
161 First Street through October 31, 2003, Cambridge, MA

 

Various Operating Leases of Office Equipment with an approximate total
commitment of $400,000

 

Strategic Collaboration Agreement dated June 9, 2000 with Schering AG

 

Amended and Restated License Agreement dated July 10, 1995 with The
General Hospital Corporation

 

Worldwide License Agreement dated September 25, 2001 with Bracco
Imaging SPA Amended and Restated Strategic Collaboration Agreement dated June
9, 2000 with Tyco/Mallinckrodt Inc

 

Reacquisition Agreement dated December 22, 2000 with Daiichi
Radioisotope Laboratories, Ltd

 

 

SCHEDULE A

 

	
  Date

  	
   

  	
  Advance/Repayment

  	
   

  	
  Amount

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]